<PAGE>
As filed with the Securities and Exchange Commission on April 30, 1999
Registration No. 333-73417
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PRE-EFFECTIVE AMENDMENT NO. 1 TO
REGISTRATION STATEMENT
ON FORM S-3
UNDER THE SECURITIES ACT OF 1933
TECHNICLONE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 95-3698422
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
14282 FRANKLIN AVENUE,
TUSTIN, CALIFORNIA 92780-7017
(714) 508-6000
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
LARRY O. BYMASTER WITH COPIES TO:
14282 FRANKLIN AVENUE, THOMAS J. CRANE, ESQ.
TUSTIN, CALIFORNIA 92780-7017 KENT M. CLAYTON, ESQ.
(714) 508-6000 RUTAN & TUCKER, LLP
(Name, address, including zip code, and , 611 ANTON BLVD.
telephone number including area code, of SUITE 1400
agent for service) COSTA MESA, CA 92626
(714) 641-5100
APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC:
From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. |_|
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. |X|
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. |_|
If delivery of the prospectus is expected to be made pursuant to Rule
434,please check the following box. |_|
The aggregate market value of the voting stock held by non-affiliates of
the Registrant was approximately $95,032,000 as of February 24, 1999, based upon
the price at which such stock was last sold in the principal market for such
stock as of such date.
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
====================================================================================================================================
TITLE OF EACH CLASS OF PROPOSED MAXIMUM PROPOSED MAXIMUM
SECURITIES TO BE AMOUNT TO BE OFFERING PRICE PER AGGREGATE OFFERING AMOUNT OF REGIS-
REGISTERED REGISTERED(1) SHARE (2) PRICE (2) TRATION FEE(3)
- ------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock, $.001 par 605,154 $ 0.875 $ 529,510 $159
value (4)
- ------------------------------------------------------------------------------------------------------------------------------------
Shares of Common Stock, 25,454 $ 1.375 $ 35,000 $ 11
$.001 par value, Issuable Upon
Exercise of Warrants to
Purchase Common Stock (5)
- ------------------------------------------------------------------------------------------------------------------------------------
Shares of Common Stock, 26,086 $ 0.875 $ 22,826 $ 7
$.001 par value, Issuable Upon
Exercise of Warrants to
Purchase Common Stock(6)
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock, $.001 par 47,727 $ 0.875 $ 41,762 $ 13
value (7)
- ------------------------------------------------------------------------------------------------------------------------------------
Common Stock, $.001 par 1,781,250 $ 0.875 $ 1,558,594 $ 468
value (8)
- ------------------------------------------------------------------------------------------------------------------------------------
Shares of Common Stock, 178,125 $ 0.875 $ 155,860 $ 47
$.001 par value, Issuable Upon
Exercise of Warrants to
Purchase Common Stock (9)
====================================================================================================================================
</TABLE>
(1) In the event of a stock split, stock dividend or similar transaction
involving the Common Stock, in order to prevent dilution, the number of
shares registered shall automatically be increased to cover the additional
shares in accordance with Rule 416(a) under the Securities Act of 1933, as
amended (the "Securities Act").
(2) In accordance with Rule 457(c), the aggregate offering price of shares of
Common Stock of Techniclone Corporation is estimated solely for purposes of
calculating the registration fees payable pursuant hereto, as determined in
accordance with Rule 457(c), using the average of the high and low sales
price reported by the Nasdaq SmallCap Market for the Common Stock on April
23, 1999, which was $0.875 per share and, with respect to shares of Common
Stock of the Company issuable upon exercise of outstanding warrants, the
higher of (i) such average sales price or (ii) the exercise price of such
warrants..
(3) Previously paid.
(4) Represents shares of Common Stock issued to Dunwoody Brokerage Services,
Inc. pursuant to the terms of a Placement Agent Agreement dated as of June
16, 1998 by and between the Company and the Registered Stockholder, as
successor in interest to Swartz Investments LLC, a Georgia limited
liability company d/b/a Swartz Institutional Finance, in connection with
the issuance of shares of Common Stock to two institutional investors
pursuant to the terms of a Regulation D Common Stock Equity Line
Subscription Agreement dated as of June 16,1998, by and between the Company
and the two institutional investors, as follows: (i) 203,636 shares of
Common Stock issued to Dunwoody Brokerage Services, Inc. on or about June
16, 1998, as a placement agent fee in connection with the placement and
sale of 2,545,454 shares of Common Stock to the two institutional
investors; (ii) 60,515 shares of Common Stock issued to Dunwoody Brokerage
Services, Inc. on or about December 24, 1998, as an adjustment to the
placement agent fee pursuant to the terms of the Placement Agent Agreement
and in connection with the issuance of an additional 96,055 shares of
Common Stock to the two institutional investors; (iii) 260,869 shares of
Common Stock were issued to Dunwoody Brokerage Services, Inc. on or about
February 2, 1999, as a placement agent fee in connection with the placement
and sale of 2,608,695 shares of Common Stock to the two institutional
investors; and (iv) 80,134 shares of Common Stock were issued to Dunwoody
Brokerage Services, Inc. on or about April 15, 1999 in connection with the
issuance of 801,347 shares of Common Stock to the two institutional
investors.
(5) Includes 20,363 shares of Common Stock issuable to Dunwoody Brokerage
Services, Inc. upon exercise of outstanding warrants, exercisable at any
time until December 31, 2004 at an exercise price of $1.375 per share,
issued to Dunwoody Brokerage Services, Inc. on or about June 16, 1998 as a
placement agent fee in connection with the placement and sale of 2,545,454
shares of Common Stock to the two institutional investors and an addtional
5,091 shares of Common Stock issuable to Dunwoody Brokerage Services, Inc.
upon exercise of outstanding warrants, exercisable at any time until
December 31, 2004 at an exercise price of $1.375 per share, issued to
Dunwoody Brokerage Services, Inc. on or about December 24, 1998, as a
placement agent fee in connection with the issuance of 96,055 shares of
Common Stock to the two institutional investors.
(6) Represents shares of Common Stock issuable to Dunwoody Brokerage Services,
Inc. upon exercise of outstanding warrants, exercisable at any time until
December 31, 2004 at an exercise price of $0.8625 per share, issued to
Dunwoody Brokerage Services, Inc. on or about February 2, 1999, as a
placement agent fee in connection with the placement and sale of 2,608,695
shares of Common Stock to the two institutional investors.
(7) Represents shares of Common Stock that may be issued to Dunwoody Brokerage
Services, Inc. on or about July 15, 1999 pursuant to the terms of the
Regulation D Common Stock Equity Line Subscription Agreement between
Techniclone Corporation and the two institutional investors upon adjustment
of the purchase price for the initial shares of Common Stock purchased by
the two institutional investors in June 1998, based on a reasonable
estimate of a potential 10-day low closing bid price immediately preceding
such date (estimated solely for purposes of this registration statement to
be not less than $1.00 per share of Common Stock, which allows Techniclone
Corporation to sell the maximum number of shares to the two institutional
investors under the terms of the Regulation D Common Stock Equity Line
Subscription Agreement). In the event the number of shares registered
hereby to be issued to Dunwoody Brokerage Services, Inc. in connection with
the issuance of the shares of Common Stock on or about such date to the two
institutional investors Institutional Investors is insufficient,
Techniclone Corporation will use other shares registered hereby for the
purpose of satisfying its obligations under the Placement Agent Agreement
and the Regulation D Common Stock Equity Line Subscription Agreement to
deliver registered shares to Dunwoody Brokerage Services, Inc. in
connection with the issuance of such shares on or about such date to the
two institutional investors.
(8) Represents shares of Common Stock issuable to Dunwoody Brokerage Services,
Inc. pursuant to the Placement Agent Agreement and the Regulation D Common
Stock Equity Line Subscription Agreement equal to 10% of the number of
shares issuable to the two institutional investors pursuant to the
Regulation D Common Stock Equity Line Subscription Agreement. Upon written
notice given by Techniclone Corporation to the two institutional investors,
no more than one time during any monthly period until June 16, 2001,
Techniclone Corporation may sell to the two institutional investors a
number of shares equal to up to $2,250,000 (which amount may be increased
up to $5,000,000 by mutual agreement of the parties), less the aggregate
dollar amount of any shares sold to the two institutional investors during
the three month period immediately preceding the date such notice is given,
divided by (i) 82.5% of the lowest closing bid price during the ten trading
days immediately preceding the date such shares are sold (estimated solely
for purposes of this registration statement to be not less than $1.00 per
share of Common Stock, which allows Techniclone Corporation to sell the
maximum number of shares to the two institutional investors under the terms
of the Regulation D Common Stock Equity Line Subscription Agreement), or
(ii) if 82.5% of such 10-day low closing bid price results in a discount of
less than twenty cents ($0.20) per share from such 10-day low closing bid
price, such 10-day low closing bid price minus twenty cents ($0.20);
provided, that the number of such shares is limited to the same number of
shares of restricted securities that the two institutional investors would
otherwise be able to sell pursuant to Rule 144(e) promulgated under the
Securities Act, subject to a maximum remaining dollar amount of $14,250,000
of shares of Common Stock and to certain other limitations and restrictions
(the "Equity Line Shares").
(9) Represents shares of Common Stock issuable to Dunwoody Brokerage Services,
Inc. upon exercise of outstanding warrants issuable to Dunwoody Brokerage
Services, Inc. pursuant to the Placement Agent Agreement and the Regulation
D Common Stock Equity Line Subscription Agreement. equal to 10% of the
number of shares issuable upon exercise of warrants issuable to the two
institutional investors pursuant to the Regulation D Common Stock Equity
Line Subscription Agreement. Pursuant to the terms of the Regulation D
Common Stock Equity Line Subscription Agreement, Techniclone Corporation is
required to issue to the two institutional investors warrants to purchase a
number of shares of Common Stock equal to 10% of the number of shares of
Common Stock sold to the two institutional investors at exercise prices
equal to the respective prices per share at which such shares were sold to
the Institutional Investors and, to the extent that the relevant minimum
aggregate commitment amount under the Regulation D Common Stock Equity Line
Subscription Agreement is not fully utilized by Techniclone Corporation,
shares of Common Stock issuable to the two institutional investors upon
exercise of warrants to be issued to the two institutional investors on
each of June 16, 1999, June 16, 2000 and June 16, 2001, to purchase a
number of shares of Common Stock equal to 10% of an amount equal to the
difference of the relevant minimum aggregate commitment amount ($6,666,667
for 1999, $13,333,333 for 2000 and $20,000,000 for 2001) minus the
aggregate amount of Common Stock sold to the two institutional investors
during all years preceding such date, divided by the 10-day low closing bid
price of the Common Stock immediately preceding such date (estimated solely
for purposes of this registration statement to be not less than $1.00 per
share of Common Stock, which allows Techniclone Corporation to sell the
maximum number of shares of Common Stock to the two institutional investors
under the terms of the Regulation D Common Stock Equity Line Subscription
Agreement), at an exercise price equal to the 10-day low closing bid price
of the Common Stock immediately preceding such date.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
MAY DETERMINE.
================================================================================
<PAGE>
SUBJECT TO COMPLETION DATED APRIL 30, 1999
PROSPECTUS
2,663,796 SHARES
[Techniclone
Corporation TECHNICLONE
Logo Here] CORPORATION
COMMON STOCK
This Prospectus relates to the resale, from time to time, of up to
2,663,796 shares of Common Stock of Techniclone Corporation by Dunwoody
Brokerage Services, Inc. This Prospectus has been prepared for the purpose of
registering the shares offered by this Prospectus under the Securities Act of
1933, as amended, to allow for future sales by Dunwoody Brokerage Services, Inc.
to the public without restriction. All or a portion of the shares offered by
this Prospectus may be offered for sale, from time to time, by Dunwoody
Brokerage Services, Inc. for its own benefit, pursuant to this Prospectus. See
"Dunwoody Brokerage Services, Inc. - The Selling Stockholder" and "Plan of
Distribution."
Dunwoody Brokerage Services, Inc. is an "underwriter" within the meaning of
the Securities Act of 1933, as amended, in connection with the sale of the
shares of Common Stock offered hereby. Dunwoody Brokerage Services, Inc. will
pay all commissions, transfer taxes and other expenses associated with the sales
of the shares of Common Stock by it. Techniclone will pay the expenses of the
preparation of this Prospectus. Techniclone will not receive any of the proceeds
from the sale of the shares of Common Stock sold by Dunwoody Brokerage Services,
Inc. Techniclone will not receive any proceeds from the exercise of the warrants
issued or issuable to Dunwoody Brokerage Services, Inc., which may only be
exercised pursuant to a cashless exercise by Dunwoody Brokerage Services, Inc.
See "Plan of Distribution."
Techniclone's Common Stock is registered pursuant to Section 12(g) of the
Securities Exchange Act of 1934, as amended, and is listed on The Nasdaq
SmallCap Market under the symbol "TCLN". On April 23, 1999, the last reported
sale price of the Common Stock on The Nasdaq SmallCap Market was $0.875 per
share.
INVESTING IN THE COMMON STOCK INVOLVES CERTAIN RISKS. SEE "RISK FACTORS"
BEGINNING ON PAGE 4.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
April, 1999
<PAGE>
TABLE OF CONTENTS
-----------------
PAGE
----
Techniclone Corporation ................................................. 3
Risk Factors ............................................................ 4
Incorporation of Certain Documents By Reference ......................... 12
The Equity Line Agreement ............................................... 13
Use of Proceeds ........................................................ 15
Dunwoody Brokerage Services, Inc. - The Selling Stockholder ............. 16
Plan of Distribution ................................................... 18
Description of Securities ............................................... 20
Legal Matters ........................................................... 21
Experts ................................................................. 21
Indemnification of Directors and Officers .............................. 21
Where to Learn More About Techniclone ................................... 22
You should rely only on the information contained in this document or to
which we have referred you. We have not authorized anyone to provide you with
information that is different. This document may only be used where it is legal
to sell these securities. The information in this document may only be accurate
on the date of this document.
2
<PAGE>
TECHNICLONE CORPORATION
Techniclone Corporation was incorporated in the State of Delaware on
September 25, 1996. On March 24, 1997, Techniclone International Corporation, a
California corporation (a predecessor company incorporated in June 1981), was
merged with and into Techniclone Corporation, a Delaware corporation. This
merger was effected for the purpose of effecting a change in our state of
incorporation from California to Delaware and making certain changes in our
charter documents. As used in this Prospectus, the terms "we," "us," "our" and
"Techniclone" refers to Techniclone Corporation, Techniclone International
Corporation, its former subsidiary, Cancer Biologics Incorporated, which was
merged into the Company on July 26, 1994 and its wholly-owned subsidiary
Peregrine Pharmaceuticals, Inc., a Delaware corporation.
Techniclone is engaged in the research, development and commercialization
of novel cancer therapeutics in two principal areas - direct tumor targeting
agents for the treatment of refractory malignant lymphoma and collateral tumor
targeting agents for the treatment of solid tumors. Our most advanced direct
tumor targeting agent candidate, Oncolym(R), is currently being studied in
advanced clinical trials for the treatment of intermediate and high-grade
relapsed or refractory B-cell non-Hodgkins lymphoma at nine participating
medical centers, and we or our licensee, Schering A.G., Germany, may add
additional clinical trial sites for Oncolym(R) in the future. Following the
completion of the clinical trials, we or our licensee, Schering A.G., Germany,
expect to file an application with the United States Food and Drug
Administration to market Oncolym(R) in the United States.
Collateral tumor targeting is the therapeutic strategy of targeting
peripheral structures and cell types, other than the viable cancer cells
directly, as a means to treat solid tumors. We are currently developing three
advanced collateral targeting agents for solid tumors: tumor necrosis therapy,
which is potentially capable of carrying a wide variety of therapeutic agents to
the interior of solid tumors and irradiating the tumor from the inside out;
vaseopermeation enhancement agents, which increase the permeability of the tumor
site and increase the concentration of killing agents at the core of the tumor;
and vascular targeting agents, which shuts down the capillaries and blood
vessels that serve solid tumors and destroys the vascular structure of the
tumor. Clinical trials of our tumor necrosis therapy agent for the treatment of
malignant glioma (I.E., brain cancer) are currently being conducted at one
medical center, with additional sites underway, and additional trials for the
treatment of pancreatic, prostrate and liver solid tumors will soon be conducted
at a clinical site in Mexico City. Our scientists are doing preliminary studies
on vaseopermeation enhancement agents and on vascular targeting agents.
To date, we have not received any significant revenues. However, on March
8, 1999 we entered into a license agreement with Schering A.G., Germany, a major
international pharmaceutical company, with respect to the development,
manufacture and marketing of our most advanced direct tumor targeting agent
candidate, Oncolym(R), pursuant to which we received an initial $3 million
payment and which provides for additional payments of up to $14 million upon the
completion of certain milestones. The agreement also provides for royalties
based on sales of Oncolym(R) products.
Our principal executive offices are located at 14282 Franklin Avenue,
Tustin, California 92780-7017 and our telephone number is (714) 508-6000.
3
<PAGE>
RISK FACTORS
INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD
CONSIDER THE FOLLOWING DISCUSSION OF RISKS AS WELL AS OTHER INFORMATION IN THIS
PROSPECTUS BEFORE PURCHASING ANY OF OUR COMMON STOCK, TOGETHER WITH ALL OF THE
OTHER INFORMATION SET FORTH HEREIN OR INCORPORATED HEREIN BY REFERENCE IN THIS
PROSPECTUS.
EXCEPT FOR HISTORICAL INFORMATION, THE INFORMATION CONTAINED IN THIS
PROSPECTUS AND IN OUR REPORTS FILED WITH THE SEC ARE "FORWARD LOOKING"
STATEMENTS ABOUT OUR EXPECTED FUTURE BUSINESS AND FINANCIAL PERFORMANCE. THESE
STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, INCLUDING, AMONG OTHERS, RISKS
RESULTING FROM ECONOMIC AND MARKET CONDITIONS, THE REGULATORY ENVIRONMENT IN
WHICH WE OPERATE, PRICING PRESSURES, ACCURATELY FORECASTING OPERATING AND
CAPITAL EXPENDITURES AND CLINICAL TRIAL COSTS, COMPETITIVE ACTIVITIES,
UNCERTAINTIES OF LITIGATION AND OTHER BUSINESS CONDITIONS, AND ARE SUBJECT TO
UNCERTAINTIES AND ASSUMPTIONS SET FORTH ELSEWHERE IN THIS PROSPECTUS. WE BASE
OUR FORWARD-LOOKING STATEMENTS ON INFORMATION CURRENTLY AVAILABLE TO US, AND WE
ASSUME NO OBLIGATION TO UPDATE THESE STATEMENTS. OUR ACTUAL OPERATING RESULTS
AND FINANCIAL PERFORMANCE MAY PROVE TO BE VERY DIFFERENT FROM WHAT WE MIGHT HAVE
PREDICTED AS OF THE DATE OF THIS PROSPECTUS DUE TO CERTAIN RISKS AND
UNCERTAINTIES. THE RISKS DESCRIBED BELOW SPECIFICALLY ADDRESS SOME OF THE
FACTORS THAT MAY AFFECT OUR FUTURE OPERATING RESULTS AND FINANCIAL PERFORMANCE.
IF WE CANNOT OBTAIN ADDITIONAL FUNDING, OUR PRODUCT DEVELOPMENT AND
COMMERCIALIZATION EFFORTS MAY BE REDUCED OR DISCONTINUED
We have expended, and will continue to expend, substantial funds on the
development of our product candidates and for clinical trials. As a result, we
have experienced negative cash flows from operations since inception and expect
the negative cash flow from operations to continue for the foreseeable future.
We currently have commitments to expend additional funds for antibody and
radioactive isotope combination services, clinical trials, product development
contracts, license contracts, severance arrangements, employment agreements,
consulting agreements, and for the repurchase of marketing rights to certain
product technology. We expect operating expenditures related to clinical trials
to increase in the future as clinical trial activity increases and scale-up for
clinical trial production continues. We also expect that the monthly negative
cash flow will continue. We will require additional funding to sustain our
research and development efforts, provide for future clinical trials, expand our
manufacturing and product commercialization capabilities, and continue our
operations until we able to generate sufficient revenue from the sale and/or
licensing of our products. Our ability to access funds under our Regulation D
Common Stock Equity Line Subscription Agreement with two institutional investors
is subject to the satisfaction of certain conditions and the failure to satisfy
these conditions may limit or preclude our ability to access such funds, which
could negatively affect our financial position unless additional financing
sources are available. We cannot be certain whether we can obtain required
additional funding on terms satisfactory to us, if at all. If we do raise
additional funds through the issuance of equity or convertible debt securities,
your stock ownership will be diluted and these new securities may have rights,
preferences or privileges senior to yours. If we are unable to raise additional
funds when necessary, we may have to reduce or discontinue development,
commercialization or clinical testing of some or all of our product candidates
or enter into financing arrangements on terms which we would not otherwise
accept.
WE HAVE HAD SIGNIFICANT LOSSES AND ANTICIPATE FUTURE LOSSES
We have experienced significant losses since inception. As of January 31,
1999, our accumulated deficit was approximately $84,429,000. We expect to incur
significant additional operating losses in the future and expect cumulative
losses to increase substantially due to expanded research and development
efforts, preclinical studies and clinical trials, and scale-up of manufacturing
4
<PAGE>
and product commercialization capabilities. We also expect losses to fluctuate
substantially from quarter to quarter. All of our products are currently in
development, preclinical studies or clinical trials, and no significant revenues
have been generated from product sales. To achieve and sustain profitable
operations, we must successfully develop and obtain regulatory approval for our
products, either alone or with others, and must also manufacture, introduce,
market and sell our products. The time frame necessary to achieve market success
for our products is long and uncertain. We do not expect to generate significant
product revenues for the next year. There can be no guarantee that we will ever
generate product revenues sufficient to become profitable or to sustain
profitability.
PROBLEMS IN PRODUCT DEVELOPMENT MAY CAUSE OUR CASH DEPLETION RATE TO INCREASE
Our ability to obtain financing and to manage expenses and our cash
depletion rate is the key to the continued development of product candidates and
the completion of ongoing clinical trials. Our cash depletion rate will vary
substantially from quarter to quarter as we fund non-recurring items associated
with clinical trials, product development, antibody manufacturing and facility
expansion and scale-up, patent legal fees and various consulting fees. We have
limited experience with clinical trials and if we encounter unexpected
difficulties with our operations or clinical trials, we may have to expend
additional funds, which would increase our cash depletion rate.
OUR PRODUCT DEVELOPMENT AND COMMERCIALIZATION EFFORTS MAY NOT BE SUCCESSFUL
Since inception, we have been engaged in the development of drugs and
related therapies for the treatment of people with cancer. Our product
candidates, which have not received regulatory approval, are generally in the
early stages of development. If the initial results from any of the clinical
trials are poor, those results will adversely effect our ability to raise
additional capital, which will affect our ability to continue full-scale
research and development for our antibody technologies. In addition, product
candidates resulting from our research and development efforts, if any, are not
expected to be available commercially for at least the next year. Our products
currently in clinical trials represent a departure from more commonly used
methods for cancer treatment. These products, if approved, may experience
under-utilization by doctors who are unfamiliar with their application in the
treatment of cancer. As with any new drug, doctors may be inclined to continue
to treat patients with conventional therapies, in most cases chemotherapy,
rather than new alternative therapies. We or our marketing partner may be
required to implement an aggressive education and promotion plan with doctors in
order to gain market recognition, understanding and acceptance of our products.
Market acceptance could also be affected by the availability of third party
reimbursement. Accordingly, we cannot guarantee that our product development
efforts, including clinical trials, or commercialization efforts will be
successful or that any of our products, if approved, can be successfully
marketed.
WE MAY NOT BE ABLE TO SCALE-UP OUR FACILITIES TO IMPLEMENT COMMERCIAL PRODUCTION
OF OUR PRODUCTS
In order to conduct clinical trials on a timely basis, obtain regulatory
approval and be commercially successful, we must scale-up our manufacturing and
product commercialization processes so that our product candidates, if approved,
can be manufactured and produced in commercial quantities. To date, we have
expended significant funds for the scale-up of our antibody manufacturing
capabilities for clinical trial requirements for two of our product candidates
and for refinement of the production processes. We intend to use existing
antibody manufacturing capacity to meet the clinical trial requirements for
these two product candidates and to support the initial commercialization of
these product candidates, if approved. In order to provide additional capacity,
we must successfully negotiate agreements with contract antibody manufacturers
to have these products produced, the cost of which is estimated to be several
million dollars in start-up costs and additional production costs on a "per run
5
<PAGE>
basis". Such contracts would also require an additional investment estimated at
five to nine million dollars over the next two years for required equipment and
related production area enhancements, and for vendor services associated with
technology transfer assistance, scale-up and production start-up, and for
regulatory assistance. We have limited manufacturing experience, and cannot make
any guarantee as to our ability to scale-up our manufacturing operations, the
suitability of our present facility for clinical trial production or commercial
production, our ability to make a successful transition to commercial production
or our ability to reach an acceptable agreement with one or more contract
manufacturers to produce any of our other product candidates, if approved, in
clinical or commercial quantities.
OUR TECHNOLOGY AND PRODUCTS MAY PROVE INEFFECTIVE OR BE TOO EXPENSIVE TO MARKET
SUCCESSFULLY
Our future success is significantly dependent on our ability to develop and
test workable products for which we will seek approval from the United States
Food & Drug Administration to market to certain defined patient groups. There is
a significant risk as to the performance and commercial success of our
technology and products. The products we are currently developing will require
significant additional laboratory and clinical testing and investment over the
foreseeable future. Although we are optimistic that we will be able to complete
development of one or more products, our proposed products may not prove to be
effective in clinical trials or they may cause harmful side effects during
clinical trials. In addition, our product candidates, if approved, may prove
impracticable to manufacture in commercial quantities at a reasonable cost
and/or with acceptable quality. Any of these factors could negatively affect our
financial position and results of operations.
OUR DEPENDENCY ON A LIMITED NUMBER OF SUPPLIERS MAY NEGATIVELY IMPACT OUR
ABILITY TO COMPLETE CLINICAL TRIALS AND MARKET OUR PRODUCTS
We currently procure, and intend in the future to procure, our antibody and
radioactive isotope combination services pursuant to negotiated contracts with
two domestic entities, one Canadian entity and one European entity. We cannot
guarantee that these suppliers will be able to qualify their facilities or label
and supply antibody in a timely manner, if at all. Prior to commercial
distribution of any of our products, if approved, we will be required to
identify and contract with a commercial company for commercial antibody and
radioactive isotope combination services. We are presently in discussions with a
few companies to provide commercial antibody and radioactive isotope combination
services. We also currently rely on, and expect in the future to rely on, our
current suppliers for all or a significant portion of our requirements for our
antibody products. Antibody that has been combined with a radioactive isotope
cannot be stockpiled against future shortages. Accordingly, any change in our
existing or future contractual relationships with, or an interruption in supply
from, any such third-party service provider or antibody supplier could
negatively impact our ability to complete ongoing clinical trials and to market
our products, if approved.
WE DO NOT HAVE A SALES FORCE TO MARKET OUR PRODUCTS
At the present time, we do not have a sales force to market any of our
products, if and when they are approved. We intend to sell our products in the
United States and internationally in collaboration with one or more marketing
partners. If and when we receive approval from the United States Food & Drug
Administration for our initial product candidates, the marketing of these
products will be contingent upon our ability to either license or enter into a
marketing agreement with a large company or our ability to recruit, develop,
train and deploy our own sales force. We do not presently possess the resources
or experience necessary to market any of our product candidates. Other than an
6
<PAGE>
agreement with Schering A.G., Germany with respect to the marketing of our
direct tumor targeting agent product, Oncolym(R), we presently have no
agreements for the licensing or marketing of our product candidates, and we
cannot assure you that we will be able to enter into any such agreements in a
timely manner or on commercially favorable terms, if at all. Development of an
effective sales force requires significant financial resources, time and
expertise. We cannot assure you that we will be able to obtain the financing
necessary to establish such a sales force in a timely or cost effective manner,
if at all, or that such a sales force will be capable of generating demand for
our product candidates, if and when they are approved.
WE MAINTAIN ONLY LIMITED PRODUCT LIABILITY INSURANCE AND MAY BE EXPOSED TO
CLAIMS IF OUR INSURANCE COVERAGE IS INSUFFICIENT
The manufacture and sale of human therapeutic products involves an inherent
risk of product liability claims. We maintain only limited product liability
insurance. We cannot assure you that we will be able to maintain existing
insurance or obtain additional product liability insurance on acceptable terms
or with adequate coverage against potential liabilities. Product liability
insurance is expensive, difficult to obtain and may not be available in the
future on acceptable terms, if at all. Our inability to obtain sufficient
insurance coverage on reasonable terms or to otherwise protect against potential
product liability claims in excess of our insurance coverage, if any, or a
product recall could negatively impact our financial position and results of
operations.
EARTHQUAKES MAY DAMAGE OUR FACILITIES
Our corporate and research facilities, where the majority of our research
and development activities are conducted, are located near major earthquake
faults which have experienced earthquakes in the past. Although we carry limited
earthquake insurance, in the event of a major earthquake or other disaster in or
near the greater Southern California area, our facilities may sustain
significant damage and our operations would be negatively affected.
THE LIQUIDITY OF OUR COMMON STOCK MAY BE ADVERSELY AFFECTED IF OUR COMMON STOCK
IS DELISTED FROM THE NASDAQ SMALLCAP MARKET
The Common Stock is presently traded on The Nasdaq SmallCap Market. To
maintain inclusion on The Nasdaq SmallCap Market, we must continue to have
either net tangible assets of at least $2,000,000, market capitalization of at
least $35,000,000, or net income (in either our latest fiscal year or in two of
our last three fiscal years) of at least $500,000. In addition, we must meet
other requirements, including, but not limited to, having a public float of at
least 500,000 shares and $1,000,000, a minimum closing bid price of $1.00 per
share of Common Stock (without falling below this minimum bid price for a period
of 30 consecutive trading days), at least two market makers and at least 300
stockholders, each holding at least 100 shares of Common Stock. At various
times, we have failed to maintain a $1.00 minimum closing bid price for extended
periods of time and expect the closing bid price of the Common Stock to fall
below the $1.00 minimum bid requirement from time to time in the future. As of
April 28, 1999, we have failed to maintain a $1.00 minimum closing bid price for
17 consecutive trading days. If we fail to meet the minimum closing bid price of
$1.00 for a period of 30 consecutive trading days, we will be notified by The
Nasdaq Stock Market and will then have a period of 90 calendar days from such
notification to achieve compliance with the applicable standard by meeting the
minimum closing bid price requirement for at least 10 consecutive trading days
during such 90 day period. We cannot guarantee that we will be able to maintain
these requirements in the future. If we fail to meet any of The Nasdaq SmallCap
Market listing requirements, the market value of the Common Stock could fall and
holders of Common Stock would likely find it more difficult to dispose of the
Common Stock. In addition, if the minimum closing bid price of the Common Stock
is not at least $1.00 per share for 10 consecutive trading days before we make a
call for proceeds under our Regulation D Common Stock Equity Line Subscription
Agreement with two institutional investors or if the Common Stock ceases to be
included on The Nasdaq SmallCap Market, we would have limited or no access to
funds under the Regulation D Common Stock Equity Line Subscription Agreement.
7
<PAGE>
Moreover, should the market price of the Common Stock fall significantly, we
would be required to issue to the two institutional investors a much greater
number of shares than we would otherwise if the market price were stable or
rising, which could cause the market price of the Common Stock to fall further
and faster. In addition, the Company and broker-dealers effecting transactions
in the Common Stock may become subject to additional disclosure and reporting
requirements applicable to low-priced securities, which may reduce the level of
trading activity in the secondary market for the Common Stock and limit or
prevent investors from readily selling their shares of Common Stock.
THE SALE OF SUBSTANTIAL SHARES OF OUR COMMON STOCK MAY DEPRESS OUR STOCK PRICE
As of April 23, 1999, we had approximately 73,352,000 shares of Common
Stock outstanding. We are also obligated to issue up to an additional
approximately 289,000 shares of Common Stock upon conversion of outstanding
shares of our 5% Adjustable Convertible Class C Preferred Stock and exercise of
related warrants, up to an additional approximately 23,000,000 shares of Common
Stock pursuant to our Regulation D Common Stock Equity Line Subscription
Agreement with two institutional investors and a related Placement Agent
Agreement and upon exercise of related warrants related thereto and an
additional approximately 12,780,000 shares of Common Stock pursuant to other
outstanding options and other warrants. The conversion rate applicable to our
Class C Preferred Stock and the purchase price for the shares of Common Stock to
be issued pursuant to the Regulation D Common Stock Equity Line Subscription
Agreement, and the exercise price of the warrants related thereto, are at a
significant discount to the market price of the Common Stock. The sale and
issuance of these shares of Common Stock, as well as subsequent sales of shares
of Common Stock in the open market, may cause the market price of the Common
Stock to fall and might impair our ability to raise additional capital through
sales of equity or equity-related securities, whether pursuant to the Regulation
D Common Stock Equity Line Subscription Agreement or otherwise. See "The Equity
Line Agreement."
OUR HIGHLY VOLATILE STOCK PRICE AND TRADING VOLUME MAY ADVERSELY AFFECT THE
LIQUIDITY OF THE COMMON STOCK
The market price of the Common Stock, and the market prices of securities
of companies in the biotechnology industry generally, have been highly volatile
and is likely to continue to be highly volatile. Also, the trading volume in the
Common Stock has been highly volatile, ranging from as few as 89,000 shares per
day to as many as 19 million shares per day over the past year, and is likely to
continue to be highly volatile. The market price of the Common Stock may be
significantly impacted by many factors, including announcements of technological
innovations or new commercial products by us or our competitors, disputes
concerning patent or proprietary rights, publicity regarding actual or potential
medical results relating to products under development by us or our competitors
and regulatory developments and product safety concerns in both the United
States and foreign countries. These and other external factors have caused and
may continue to cause the market price and demand for the Common Stock to
fluctuate substantially, which may limit or prevent investors from readily
selling their shares of Common Stock and may otherwise negatively affect the
liquidity of the Common Stock.
WE MAY NOT BE ABLE TO COMPETE WITH OUR COMPETITORS IN THE BIOTECHNOLOGY INDUSTRY
The biotechnology industry is intensely competitive. It is also subject to
rapid change and sensitive to new product introductions or enhancements. We
expect to continue to experience significant and increasing levels of
competition in the future. Virtually all of our existing competitors have
greater financial resources, larger technical staffs, and larger research
budgets than we have, as well as greater experience in developing products and
running clinical trials. Two of our competitors, Idec Pharmaceuticals
Corporation and Coulter Pharmaceuticals, Inc., each has a lymphoma antibody that
may compete with our direct tumor targeting agent product, Oncolym(R). Idec
8
<PAGE>
Pharmaceuticals Corporation is currently marketing its lymphoma product for low
grade non-Hodgkins lymphoma and we believe that Coulter Pharmaceuticals, Inc.
will be marketing its respective lymphoma product prior to the time our
Oncolym(R) product will be submitted to the United States Food & Drug
Administration for marketing approval. Coulter Pharmaceuticals, Inc. has also
announced that it intends to seek to conduct clinical trials of its antibody
treatment for intermediate and/or high grade non-Hodgkins lymphomas. In
addition, there may be other companies which are currently developing
competitive technologies and products or which may in the future develop
technologies and products which are comparable or superior to our technologies
and products. Some or all of these companies may also have greater financial and
technical resources than we have. Accordingly, we cannot assure you that we will
be able to compete successfully with our existing and future competitors or that
competition will not negatively affect our financial position or results of
operations in the future.
WE MAY NOT BE SUCCESSFUL IF WE ARE UNABLE TO OBTAIN AND MAINTAIN PATENTS AND
LICENSES TO PATENTS
Our success depends, in large part, on our ability to obtain or maintain a
proprietary position in our products through patents, trade secrets and orphan
drug designations. We have been granted several United States patents and have
submitted several United States patent applications and numerous corresponding
foreign patent applications, and have also obtained licenses to patents or
patent applications owned by other entities. However, we cannot assure you that
any of these patent applications will be granted or that our patent licensors
will not terminate any of our patent licenses. We also cannot guarantee that any
issued patents will provide competitive advantages for our products or that any
issued patents will not be successfully challenged or circumvented by our
competitors. Although we believe that our patents and our licensors' patents do
not infringe on any third party's patents, we cannot be certain that we can
avoid litigation involving such patents or other proprietary rights. Patent and
proprietary rights litigation entails substantial legal and other costs, and we
may not have the necessary financial resources to defend or prosecute our rights
in connection with any litigation. Responding to, defending or bringing claims
related to patents and other intellectual property rights may require our
management to redirect our human and monetary resources to address these claims
and may take years to resolve.
OUR PRODUCT DEVELOPMENT AND COMMERCIALIZATION EFFORTS MAY BE REDUCED OR
DISCONTINUED DUE TO DIFFICULTIES OR DELAYS IN CLINICAL TRIALS
We may encounter unanticipated problems, including development,
manufacturing, distribution, financing and marketing difficulties, during the
product development, approval and commercialization process. Our product
candidates may take longer than anticipated to progress through clinical trials
or patient enrollment in the clinical trials may be delayed or prolonged
significantly, thus delaying the clinical trials. Delays in patient enrollment
will result in increased costs and further delays. If we experience any such
difficulties or delays, we may have to reduce or discontinue development,
commercialization or clinical testing of some or all of our product candidates.
OUR PRODUCT DEVELOPMENT AND COMMERCIALIZATION EFFORTS MAY BE REDUCED OR
DISCONTINUED DUE TO DELAYS OR FAILURE IN OBTAINING REGULATORY APPROVALS
We will need to do substantial additional development and clinical testing
prior to seeking any regulatory approval for commercialization of our product
candidates. Testing, manufacturing, commercialization, advertising, promotion,
export and marketing, among other things, of our proposed products are subject
to extensive regulation by governmental authorities in the United States and
other countries. The testing and approval process requires substantial time,
effort and financial resources and we cannot guarantee that any approval will be
granted on a timely basis, if at all. Companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in conducting
advanced human clinical trials, even after obtaining promising results in
9
<PAGE>
earlier trials. Furthermore, the United States Food & Drug Administration may
suspend clinical trials at any time on various grounds, including a finding that
the subjects or patients are being exposed to an unacceptable health risk. Also,
even if regulatory approval of a product is granted, such approval may entail
limitations on the indicated uses for which it may be marketed. Accordingly, we
may experience difficulties and delays in obtaining necessary governmental
clearances and approvals to market our products, and we may not be able to
obtain all necessary governmental clearances and approvals to market our
products. At least initially, we intend, to the extent possible, to rely on
licensees to obtain regulatory approval for marketing our products. The failure
by us or our licensees to adequately demonstrate the safety and efficacy of any
of our product candidates under development could delay, limit or prevent
regulatory approval of the product, which may require us to reduce or
discontinue development, commercialization or clinical testing of some or all of
our product candidates.
OUR PRODUCTS, IF APPROVED, MAY NOT BE COMMERCIALLY VIABLE DUE TO HEALTH CARE
REFORM AND THIRD-PARTY REIMBURSEMENT LIMITATIONS
Recent initiatives to reduce the federal deficit and to reform health care
delivery are increasing cost-containment efforts. We anticipate that Congress,
state legislatures and the private sector will continue to review and assess
alternative benefits, controls on health care spending through limitations on
the growth of private health insurance premiums and Medicare and Medicaid
spending, price controls on pharmaceuticals and other fundamental changes to the
health care delivery system. Legislative debate is expected to continue in the
future, and market forces are expected to drive reductions of health care costs.
Any such changes could negatively impact the commercial viability of our
products, if approved. Our ability to successfully commercialize our product
candidates, if and when they are approved, will depend in part on the extent to
which appropriate reimbursement codes and authorized cost reimbursement levels
of such products and related treatment are obtained from governmental
authorities, private health insurers and other organizations, such as health
maintenance organizations. In the absence of national Medicare coverage
determination, local contractors that administer the Medicare program, within
certain guidelines, can make their own coverage decisions. Accordingly, there
can be no assurance that any of our product candidates, if approved and when
commercially available, will be included within the then current Medicare
coverage determination or the coverage determination of state Medicaid programs,
private insurance companies and other health care providers. In addition,
third-party payers are increasingly challenging the prices charged for medical
products and services. Also, the trend toward managed health care and the growth
of health maintenance organizations in the United States may all result in lower
prices for our products, if approved and when commercially available, than we
currently expect. The cost containment measures that health care payers and
providers are instituting and the effect of any health care reform could
negatively affect our financial performance, if and when one or more of our
products are approved and available for commercial use.
OUR MANUFACTURING AND USE OF HAZARDOUS AND RADIOACTIVE MATERIALS MAY RESULT IN
OUR LIABILITY FOR DAMAGES, INCREASED COSTS AND INTERRUPTION OF ANTIBODY
SUPPLIES
The manufacturing and use of our products require the handling and disposal
of the radioactive isotope I131. We currently rely on, and intend in the future
to rely on, our current contract manufacturers to combine antibodies with
radioactive I131 isotope in our products and to comply with various local, state
and or national and international regulations regarding the handling and use of
radioactive materials. Violation of these local, state, national or
international regulations by these companies or a clinical trial site could
significantly delay completion of the trials. Violations of safety regulations
could occur with these manufacturers, so there is also a risk of accidental
contamination or injury. Accordingly, we could be held liable for any damages
that result from an accident, contamination or injury caused by the handling and
disposal of these materials, as well as for unexpected remedial costs and
10
<PAGE>
penalties that may result from any violation of applicable regulations. In
addition, we may incur substantial costs to comply with environmental
regulations. In the event of any noncompliance or accident, the supply of
antibodies for use in clinical trials or commercial products could also be
interrupted.
OUR OPERATIONS AND FINANCIAL PERFORMANCE COULD BE NEGATIVELY AFFECTED IF WE
CANNOT ATTRACT AND RETAIN KEY PERSONNEL
Our success is dependent, in part, upon a limited number of key executive
officers and technical personnel remaining employed with us, including Larry O.
Bymaster, our President and Chief Executive Officer, Steven C. Burke, our Chief
Financial Officer, and Dr. John Bonfiglio, our Vice President of Business
Development and interim Vice President of Clinical and Regulatory Affairs. We
also believe that our future success will depend largely upon our ability to
attract and retain highly-skilled research and development and technical
personnel. We face intense competition in our recruiting activities, including
larger companies with greater resources. We do not know if we will be successful
in attracting or retaining skilled personnel. The loss of certain key employees
or our inability to attract and retain other qualified employees could
negatively affect our operations and financial performance.
OUR BUSINESS MAY BE ADVERSELY EFFECTED IF OUR COMPUTER SYSTEMS AND THE COMPUTER
SYSTEMS OF OUR SUPPLIERS ARE NOT YEAR 2000 COMPLIANT
We are aware of the issues associated with the programming code in existing
computer systems as the year 2000 approaches. The year 2000 problem is pervasive
and complex. The issue is whether computer systems will properly recognize date-
sensitive information in the year 2000 due to the fact that the programming in
most computer systems use a two digit year value, which value will rollover to
"00" as of January 1, 2000. Systems that do not properly recognize such
information could generate erroneous data or cause a system to fail. We have
identified substantially all of our major hardware and software platforms in use
and have modified and upgraded our hardware, software and information technology
and other systems to be year 2000 compliant. We do not presently believe that
the year 2000 problem will pose significant operational problems for our
internal computer systems or have a negative affect on our operations. However,
we cannot assure you that any year 2000 compliance problems of our suppliers
will not negatively affect our operations. Because uncertainty exists concerning
the potential costs and effects associated with any year 2000 compliance, we
intend to continue to make efforts to ensure that third parties with whom we
have relationships are year 2000 compliant. We have not incurred significant
costs to date associated with year 2000 compliance and presently believe
estimated future costs will not be material. However, actual results could
differ materially from our expectations due to unanticipated technological
difficulties or project delays. If we or any third parties upon which we rely
are unable to address the year 2000 issue in a timely manner, it could have an
adverse impact on our operations. In order to assure that this does not occur,
we have developed a contingency plan and intend to devote all resources required
to attempt to resolve any significant year 2000 problems in a timely manner.
11
<PAGE>
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference" into this Prospectus the
documents we file with them, which means that we can disclose important
information to you by referring you to these documents. The information that we
incorporate by reference into this Prospectus is considered to be part of this
Prospectus, and information that we file later with the SEC automatically
updates and supersedes any information in this Prospectus. We incorporate by
reference into this Prospectus the documents listed below:
o Annual Report on Form 10-K for the fiscal year ended April 30,
1998, as filed with the SEC on July 29, 1998 pursuant to Section
13(a) of the Securities Exchange Act of 1934, as amended
("Exchange Act");
o Definitive Proxy Statement with respect to the Annual Meeting of
Stockholders held on October 13, 1998, as filed with the SEC on
August 27, 1998;
o Quarterly Report on Form 10-Q for the quarter ended July 31,
1998, as filed with the SEC on September 14, 1998;
o Quarterly Report on Form 10-Q for the quarter ended October 31,
1998, as filed with the SEC on December 15, 1998;
o Quarterly Report on Form 10-Q for the quarter ended January 31,
1999, as filed with the SEC on March 12, 1999;
o Current Report on Form 8-K, as filed with the SEC on April 16,
1999;
o Current Report on Form 8-K, as filed with the SEC on March 18,
1999;
o Current Report on Form 8-K, as filed with the SEC on January 7,
1999;
o Current Report on Form 8-K, as filed with the SEC on June 29,
1998;
o Current Report on Form 8-K, as filed with the SEC on March 9,
1998;
o Current Report on Form 8-K, as filed with the SEC on November 24,
1997;
o Current Report on Form 8-K, as filed with the SEC on May 12,
1997, as amended by Form 8-K/A Amendment No. 1 to such Form 8-K
as filed with the SEC on October 2, 1997, and as further amended
by Form 8-K/A Amendment No. 2 to such Form 8-K as filed with the
SEC on October 14, 1997;
o Definitive Proxy Statement with respect to a Special Meeting of
Stockholders held on April 23, 1998, as filed with the SEC on
March 17, 1998;
o The description of the Company's Common Stock contained in the
Company's Registration Statement on Form 8-A and Form 8-B
(Registration of Successor Issuers) filed under the Exchange Act,
including any amendment or report filed for the purpose of
updating such description; and
o All other reports filed by the Company pursuant to Section 13(a)
or 15(d) of the Exchange Act since the end of the Company's
fiscal year ended April 30, 1998.
All documents we have filed with the SEC pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act subsequent to the date of this Prospectus and
prior to the filing of a post-effective amendment indicating that all securities
offered have been sold (or which re-registers all securities then remaining
unsold), are deemed to be incorporated herein by this reference and to be made a
part hereof from the date of filing of such documents.
We will provide, without charge, upon written or oral request of any person
to whom a copy of this Prospectus is delivered, a copy of any or all of the
foregoing documents and information that has been or may be incorporated by
reference herein (other than exhibits to such documents). Requests for such
documents and information should be directed to Techniclone Corporation,
Attention: Steven C. Burke, Chief Financial Officer, 14282 Franklin Avenue,
Tustin, California 92780-7017, telephone number (714) 508-6000.
12
<PAGE>
THE EQUITY LINE AGREEMENT
On June 16, 1998, Techniclone entered into a Regulation D Common Stock
Equity Line Subscription Agreement with two institutional investors, pursuant to
which Techniclone may issue and sell, from time to time, shares of its Common
Stock for cash consideration up to an aggregate of $20 million. Techniclone also
entered into a Placement Agent Agreement with Swartz Investments, LLC, a Georgia
limited liability company doing business as Swartz Institutional Finance,
whereby Techniclone engaged the services of Swartz Investments, LLC as placement
agent in connection with the placement of securities of Techniclone with the two
institutional investors pursuant to the Regulation D Common Stock Equity Line
Subscription Agreement. Swartz Investments, LLC subsequently assigned and
conveyed all of its rights under the Placement Agent Agreement and a related
Registration Rights Agreement to Dunwoody Brokerage Services, Inc. and also
transferred to Dunwoody Brokerage Services, Inc. all of the shares of Common
Stock and warrants to purchase shares of Common Stock previously issued to
Swartz Investments, LLC. Dunwoody Brokerage Services, Inc. is a broker-dealer
registered with the SEC and the National Association of Securities Dealers, Inc.
with respect to which Swartz Investments, LLC is an Office of Supervisory
Jurisdiction (OSJ).
The following table sets forth certain information as of April 23, 1999,
with respect to securities of Techniclone issued to the two institutional
investors and Dunwoody Brokerage Services, Inc. pursuant to the Regulation D
Common Stock Equity Line Subscription Agreement and the Placement Agent
Agreement:
<TABLE>
<CAPTION>
Shares of Shares subject Shares of Shares subject
Common Stock to Warrants Common Stock to Warrants
Issued to the Issued to the Issued to Dun- Issued to Dun-
Amount Institutional Institutional woody Brokerage woody Brokerage
Date Funded Investors Investors(1) Services, Inc. Services, Inc.(1)
- --------------- ---------- -------------- -------------- --------------- -----------------
<S> <C> <C> <C> <C> <C>
June 16, 1998 $3,500,000 2,545,454(2) 254,454(3) 203,636 20,363(3)
Dec. 24, 1998 96,055(4) 60,515(4) 5,091(3)
Feb. 2, 1999 $2,250,000 2,608,695(5) 260,868(6) 260,869 26,086(6)
April 15, 1999 801,347(7) 80,134(7)
</TABLE>
- ----------------
(1) Warrants are exercisable, on a cashless basis only, at any time through
December 31, 2004.
(2) Purchase price of $1.375 per share. Subject to adjustment on or about July
15, 1999, if the 10-day low closing bid price immediately preceding such
date is less than $1.375 per share, which will obligate Techniclone to
issue a number of additional shares of Common Stock equal to the difference
between the amount of shares which would have been issued for $1,750,000
(half of $3,500,000) if the purchase price had been the 10-day low closing
bid price immediately preceding such date for $1,750,000 and one-half of
the amount of shares actually issued (1,272,727 shares).
(3) Exercise price of $1.375 per share.
(4) Issued pursuant to a separate agreement between Techniclone and the two
institutional investors.
(5) Purchase price of $0.8625 per share.
(6) Exercise price of $0.8625 per share.
(7) Issued in connection with an adjustment on or about April 15, 1999 to the
purchase price for one-half of the initial shares sold to the two
institutional investors on or about June 16, 1998, pursuant to the terms of
the Regulation D Common Stock Equity Line Subscription Agreement.
13
<PAGE>
Pursuant to the terms of the Regulation D Common Stock Equity Line
Subscription Agreement, Techniclone may from time to time until June 16, 2001,
in its sole discretion and subject to certain restrictions and limitations set
forth in the Regulation D Common Stock Equity Line Subscription Agreement, sell
to the two institutional investors, no more than one time during any monthly
period upon written notice given by Techniclone to the two institutional
investors, a number of shares of Common Stock equal to up to $2,250,000 (which
amount may be increased up to $5,000,000 by mutual agreement of the parties)
less the aggregate dollar amount of any shares sold to the two institutional
investors during the three month period immediately preceding the date on which
such notice is given. The purchase price for the shares to be sold to the
institutional investors is equal to 82.5% of the 10-day low closing bid price
immediately preceding such Notice Date, or, if 82.5% of such 10-day low closing
bid price results in a discount of less than twenty cents ($0.20) per share from
such 10-day low closing bid price, a purchase price per share equal to such
10-day low closing bid price minus twenty cents ($0.20). The number of such
shares which may be sold to the two institutional investors at any one time is
limited to the same number of shares of restricted securities that the
institutional investors would otherwise be able to sell pursuant to Rule 144(e)
promulgated under the Securities Act of 1933, and is also subject to a maximum
dollar amount of $14,250,000 as of the date of this Prospectus. In addition, at
the time of each sale of shares of Common Stock, the two institutional investors
will be issued warrants, expiring on December 31, 2004, to purchase a number of
shares of Common Stock equal to 10% of the number of shares of Common Stock sold
in such sale at an exercise price equal to the price per share at which such
shares were sold to the institutional investors. If Techniclone has not fully
utilized the relevant commitment amount under the Regulation D Common Stock
Equity Line Subscription Agreement, Techniclone may also be obligated to issue
to the two institutional investors on June 23, 1999, June 23, 2000 and June 23,
2001, warrants to purchase a number of shares of Common Stock equal to 10% of an
amount equal to the difference of the relevant minimum commitment amount
($6,666,667 for 1999, $13,333,333 for 2000 and $20,000,000 for 2001) minus the
aggregate amount of Common Stock sold to the institutional investors during all
years preceding such date, divided by the 10-day low closing bid price of the
Common Stock immediately preceding such date, at an exercise price equal to the
10-day low closing bid price of the Common Stock immediately preceding such
date.
Pursuant to the terms of the Placement Agent Agreement, Dunwoody Brokerage
Services, Inc. is entitled to receive the following compensation as a placement
agent fee in connection with the placement and sale of securities of Techniclone
to the two institutional investors:
o a cash placement fee equal to seven percent (7%) of the purchase price
of any and all securities placed pursuant to the Regulation D Common
Stock Equity Line Subscription Agreement;
o a non-accountable expense allowance equal to one percent (1%) of the
purchase price of any and all securities placed up to the aggregate
purchase price of the first $10 million of securities placed pursuant
to the Regulation D Common Stock Equity Line Subscription Agreement;
o a one time non-accountable expenses allowance equal to one hundred
thousand dollars for any and all securities placed in excess of the
aggregate purchase price of the first $10 million of securities placed
pursuant to the Regulation D Common Stock Equity Line Subscription
Agreement (such non-accountable expenses allowance to be paid upon
placement of any securities resulting in an aggregate purchase price in
excess of $10,100,000 placed pursuant to the Regulation D Common Stock
Equity Line Subscription Agreement); and
o an amount of securities equal to ten percent (10%) of all Common Stock
issued pursuant to the Regulation D Common Stock Equity Line
Subscription Agreement and an amount of securities equal to ten percent
(10%) of all warrants issued pursuant to the Regulation D Common Stock
Equity Line Subscription Agreement.
14
<PAGE>
Techniclone's ability to require the two institutional investors to
purchase shares of its Common Stock under the Regulation D Common Stock Equity
Line Subscription Agreement is subject to certain conditions and limitations,
including:
o the representations and warranties of Techniclone set forth in the
Regulation D Common Stock Equity Line Subscription Agreement must be
true and correct in all material respects as of the date of each sale;
o Techniclone shall have performed and complied with all obligations
under the Regulation D Common Stock Equity Line Subscription Agreement,
the Registration Rights Agreement and the warrants issued to the two
institutional investors required to be performed as of the date of each
sale;
o no statute, rule, regulation, executive order, decree, ruling or
injunction shall be in effect which prohibits or directly and adversely
affects any of the transactions contemplated by the Regulation D Common
Stock Equity Line Subscription Agreement;
o at the time of a sale, there shall have been no material adverse change
in Techniclone's business prospects or financial condition, except as
disclosed in Techniclone's most recent periodic reports filed since
June 16, 1998 with the SEC pursuant to the Exchange Act of 1934, as
amended;
o Techniclone's Common Stock shall not have been delisted from The Nasdaq
SmallCap Market nor suspended from trading;
o the closing bid price of the Common Stock on any trading during the ten
days preceding the date of the sale cannot be less than or equal to
$0.50; and
o if the closing bid price of the Common Stock on any trading day during
the ten trading days preceding the date of the sale is less than $1.00
but greater than $0.50, Techniclone may only require the purchase by
the two institutional investors of an amount of shares not greater than
15% of the amount that would otherwise be available to Techniclone
pursuant to the terms of the Regulation D Common Stock Equity Line
Subscription Agreement.
Pursuant to the requirements of the Placement Agent Agreement and a related
Registration Rights Agreement dated as of June 16, 1998, between Techniclone,
the two institutional investors and Dunwoody Brokerage Services, Inc., as
successor in interest to Swartz Investments, LLC, Techniclone has filed a
registration statement, of which this Prospectus forms a part, in order to
permit Dunwoody Brokerage Services, Inc. to resell to the public the shares of
Common Stock issued and issuable to Dunwoody Brokerage Services, Inc. pursuant
to the Placement Agent Agreement and any shares of Common Stock that Dunwoody
Brokerage Services, Inc. may acquire upon exercise of warrants issued and
issuable to Dunwoody Brokerage Services, Inc. pursuant to the Placement Agent
Agreement.
The two institutional investors and Dunwoody Brokerage Services, Inc. have
agreed that they will not create or increase a net short position with respect
to the Common Stock during the ten trading days prior to any sale of shares of
Common Stock to the institutional investors or during the thirty calendar days
prior to July 15, 1999. The two institutional investors and Dunwoody Brokerage
Services, Inc. have further agreed that they will not engage in any trading
practice or activity for the purpose of manipulating the price of the Common
Stock or otherwise engage in any trading practice or activity that violates the
rules and regulations of the SEC.
USE OF PROCEEDS
The proceeds from the sale of the shares of Common Stock offered hereby
will be received directly by Dunwoody Brokerage Services, Inc. Techniclone will
not receive any proceeds from the sale of the shares of Common Stock offered
hereby. Techniclone will not receive any proceeds from the exercise of any
warrants by Dunwoody Brokerage Services, Inc., which may only be exercised
pursuant to a cashless exercise by Dunwoody Brokerage Services, Inc.
15
<PAGE>
DUNWOODY BROKERAGE SERVICES, INC. - THE SELLING STOCKHOLDER
Dunwoody Brokerage Services, Inc. may, from time to time, offer and sell
any or all of the shares of Common Stock offered by this Prospectus. All of the
shares of Common Stock offered pursuant to this Prospectus are offered by
Dunwoody Brokerage Services, Inc. Any sales will be for the account of Dunwoody
Brokerage Services, Inc. and Techniclone will not receive any of the proceeds
from the sale of the Shares by Dunwoody Brokerage Services, Inc. The following
table sets forth certain information as of April 23, 1999, with respect to
Dunwoody Brokerage Services, Inc.
<TABLE>
<CAPTION>
MAXIMUM NUMBER
SHARES BENEFICIALLY OF SHARES TO BE SOLD SHARES BENEFICIALLY
OWNED PRIOR TO OFFERING(1) PURSUANT TO THIS PROSPECTUS OWNED AFTER OFFERING(2)
NAME OF -------------------------- --------------------------- -----------------------
REGISTERED STOCKHOLDER NUMBER PERCENT NUMBER PERCENT
- ---------------------- ------ ------- ------ -------
<S> <C> <C> <C> <C> <C>
Dunwoody Brokerage
Services, Inc.(3). 2,663,796 3.6% 2,663,796 0 0.0%
8309 Dunwoody Place
Atlanta, GA 30350
</TABLE>
- --------------
(1) Includes (solely for purposes of this Prospectus, and assuming a 10-day low
closing bid price of not less than $1.00 per share, which allows
Techniclone to sell the maximum number of shares of Common Stock to the two
institutional investors under the terms of the Regulation D Common Stock
Equity Line Subscription Agreement) up to an aggregate of 2,007,102 shares
of Common Stock that may be acquired by Dunwoody Brokerage Services, Inc.
pursuant to the Placement Agent Agreement in connection with the issuance
and sale of shares of Common Stock to the two institutional investors
pursuant to the Regulation D Common Stock Equity Line Subscription
Agreement (including up to 178,125 shares of Common Stock issuable upon the
exercise of warrants that may be issued to Dunwoody Brokerage Services,
Inc.). See "The Equity Line Agreement." Based on an aggregate of 73,352,205
shares of Common Stock issued and outstanding as of April 23, 1999.
(2) Assumes that all of the Shares are sold pursuant to this Prospectus.
(3) As of the date of this Prospectus, Dunwoody Brokerage Services, Inc. owns
656,694 shares of Common Stock, including 51,540 shares of Common Stock
issuable upon exercise of outstanding warrants which are currently
exercisable, which represents less than 1% of the issued outstanding Common
Stock as of April 23, 1999. Also includes (solely for purposes of this
Prospectus, and assuming a 10-day low closing bid price of not less than
$1.00 per share, which allows Techniclone to sell the maximum number of
shares of Common Stock to the two institutional investors under the terms
of the Regulation D Common Stock Equity Line Subscription Agreement) up to
an aggregate of 2,007,102 shares of Common Stock that may be acquired by
Dunwoody Brokerage Services, Inc. pursuant to the Placement Agent Agreement
in connection with the issuance and sale of shares of Common Stock to the
two institutional investors pursuant to the Regulation D Common Stock
Equity Line Subscription Agreement (including up to 178,125 shares of
Common Stock issuable upon the exercise of warrants that may be issued to
Dunwoody Brokerage Services, Inc.). See "The Equity Line Agreement."
Dunwoody Brokerage Services, Inc. has not had any material relationship
with Techniclone or any of its affiliates within the past three years other than
as a result of the ownership of securities of Techniclone, through the placement
by Dunwoody Brokerage Services, Inc. or its affiliates of securities of
Techniclone or as a result of the negotiation and the execution of the Placement
Agent Agreement and the Regulation D Common Stock Equity Line Subscription
Agreement. The natural persons controlling Dunwoody Brokerage Services, Inc. are
Robert L. Hopkins and Dwight B. Bronnum.
16
<PAGE>
The shares of Common Stock offered hereby by Dunwoody Brokerage Services,
Inc. were or will be acquired pursuant to the Placement Agent Agreement or upon
exercise of warrants issued to Dunwoody Brokerage Services, Inc. Of the
2,663,796 shares of Common Stock offered by Dunwoody Brokerage Services, Inc.
pursuant to this Prospectus:
o 605,154 shares are currently issued and outstanding;
o up to 1,781,250 shares may be issued to Dunwoody Brokerage Services,
Inc. pursuant to the terms of the Placement Agent Agreement dated as of
June 16, 1998 between Techniclone and Dunwoody Brokerage Services,
Inc., as successor in interest to Swartz Investments LLC, a Georgia
limited liability company d/b/a Swartz Institutional Finance, in
connection with the issuance of shares of Common Stock to two
institutional investors pursuant to the terms of a Regulation D Common
Stock Equity Line Subscription Agreement dated as of June 16, 1998;
o up to an aggregate of 47,727 shares may be issued to Dunwoody Brokerage
Services, Inc. on or about July 15, 1999 upon adjustment of the
purchase price for the initial shares of Common Stock purchased by the
two institutional investors in June 1998, pursuant to the terms of the
Regulation D Common Stock Equity Line Subscription Agreement; and
o up to 25,454 shares may be issued to Dunwoody Brokerage Services, Inc.
upon exercise of outstanding warrants at an exercise price of $1.375
per share, up to 26,086 shares may be issued to Dunwoody Brokerage
Services, Inc. upon exercise of outstanding warrants at an exercise
price of $0.8625 per share, and up to an additional 178,125 shares may
be issued to Dunwoody Brokerage Services, Inc. upon exercise of
warrants issuable to Dunwoody Brokerage Services, Inc. pursuant to the
Placement Agent Agreement. See "The Equity Line Agreement."
Pursuant to the Placement Agent Agreement and the Registration Rights
Agreement, Techniclone agreed to register the shares of Common Stock offered
hereby under the Securities Act of 1933 for resale by Dunwoody Brokerage
Services, Inc. to permit their resale by Dunwoody Brokerage Services, Inc. from
time to time to the public without restriction. Techniclone will prepare and
file such amendments and supplements to the registration statement as may be
necessary in accordance with the rules and regulations of the Securities Act of
1933 to keep it effective until the earlier to occur of (i) the date as of which
all of the shares of Common Stock may be resold in a public transaction without
volume limitations or other material restrictions without registration under the
Securities Act of 1933, including without limitation, pursuant to Rule 144 under
the Securities Act of 1933 or (ii) the date as of which all of the shares of
Common Stock offered hereby have been resold.
Techniclone has agreed to pay the expenses (other than broker discounts and
commissions, if any) in connection with this Prospectus.
17
<PAGE>
PLAN OF DISTRIBUTION
Techniclone has been advised by Dunwoody Brokerage Services, Inc. that all
or a portion of the shares of Common Stock offered by this Prospectus may be
offered for sale, from time to time, by Dunwoody Brokerage Services, Inc. in one
or more private or negotiated transactions, in open market transactions on the
Nasdaq SmallCap Market, in settlement of short sale transactions, in settlement
of option transactions, or otherwise, or a combination of these methods, at
prices and terms then obtainable, at fixed prices, at prices then prevailing at
the time of sale, at prices related to such prevailing prices, or at negotiated
prices or otherwise. Dunwoody Brokerage Services, Inc. may effect these
transactions by selling the shares of Common Stock offered hereby directly to
one or more purchasers or to or through other broker-dealers or agents
including: (a) in a block trade in which the broker or dealer so engaged will
attempt to sell the shares as agent, but may position and resell a portion of
the block as principal to facilitate the transaction; (b) in purchases by
another broker or dealer and resale by such broker or dealer as a principal for
its account pursuant to this Prospectus; (c) in ordinary brokerage transactions
and (d) in transactions in which the broker solicits purchasers. The
compensation to a particular underwriter, broker-dealer or agent may be in
excess of customary commissions.
To Techniclone's knowledge, Dunwoody Brokerage Services, Inc. has made no
arrangement with any brokerage firm (other than itself) for the sale of the
shares of Common Stock offered hereby. Techniclone has been advised by Dunwoody
Brokerage Services, Inc. that it presently intends to dispose of the shares of
Common Stock offered hereby through itself or through other broker-dealers in
ordinary brokerage transactions at market prices prevailing at the time of the
sale. However, depending on market conditions and other factors, Dunwoody
Brokerage Services, Inc. may also dispose of the shares through one or more of
the other methods described above. Concurrently with sales under this
Prospectus, Dunwoody Brokerage Services, Inc. may effect other sales of the
shares of Common Stock offered hereby under Rule 144 or other exempt resale
transactions. There can be no assurance that Dunwoody Brokerage Services, Inc.
will sell any or all of the shares of Common Stock offered hereby.
Dunwoody Brokerage Services, Inc. is an "underwriter" within the meaning of
the Securities Act, in connection with the sale of the Shares offered hereby.
Any other broker-dealers or agents who act in connection with the sale of the
Shares may also be deemed to be underwriters. Profits on any resale of the
shares of Common Stock offered hereby by Dunwoody Brokerage Services, Inc. and
any discounts, commissions or concessions received by any such broker-dealers or
agents may be deemed to be underwriting discounts and commissions under the
Securities Act of 1933, as amended.
Any broker-dealer participating in such transactions as agent may receive
commissions from Dunwoody Brokerage Services, Inc. (and, if they act as agent
for the purchaser of such shares, from such purchaser). Broker-dealers may agree
with Dunwoody Brokerage Services, Inc. to sell a specified number of shares of
Common Stock offered hereby at a stipulated price per share and, to the extent
such a broker-dealer is unable to do so acting as agent for Dunwoody Brokerage
Services, Inc., to purchase as principal any unsold shares of Common Stock at
the price required to fulfill the broker-dealer commitment to Dunwoody Brokerage
Services, Inc. Broker-dealers who acquire shares of Common Stock offered hereby
as principal may thereafter resell such shares from time to time in transactions
(which may involve crosses and block transactions and which may involve sales to
and through other broker-dealers, including transactions of the nature described
above) in the over-the-counter market, in negotiated transactions or otherwise
at market prices prevailing at the time of sale or at negotiated prices, and in
connection with such resales may pay to or receive from the purchasers of such
shares commissions computed as described above. To the extent required under the
Securities Act of 1933, as amended, a supplemental prospectus will be filed,
disclosing (a) the name of any such broker-dealers; (b) the number of shares of
Common Stock involved; (c) the price at which such shares are to be sold; (d)
the commissions paid or discounts or concessions allowed to such broker-dealers,
where applicable; (e) that such broker-dealers did not conduct any investigation
to verify the information set out or incorporated by reference in this
Prospectus, as supplemented; and (f) other facts material to the transaction.
18
<PAGE>
Under applicable rules and regulations under the Exchange Act of 1934, as
amended, any person engaged in a distribution of the shares of Common Stock
offered hereby may not simultaneously engage in market making activities with
respect to the shares for a period beginning when such person becomes a
distribution participant and ending upon such person's completion of
participation in the distribution, including stabilization activities in the
Common Stock to effect covering transactions, to impose penalty bids or to
effect passive marketing making bids. In addition to and without limiting the
foregoing, in connection with transactions in the shares of Common Stock offered
hereby, Techniclone and Dunwoody Brokerage Services, Inc. may be subject to
applicable provisions of the Exchange Act of 1934, as amended, and the rules and
regulations thereunder, including, without limitation, Rule 10b-5 thereof and,
insofar as Techniclone and Dunwoody Brokerage Services, Inc. are distribution
participants, Regulation M and Rules 100, 101, 102, 103, 104 and 105 thereof.
All of the foregoing may affect the marketability of the shares of Common Stock
offered hereby.
Dunwoody Brokerage Services, Inc. has agreed that it will not create or
increase a net short position with respect to the Common Stock during the ten
trading days prior to any date on which shares are to be sold to the two
institutional investors pursuant to the Regulation D Common Stock Equity Line
Subscription Agreement or during the thirty calendar days prior to July 15,
1999. Dunwoody Brokerage Services, Inc. has further agreed that it will not
engage in any trading practice or activity for the purpose of manipulating the
price of the Common Stock or otherwise engage in any trading practice or
activity that violates the rules and regulations of the SEC.
Dunwoody Brokerage Services, Inc. will pay all commissions, transfer taxes
and other expenses associated with the sales of shares of Common Stock by it.
The shares of Common Stock offered hereby are being registered pursuant to
contractual obligations of Techniclone, and Techniclone has agreed to pay the
expenses of the preparation of this Prospectus. Techniclone has also agreed to
indemnify Dunwoody Brokerage Services, Inc. against certain liabilities,
including, without limitation, liabilities arising under the Securities Act of
1933, as amended.
Techniclone will not receive any proceeds from the exercise by Dunwoody
Brokerage Services, Inc. of any warrants which it now holds or may in the future
receive pursuant to the Placement Agent Agreement , which may only be exercised
pursuant to a cashless exercise by Dunwoody Brokerage Services, Inc. Techniclone
will not receive any of the proceeds from the sale of the shares of Common Stock
offered hereby by Dunwoody Brokerage Services, Inc.
In order to comply with the securities laws of certain states, if
applicable, the shares of Common Stock offered hereby may be sold in these
jurisdictions only through registered or licensed brokers or dealers. In
addition, in certain states the shares of Common Stock offered hereby may not be
sold unless such shares have been registered or qualified for sale in these
states or an exemption from registration or qualification is available and
complied with.
The Common Stock is currently traded on The Nasdaq SmallCap Market under
the symbol "TCLN".
19
<PAGE>
DESCRIPTION OF SECURITIES
As of the date of this Prospectus, the authorized capital stock of
Techniclone consists of 120,000,000 shares of Common Stock, par value $.001 per
share, and 5,000,000 shares of Preferred Stock, par value $.001 per share, of
which 10,000 shares are designated as Series B Convertible Preferred Stock
("Class B Stock") and 17,200 shares are designated as 5% Adjustable Convertible
Class C Preferred Stock ("Class C Stock"). As of April 23, 1999, there were
73,352,205 shares of Common Stock outstanding held by 5,863 stockholders of
record, 121 shares of Class C Stock outstanding held by 3 holders of record and
no shares of Class B Stock outstanding.
Holders of Common Stock are entitled to one vote per share on all matters
to be voted upon by the stockholders. Subject to preferences that may be
applicable to the holders of outstanding shares of Preferred Stock, if any, the
holders of Common Stock are entitled to receive such lawful dividends as may be
declared by the Board of Directors. In the event of liquidation, dissolution or
winding up of Techniclone, and subject to the rights of the holders of
outstanding shares of Preferred Stock, if any, the holders of shares of Common
Stock shall be entitled to receive pro rata all of the remaining assets of
Techniclone available for distribution to its stockholders. There are no
redemption or sinking fund provisions applicable to the Common Stock. All
outstanding shares of Common Stock are fully paid and nonassessable, and shares
of Common Stock to be issued pursuant to this offering shall be fully paid and
nonassessable.
Warrants which are currently held by Dunwoody Brokerage Services, Inc. or
which may be issued in the future to Dunwoody Brokerage Services, Inc. pursuant
to the Placement Agent Agreement are exercisable at any time beginning on the
date of issuance thereof and ending on December 31, 2004. The shares of Common
Stock underlying the warrants, when issued upon exercise in whole or in part,
will be fully paid and nonassessable, and Techniclone will pay any transfer tax
incurred as a result of the issuance of the Common Stock to the holder upon its
exercise.
Each of the warrants contain provisions that protect the holder against
dilution by adjustment of the exercise price. Such adjustments will occur in the
event, among others, of a merger, stock split or reverse stock split, stock
dividend or recapitalization. Techniclone is not required to issue fractional
shares upon the exercise of any of the warrants. The holder of the warrants will
not possess any rights as a stockholder of the Company until such holder
exercises the warrants. The warrants may be exercised upon surrender on or
before the expiration date of the relevant warrant at the offices of
Techniclone, with an exercise form completed and executed as indicated,
accompanied by payment of the exercise price for the number of shares with
respect to which the warrant is being exercised. The exercise price is payable
only pursuant to a "cashless exercise," in which that number of shares of Common
Stock underlying the warrant having a fair market value equal to the aggregate
exercise price are canceled as payment of the exercise price.
For the life of each of the warrants, the holder thereof has the
opportunity to profit from a rise in the market price of the Common Stock
without assuming the risk of ownership of the shares of Common Stock issuable
upon the exercise of the warrant. The holder of the warrant may be expected to
exercise the warrant at a time when Techniclone would, in all likelihood, be
able to obtain any needed capital by an offering of Common Stock on terms more
favorable than those provided for by the warrants. Furthermore, the terms on
which Techniclone could obtain additional capital during the life of the
warrants may be adversely affected.
This Prospectus does not cover any shares of Common Stock issued or
issuable to the two institutional investors pursuant to the Regulation D Common
Stock Equity Line Subscription Agreement or shares of Common Stock issuable upon
exercise of warrants issued or issuable to the two institutional investors
pursuant to the Regulation D Common Stock Equity Line Subscription Agreement,
which shares have been separately registered for resale under the Securities Act
of 1933, as amended, and are the subject of a separate Prospectus.
20
<PAGE>
LEGAL MATTERS
The validity of the shares of Common Stock offered hereby will be passed
upon for Techniclone by Rutan & Tucker, LLP, Costa Mesa, California.
EXPERTS
The consolidated financial statements and related consolidated financial
statement schedule, incorporated in this Prospectus by reference from
Techniclone Corporation's Annual Report on Form 10-K for the year ended April
30, 1998, have been audited by Deloitte & Touche LLP, independent auditors, as
stated in their report (which expresses an unqualified opinion and includes an
explanatory paragraph regarding substantial doubt about Techniclone's ability to
continue as a going concern), which is incorporated herein by reference, and
have been so incorporated in reliance upon the report of such firm given upon
their authority as experts in accounting and auditing.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
Techniclone's Bylaws provide that Techniclone will indemnify its directors
and officers and may indemnify its employees and other agents to the fullest
extent permitted by law. Techniclone believes that indemnification under its
Bylaws covers at least negligence and gross negligence by indemnified parties,
and permits Techniclone to advance litigation expenses in the case of
stockholder derivative actions or other actions, against an undertaking by the
indemnified party to repay such advances if it is ultimately determined that the
indemnified party is not entitled to indemnification. Techniclone has liability
insurance for its officers and directors.
In addition, Techniclone's Certificate of Incorporation provides that,
pursuant to Delaware law, its directors shall not be liable for monetary damages
for breach of the directors' fiduciary duty as a director to Techniclone and its
stockholders. This provision in the Certificate of Incorporation does not
eliminate the directors' fiduciary duty, and in appropriate circumstances
equitable remedies such as injunctive or other forms of non-monetary relief will
remain available under Delaware law. In addition, each director will continue to
be subject to liability for breach of the director's duty of loyalty to
Techniclone for acts or omissions not in good faith or involving intentional
misconduct, for knowing violations of law, for actions leading to improper
personal benefit to the director, and for payment of dividends or approval of
stock repurchases or redemptions that are unlawful under Delaware law. The
provision also does not affect a director's responsibilities under any other
law, such as the federal securities laws or state or federal environmental laws.
Provisions of Techniclone's Bylaws require Techniclone, among other things,
to indemnify them against certain liabilities that may arise by reason of their
status or service as directors or officers (other than liabilities arising from
actions not taken in good faith or in a manner the indemnitee believed to be
opposed to the best interests of Techniclone) to advance their expenses incurred
as a result of any proceeding against them as to which they could be indemnified
and to obtain directors' insurance if available on reasonable terms. Insofar as
indemnification for liabilities arising under the Securities Act of 1933, as
amended, may be permitted to directors, officers or persons controlling
Techniclone pursuant to the foregoing provisions, Techniclone has been informed
that in the opinion of the SEC, such indemnification is against public policy as
expressed in the Securities Act of 1933, as amended, and is therefore
unenforceable. Techniclone believes that its Certificate of Incorporation and
Bylaw provisions are necessary to attract and retain qualified persons as
directors and officers.
21
<PAGE>
Techniclone has in place a directors' and officers' liability insurance
policy that, subject to the terms and conditions of the policy, insures the
directors and officers of Techniclone against losses arising from any wrongful
act (as defined by the policy) in his or her capacity as a director of officer.
The policy reimburses Techniclone for amounts which Techniclone lawfully
indemnifies or is required or permitted by law to indemnify its directors and
officers.
WHERE TO LEARN MORE ABOUT TECHNICLONE
Techniclone has filed with the SEC a registration statement on Form S-3
under the Securities Act of 1933, as amended, relating to the shares of Common
Stock being offered pursuant to this Prospectus. For further information
pertaining to the Common Stock and the shares of Common Stock to which this
Prospectus relates, reference is made to such registration statement. This
Prospectus constitutes the prospectus of Techniclone filed as a part of the
registration statement and it does not contain all information set forth in the
registration statement, certain portions of which have been omitted in
accordance with the rules and regulations of the SEC. In addition, Techniclone
is subject to the informational requirements of the Exchange Act of 1934, as
amended, and, in accordance therewith, files reports, proxy statements and other
information with the SEC relating to its business, financial statements and
other matters. Reports and proxy and information statements filed pursuant to
Section 14(a) and 14(c) of the Exchange Act and other information filed with the
SEC as well as copies of the registration statement can be inspected and copied
at the public reference facilities maintained by the SEC at Room 1024, Judiciary
Plaza, 450 Fifth Street, N.W., Washington, D.C. 20549, and at the SEC's Midwest
Regional Offices at 500 West Madison Street, Chicago, Illinois 60606 and
Northeast Regional Office at 7 World Trade Center, New York, New York 10048.
Copies of such material can also be obtained at prescribed rates from the Public
Reference Section of the SEC at its principal office at Judiciary Plaza, 450
Fifth Street, N.W., Washington, D.C. 20549. Such material may also be obtained
electronically by visiting the SEC's web site on the Internet at
http://www.sec.gov. The Common Stock of Techniclone is traded on The Nasdaq
SmallCap Market under the symbol "TCLN". Reports, proxy statements and other
information concerning Techniclone may be inspected at the National Association
of Securities Dealers, Inc., at 1735 K Street, N.W., Washington D.C. 20006.
22
<PAGE>
================================================================================
YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS DOCUMENT OR TO WHICH
WE HAVE REFERRED YOU. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH
INFORMATION THAT IS DIFFERENT. THIS DOCUMENT MAY ONLY BE USED WHERE IT IS LEGAL
TO SELL THESE SECURITIES. THE INFORMATION IN THIS DOCUMENT MAY ONLY BE ACCURATE
ON THE DATE OF THIS DOCUMENT.
----------------------------------
TABLE OF CONTENTS
PAGE
----
Techniclone Corporation.............................................. 3
Risk Factors......................................................... 4
Incorporation of Certain Documents By Reference...................... 12
The Equity Line Agreement............................................ 13
Use of Proceeds...................................................... 15
Dunwoody Brokerage Services, Inc. - The Selling Stockholder.......... 16
Plan of Distribution................................................. 18
Description of Securities............................................ 20
Legal Matters........................................................ 21
Experts.............................................................. 21
Indemnification of Directors and Officers............................ 21
Where to Learn More About Techniclone................................ 22
-------------------------------
2,663,796 SHARES
[Techniclone
Corporation TECHNICLONE
Logo Here] CORPORATION
COMMON STOCK
-----------------
PROSPECTUS
-----------------
April, 1999
================================================================================
<PAGE>
PART II. INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCES AND DISTRIBUTION
The following table sets forth the estimated expenses in connection with
the offering described in this registration statement:
SEC registration fee..............................$ 912
Printing and engraving expenses................... 2,500
Legal fees and expenses........................... 25,000
Blue Sky fees and expenses........................ 2,500
Accounting fees and expenses...................... 10,000
Miscellaneous..................................... 5,000
------------
Total.....................................$ 45,912
============
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Techniclone Corporation's Certificate of Incorporation (the "Certificate")
and Bylaws include provisions that eliminate the directors' personal liability
for monetary damages to the fullest extend possible under Delaware Law or other
applicable law (the "Director Liability Provision"). The Director Liability
Provision eliminates the liability of directors to Techniclone and its
stockholders for monetary damages arising out of any violation by a director of
his fiduciary duty of due care. However, the Director Liability Provision does
not eliminate the personal liability of a director for (i) breach of the
director's duty of loyalty, (ii) acts or omissions not in good faith or
involving intentional misconduct or knowing violation of law, (iii) payment of
dividends or repurchases or redemption of stock other than from lawfully
available funds, or (iv) any transactions from which the director derived an
improper benefit. The Director Liability Provision also does not affect a
director's liability under the federal securities laws or the recovery of
damages by third parties. Furthermore, pursuant to Delaware Law, the limitation
liability afforded by the Director Liability Provision does not eliminate a
director's personal liability for breach of the director's duty of due care.
Although the directors would not be liable for monetary damages to Techniclone
or its stockholders for negligent acts or commissions in exercising their duty
of due care, the directors remain subject to equitable remedies, such as actions
for injunction or rescission, although these remedies, whether as a result of
timeliness or otherwise, may not be effective in all situations. With regard to
directors who also are officers of Techniclone, these persons would be insulated
from liability only with respect to their conduct as directors and would not be
insulated from liability for acts or omissions in their capacity as officers.
These provisions may cover actions undertaken by the Board of Directors, which
may serve as the basis for a claim against Techniclone under the federal and
state securities laws. Techniclone has been advised that it is the position of
the SEC that insofar as the foregoing provisions may be involved to disclaim
liability for damages arising under the Securities Act of 1933, as amended (the
"Securities Act"), such provisions are against public policy as expressed in the
Securities Act and are therefore unenforceable.
Delaware law provides a detailed statutory framework covering
indemnification of directors, officers, employees or agents of Techniclone
against liabilities and expenses arising out of legal proceedings brought
against them by reason of their status or service as directors, officers,
employees or agents. Section 145 of the Delaware General Corporation Law
("Section 145") provides that a director, officer, employee or agent of a
corporation (i) shall be indemnified by the corporation for expenses actually
and reasonably incurred in defense of any action or proceeding if such person is
sued by reason of his service to the corporation, to the extent that such person
has been successful in defense of such action or proceeding, or in defense of
any claim, issue or matter raised in such litigation, (ii) may, in actions other
II-1
<PAGE>
than actions by or in the right of the corporation (such as derivative actions),
be indemnified for expenses actually and reasonably incurred, judgments, fines
and amounts paid in settlement of such litigation, even if he is not successful
on the merits, if he acted in good faith and in a manner he reasonably believed
to be in or not opposed to the best interests of the corporation (and in a
criminal proceeding, if he did not have reasonable cause to believe his conduct
was unlawful), and (iii) may be indemnified by the corporation for expenses
actually and reasonably incurred (but not judgments or settlements) of any
action by the corporation or of a derivative action (such as a suit by a
stockholder alleging a breach by the director or officer of a duty owed to the
corporation), even if he is not successful, provided that he acted in good faith
and in a manner reasonably believed to be in or not opposed to the best
interests of the corporation, provided that no indemnification is permitted
without court approval if the director has been adjudged liable to the
corporation.
Delaware Law also permits a corporation to elect to indemnify its officers,
directors, employees and agents under a broader range of circumstances than that
provided under Section 145. The Certificate contains a provision that takes full
advantage of the permissive Delaware indemnification laws (the "Indemnification
Provision") and provides that Techniclone is required to indemnify its officers,
directors, employees and agents to the fullest extent permitted by law,
including those circumstances in which indemnification would otherwise be
discretionary, provided, however, that prior to making such discretionary
indemnification, Techniclone must determine that the person acted in good faith
and in a manner he or she believed to be in the best interests of the
corporation and, in the case of any criminal action or proceeding, the person
had no reason to believe his or her conduct was unlawful.
In furtherance of the objectives of the Indemnification Provision,
Techniclone has also entered into agreements to indemnify its directors and
executive officers, in addition to the indemnification provided for in
Techniclone's Certificate and Bylaws (the "Indemnification Agreements").
Techniclone believes that the Indemnification Agreements are necessary to
attract and retain qualified directors and executive officers. Pursuant to the
Indemnification Agreements, an indemnitee will be entitled to indemnification to
the extent permitted by Section 145 or other applicable law. In addition, to the
maximum extent permitted by applicable law, an indemnitee will be entitled to
indemnification for any amount or expense which the indemnitee actually and
reasonably incurs as a result of or in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, preparing to be a witness, or
otherwise participating in any threatened, pending or completed claim, suit,
arbitration, inquiry or other proceeding (a "Proceeding") in which the
indemnitee is threatened to be made or is made a party or participant as a
result of his or her position with Techniclone, provided that the indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or
not opposed to the best interests of Techniclone and had no reasonable cause to
believe his or her conduct was unlawful. If the Proceeding is brought by or in
the right of Techniclone and applicable law so provides, the Indemnification
Agreement provides that no indemnification against expenses shall be made in
respect of any claim, issue or matter in the Proceeding as to which the
indemnitee shall have been adjudged liable to Techniclone.
Insofar as indemnification for liabilities arising under the Securities
Act, may be permitted to directors, officers or persons controlling Techniclone
pursuant to the foregoing provisions, Techniclone has been advised that in the
opinion of the Securities and Exchange Commission, such indemnification is
against public policy as expressed in the Securities Act and is, therefore,
unenforceable.
II-2
<PAGE>
ITEM 16. EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
3.1..... Certificate of Incorporation of Techniclone Corporation, a
Delaware corporation (Incorporated by reference to Exhibit
B to the Company's 1996 Proxy Statement as filed with the
SEC on or about August 20, 1996)
3.2..... Bylaws of Techniclone Corporation, a Delaware
corporation (Incorporated by reference to Exhibit C to the
Company's 1996 Proxy Statement as filed with the SEC on
or about August 20, 1996)
3.3..... Certificate of Designation of 5% Adjustable Convertible
Class C Preferred Stock as filed with the Delaware
Secretary of State on April 23, 1997. (Incorporated by
reference to Exhibit 3.1 contained in Registrant's Current
Report on Form 8-K as filed with the SEC on or about May
12, 1997)
4.1..... Form of Certificate for Common Stock (Incorporated by
reference to the exhibit of the same number contained in
the Registrants' Annual Report on Form 10-K for the fiscal
year ended April 30, 1998)
4.4..... Form of Subscription Agreement entered into with Series B
Convertible Preferred Stock Subscribers (Incorporated by
reference to Exhibit 4.1 contained in Registrant's Report
on Form 8-K dated December 27, 1995, as filed with the SEC
on or about January 24, 1996)
4.5..... Registration Rights Agreement dated December 27, 1995,
by and among Swartz Investments, Inc. and the holders of
the Registrant's Series B Convertible Preferred Stock
(incorporated by reference to Exhibit 4.2 contained in
Registrant's Current Report on Form 8-K dated
December 27, 1995 as filed with the SEC on or about
January 24, 1996)
4.6..... Warrant to Purchase Common Stock of Registrant issued
to Swartz Investments, Inc. (Incorporated by reference to
Exhibit 4.3 contained in Registrant's Current Report on
Form 8-K dated December 27, 1995 as filed with the SEC
on or about January 24, 1996)
II-3
<PAGE>
4.7..... 5% Preferred Stock Investment Agreement between Registrant
and the Investors named therein (Incorporated by reference
to Exhibit 4.1 contained in Registrant's Current Report on
Form 8-K as filed with the SEC on or about May 12, 1997)
4.8..... Registration Rights Agreement between the Registrant and
the holders of the Class C Preferred Stock (Incorporated by
reference to Exhibit 4.2 contained in Registrant's Current
Report on Form 8-K as filed with the SEC on or about May
12, 1997)
4.9..... Form of Stock Purchase Warrant to be issued to the holders
of the Class C Preferred Stock upon conversion of the Class
C Preferred Stock (Incorporated by reference to Exhibit 4.3
contained in Registrant's Current Report on Form 8-K as
filed with the SEC on or about May 12, 1997)
4.10.... Regulation D Common Equity Line Subscription Agreement
dated as of June 16, 1998 between the Registrant and the
Subscribers named therein (the "Equity Line Subscribers")
(Incorporated by reference to Exhibit 4.4 contained in
Registrant's Report on Form 8-K dated as filed with the SEC
on or about June 29, 1998)
4.11.... Form of Amendment to Regulation D Common Stock Equity Line
Subscription Agreement (incorporated by reference to
Exhibit 4.5 contained in Registrant's Current Report on
Form 8-K filed with the SEC on or about June 29, 1998)
4.12.... Registration Rights Agreement dated as of June 16, 1998
between the Registrant and the Equity Line Subscribers
(Incorporated by reference to Exhibit 4.6 contained in
Registrant's Current Report on Form 8-K as filed with the
SEC on or about June 29, 1998)
4.13.... Form of Stock Purchase Warrant to be issued to the Equity
Line Subscribers pursuant to the Regulation D Common
Stock Equity Subscription Agreement (Incorporated by
reference to Exhibit 4.7 contained in Registrant's Current
Report on Form 8-K as filed with the SEC on or about June
29, 1998)
4.14.... Placement Agent Agreement dated as of June 16, 1998, by
and between the Registrant and Swartz Investments LLC,
a Georgia limited liability company d/b/a Swartz
II-4
<PAGE>
Institutional Finance (Incorporated by reference to the
exhibit contained in Registration's Registration Statement
on Form S-3 (File No. 333-63773)
4.15.... Second Amendment to Regulation D Common Stock Equity
Line Subscription Agreement dated as of September 16,
1998, by and among the Registrant, The Tail Wind Fund,
Ltd. and Resonance Limited (Incorporated by reference to
the exhibit contained in Registration's Registration
Statement on Form S-3 (File No. 333-63773)
5....... Opinion of Rutan & Tucker, LLP*
10.22... 1982 Stock Option Plan (Incorporated by reference to the
exhibit contained in Registrant's Registration Statement on
Form S-8 (File No. 2-85628))
10.23... Incentive Stock Option, Nonqualified Stock Option and
Restricted Stock Purchase Plan - 1986 (Incorporated by
reference to the exhibit contained in Registrant's
Registration Statement on Form S-8 (File No. 33-15102))
10.24... Cancer Biologics Incorporated Incentive Stock Option,
Nonqualified Stock Option and Restricted Stock Purchase
Plan - 1987 (Incorporated by reference to the exhibit
contained in Registrant's Registration Statement on Form
S-8 (File No. 33-8664))
10.25... Amendment to 1982 Stock Option Plan dated March 1, 1988
(Incorporated by reference to the exhibit of the same
number contained in Registrants' Annual Report on Form
10-K for the year ended April 30, 1988)
10.26... Amendment to 1986 Stock Option Plan dated March 1, 1988
(Incorporated by reference to the exhibit of the same
number contained in Registrant's Annual Report on Form
10-K for the year ended April 30, 1988)
10.31... Agreement dated February 5, 1996, between Cambridge
Antibody Technology, Ltd. and Registrant (Incorporated by
reference to Exhibit 10.1 contained in Registrant's Current
Report on Form 8-K dated February 5, 1996, as filed with
the SEC on or about February 8, 1996)
10.32... Distribution Agreement dated February 29, 1996, between
Biotechnology Development, Ltd. and Registrant
(Incorporated by reference to Exhibit 10.1 contained in
II-5
<PAGE>
Registrant's Current Report on Form 8-K dated February 29,
1996, as filed with the SEC on or about March 7, 1996)
10.33... Option Agreement dated February 29, 1996, by and between
Biotechnology Development, Ltd. And Registrant
(Incorporated by reference to Exhibit 10.2 contained in
Registrant's Current Report on Form 8-K dated February
29, 1996, as filed with the SEC on or about March 7, 1996)
10.35... Incentive Stock Option and Nonqualified Stock Option
Plan-1993 (Incorporated by reference to the exhibit
contained in Registrants' Registration Statement on Form
S-8 (File No. 33-87662))
10.40... 1996 Stock Incentive Plan (Incorporated by reference to the
exhibit contained in Registrants' Registration Statement on
Form S-8 (File No. 333-17513))
10.41... Stock Exchange Agreement dated as of January 15, 1997
among the stockholders of Peregrine Pharmaceuticals, Inc.
and Registrant (Incorporated by reference to Exhibit 2.1 to
Registrants' Quarterly Report on Form 10-Q for the quarter
ended January 31, 1997)
10.42... First Amendment to Stock Exchange Agreement among the
Stockholders of Peregrine Pharmaceuticals, Inc. and
Registrant (Incorporated by reference to Exhibit 2.1
contained in Registrant's Current Report on Form 8-K as
filed with the SEC on or about May 12, 1997)
10.43... Termination and Transfer Agreement dated as of November 14,
1997 by and between Registrant and Alpha Therapeutic
Corporation (Incorporated by reference to Exhibit 10.1
contained in Registrant's Current Report on Form 8-K as
filed with the SEC on or about November 24, 1997)
10.44... Severance Agreement between Lon H. Stone and the
Registrant dated July 28, 1998 (Incorporated by reference
to the exhibit contained in Registrant's Quarterly Report
on Form 10-Q for the fiscal quarter ended October 31, 1998,
as filed with the SEC on or about December 15, 1998)
10.45... Severance Agreement between William (Bix) V. Moding
and the Registrant dated September 25, 1998 (Incorporated
by reference to the exhibit contained in Registrant's
Quarterly Report on Form 10-Q for the fiscal quarter ended
October 31, 1998, as filed with the SEC on or about
December 15, 1998)
II-6
<PAGE>
10.46... Option Agreement dated October 23, 1998 between
Biotechnology Development Ltd. and the Registrant
(Incorporated by reference to the exhibit contained in
Registrant's Quarterly Report on Form 10-Q for the fiscal
quarter ended October 31, 1998, as filed with the SEC on
or about December 15, 1998)
10.47... Real Estate Purchase Agreement by and between
Techniclone Corporation and 14282 Franklin Avenue
Associates, LLC dated December 24, 1998 (Incorporated
by reference to Exhibit 10.47 to Registrants' Quarterly
Report on Form 10-Q for the quarter ended January 31,
1999)
10.48... Lease and Agreement of Lease between TNCA, LLC, as
Landlord, and Techniclone Corporation, as Tenant, dated as
of December 24, 1998 (Incorporated by reference to Exhibit
10.48 to Registrants' Quarterly Report on Form 10-Q for
the quarter ended January 31, 1999)
10.49... Promissory Note dated as of December 24, 1998 between
Techniclone Corporation (Payee) and TNCA Holding, LLC
(Maker) for $1,925,000 (Incorporated by reference to
Exhibit 10.49 to Registrants' Quarterly Report on Form 10-
Q for the quarter ended January 31, 1999)
10.50... Pledge and Security Agreement dated as of December 24,
1998 for $1,925,000 Promissory Note between Grantors
and Techniclone Corporation (Secured Party) (Incorporated
by reference to Exhibit 10.50 to Registrants' Quarterly
Report on Form 10-Q for the quarter ended January 31,
1999)
10.51... Final fully-executed copy of the Regulation D Common Stock
Equity Line Subscription Agreement dated as of June 16,
1998 between the Registrant and the Subscribers named
therein*
23.1.... Consent of Rutan & Tucker, LLP (contained in Exhibit 5)*
23.2.... Consent of Deloitte & Touche LLP*
- -------------------------
* Filed herewith.
ITEM 17. UNDERTAKINGS
(a) The undersigned Registrant hereby undertakes:
II-7
<PAGE>
(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of
the Securities Act;
(ii) To reflect in the prospectus any facts or events arising
after the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price present no more than a 20% change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in the
effective Registration Statement;
(iii) To include any material information with respect to the
plan of distribution not previously disclosed in the Registration Statement or
any material change to such information in the Registration Statement;
PROVIDED, HOWEVER, that paragraphs (1)(i) and (1)(ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by the Registrant pursuant to
Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are
incorporated by reference in the Registration Statement.
(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial BONA
FIDE offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at the time shall be deemed to be
the initial BONA FIDE offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
registrant pursuant to the provisions described under Item 15 above, or
otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the
payment by the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
II-8
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this
Pre-Effective Amendment No. 1 to Registration Statement on Form S-3 to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of
Tustin, State of California, on April 29, 1999
TECHNICLONE CORPORATION
By: /S/ LARRY O. BYMASTER
------------------------------------
Larry O. Bymaster, President
In accordance with the requirements of the Securities Act of 1933, this
Pre-Effective Amendment No. 1 to Registration Statement on Form S-3 has been
signed by the following persons in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
/s/ Larry O. Bymaster President, Chief Executive April 29, 1999
- -------------------------------- Officer and Director (Principal
Larry O. Bymaster Executive Officer)
/s/ Steven C. Burke Chief Financial Officer April 29, 1999
- -------------------------------- (Principal Financial and
Steven C. Burke Principal Accounting Officer)
/s/ Thomas R. Testman Chairman of the Board April 26, 1999
- --------------------------------
Thomas R. Testman
/s/ Rock Hankin Director April 26, 1999
- --------------------------------
Rock Hankin
/s/ William C. Shepherd
- -------------------------------- Director April 29, 1999
William C. Shepherd
- -------------------------------- Director April ___, 1999
Carmelo J. Santoro, Ph.D.
/s/ Clive R. Taylor Director April 28, 1999
- --------------------------------
Clive R. Taylor, M.D., Ph.D.
</TABLE>
II-9
<PAGE>
EXHIBIT INDEX
SEQUENTIALLY
NUMBERED
EXHIBIT NO. DESCRIPTION PAGE
- ----------- ----------- ------------
5 Opinion of Rutan & Tucker, LLP _____
10.51 Final fully-executed copy of the _____
Regulation D Common Stock Equity
Line Subscription Agreement dated
as of June 16, 1998 between the
Registrant and the Subscribers named
therein
23.2 Consent of Deloitte & Touche LLP _____
II-10
EXHIBIT 5
April 30, 1999
Techniclone Corporation
14282 Franklin Avenue
Tustin, California 92780-7017
Re: Registration Statement on Form S-3:
Techniclone Corporation Common Stock, par value $.001 per share
---------------------------------------------------------------
Ladies and Gentlemen:
We are rendering this opinion in connection with Pre-Effective Amendment
No. 1 to Registration Statement on Form S-3 (the "Amended Registration
Statement"), filed by Techniclone Corporation (the "Company") with the
Securities and Exchange Commission under the Securities Act of 1933, as amended,
on April 30, 1999. The Amended Registration Statement relates to the resale of
up to 2,663,796 shares of common stock, $.001 par value, of the Company by
Dunwoody Brokerage Services, Inc. (the "Shares").
In our capacity as your counsel in connection with this transaction, we
have examined the proceedings taken and are familiar with the proceedings
proposed to be taken by you in connection with the authorization and issuance of
the securities in the manner set forth in the Amended Registration Statement. We
have examined such documents as we consider necessary to render this opinion. In
such examination, we have assumed the authenticity of all documents submitted to
us as originals, the conformity with originals of all documents submitted to us
as copies and the genuineness of all signatures. We have also assumed the legal
capacity of all natural persons and that, with respect to all parties to
agreements or instruments relevant hereto other than the Company, such parties
had the requisite power and authority to execute, deliver and perform such
agreements or instruments, that such agreements or instruments have been duly
authorized by all requisite action and have been executed and delivered by such
parties and that such agreements or instruments are valid, binding and
enforceable obligations of such parties.
Based upon the foregoing and the compliance with applicable state
securities laws by the Company and the additional proceedings to be taken by the
Company as referred to above, we are of the opinion that the Shares have been
duly authorized, and when issued by the Company upon receipt of payment therefor
(to the extent required), the Shares will be validly issued, fully paid and
nonassessable.
Our opinions herein are limited to the effect on the subject transaction of
United States Federal law and the General Corporation Law of the State of
Delaware. We assume no responsibility regarding the applicability thereto, or
the effect thereon, of the laws of any other jurisdiction.
We hereby consent to the filing of this opinion as an exhibit to the
Amended Registration Statement and to the reference to our firm contained under
the caption "Legal Matters" in the prospectus which is a part of the Amended
Registration Statement.
Respectfully submitted,
/s/ Rutan & Tucker, LLP
<PAGE> 1
TECHNICLONE CORPORATION
REGULATION D
COMMON STOCK EQUITY LINE
SUBSCRIPTION AGREEMENT
THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE OR OTHER SECURITIES AUTHORITIES. THEY MAY NOT
BE SOLD OR TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR
AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE FEDERAL AND STATE
SECURITIES LAWS.
THIS SUBSCRIPTION AGREEMENT DOES NOT CONSTITUTE AN OFFER TO SELL, OR A
SOLICITATION OF AN OFFER TO PURCHASE, ANY OF THE SECURITIES DESCRIBED HEREIN BY
OR TO ANY PERSON IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD
BE UNLAWFUL. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE
SECURITIES AUTHORITIES, NOR HAVE SUCH AUTHORITIES CONFIRMED THE ACCURACY OR
DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. SUBSCRIBERS
MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS
INVOLVED. SEE THE RISK FACTORS SET FORTH IN THE ATTACHED DISCLOSURE DOCUMENTS AS
EXHIBIT J.
SEE ADDITIONAL LEGENDS AT SECTIONS 4.7 and 10.
-5-
<PAGE> 2
THIS REGULATION D COMMON STOCK EQUITY LINE SUBSCRIPTION AGREEMENT
(this "Agreement") is made as of the 16th day of June, 1998, by and between
Techniclone Corporation, a corporation duly organized and existing under the
laws of the State of Delaware (the "Company"), and the undersigned subscriber
executing this Agreement ("Subscriber").
RECITALS:
WHEREAS, the parties desire that, upon the terms and subject to
the conditions contained herein, the Company shall issue to the Subscriber, and
the Subscriber shall purchase from the Company, from time to time as provided
herein, shares of the Company's Common Stock, par value $0.01 per share (the
"Common Stock"), as part of an offering of Common Stock by the Company to
Subscriber and Other Subscribers, as defined below, for a maximum aggregate
offering amount of $20,000,000 (the "Maximum Offering Amount"); and
WHEREAS, the solicitation of this subscription and, if accepted
by the Company, the offer and sale of the Common Stock are being made in
reliance upon the provisions of Section 4(2) and upon the provisions of
Regulation D ("Regulation D"), each promulgated under the Securities Act of
1933, as amended and the rules and regulations promulgated thereunder (the
"Act"), and/or upon such other exemption from the registration requirements of
the Securities Act as may be available with respect to any or all of the
purchases of Common Stock to be made hereunder.
TERMS:
NOW, THEREFORE, the parties hereto agree as follows:
1. Certain Definitions. As used in this Agreement (including the
recitals above), the following terms shall have the following meanings (such
meanings to be equally applicable to both the singular and plural forms of the
terms defined):
"Act" shall mean the Securities Act of 1933, as amended.
"Accredited Investor" shall have the meaning set forth in Section
3.1.
"Advance Call Notice" shall have the meaning set forth in Section
2.3.1 (a), the form of which is attached hereto as Exhibit E.
-6-
<PAGE> 3
"Advance Call Notice Confirmation" shall have the meaning set
forth in Section 2.3.1 (a), the form of which is attached hereto as Exhibit F.
"Advance Call Notice Date" shall have the meaning set forth in
Section 2.3.1(a).
"Aggregate Initial Tranche Dollar Amount" shall have the meaning
set forth in Section 2.1.
"Aggregate Quarterly Dollar Maximum" shall equal Two Million Two
Hundred Fifty Thousand Dollars ($2,250,000), which amount may be increased up to
Five Million Dollars ($5,000,000) by mutual agreement between the parties.
"Agreement" shall mean this Regulation D Common Stock Equity Line
Agreement.
"Blackout Period" shall have the meaning set forth in the
Registration Rights Agreement.
"BTD Buyout" shall have the meaning set forth in Section 5.25.
"Business Day" shall mean a time period beginning at the time of
day in question and ending at the same time of day on the next day normally
considered a business day.
"Call Closing" shall have the meaning set forth in Section 2.3.3.
"Call Closing Date" shall have the meaning set forth in Section
2.3.3.
"Call Date" shall mean the date that is specified by the Company
in any Call Notice for which the Company intends to exercise a Call for Proceeds
under Section 2.3.1.
"Call Dollar Amount" shall have the meaning as set forth Section
2.3.1(b).
"Call for Proceeds" shall have the meaning set forth in Section
2.3.
"Call Notice" shall have the meaning set forth in Section
2.3.1(b), the form of which is attached hereto as Exhibit G.
"Call Notice Confirmation" shall have the meaning set forth in
Section 2.3.1(b), the form of which is attached hereto as Exhibit H.
"Call Reset Price" shall have the meaning set forth in Section
2.3.5.
"Call Reset Shares" shall have the meaning set forth in Section
2.3.5.
"Call Shares" shall have the meaning set forth in Section
2.3.1(c).
-7-
<PAGE> 4
"Call Share Price" shall have the meaning set forth in Section
2.3.1(d).
"Cap Amount" shall have the meaning set forth in Section 2.2.5.
"Cap Shortfall Dollar Amount" shall have the meaning set forth in
Section 2.2.6.
"Cap Limit Shares" shall have the meaning set forth in Section
2.2.5.
"Capital Raising Limitations" shall have the meaning set forth in
Section 6.6.1.
"Capitalization Schedule" shall have the meaning set forth in
Section 3.2.4, attached hereto as Exhibit K.
"Commitment Anniversary Date" shall have the meaning set forth in
Section 2.4.2.
"Closing" shall mean one of the closings of a purchase and sale
of Common Stock pursuant to Section 2.
"Closing Bid Price" means, for any security as of any date, the
last closing bid price for such security on The Nasdaq Small Cap Market as
reported by Nasdaq, or, if the Nasdaq Small Cap Market is not the principal
securities exchange or trading market for such security, the last closing bid
price of such security on the principal securities exchange or trading market
where such security is listed or traded as reported by such principal securities
exchange or trading market, or if the foregoing do not apply, the last closing
bid price of such security in the over-the-counter market on the electronic
bulletin board for such security, or, if no closing bid price is reported for
such security, the average of the bid prices of any market makers for such
security as reported in the "pink sheets" by the National Quotation Bureau, Inc.
If the Closing Bid Price cannot be calculated for such security on such date on
any of the foregoing bases, the Closing Bid Price of such security on such date
shall be the fair market value as mutually determined by the Company and the
Subscribers in this Offering. If the Company and the Subscribers in this
Offering are unable to agree upon the fair market value of the Common Stock,
then such dispute shall be resolved by an investment banking firm mutually
acceptable to the Company and the Subscribers in this offering and any fees and
costs associated therewith shall be paid by the Company.
"Common Stock" shall mean the common stock of the Company, par
value $0.001 per share.
-8-
<PAGE> 5
"Common Shares" shall mean the shares of Common Stock of the
Company.
"Company" shall mean Techniclone Corporation."
"Delisting Event" shall have the meaning set forth in the
Registration Rights Agreement.
"Disclosure Documents" shall have the meaning as set forth in
Section 3.2.4.
"Effective Date" shall have the meaning set forth in Section
2.3.1.
"Escrow Account" shall have the meaning set forth in Section
2.2.3.
"Escrow Agent" shall have the meaning set forth in Section 2.2.3.
"Escrow Agreement" shall mean that certain Escrow Agreement and
Instructions entered into by the Company, Subscriber and Escrow Agent on even
date herewith, in the form attached hereto as Exhibit C or such other form as
agreed upon by the parties.
"Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.
"Hard Floor Price" shall equal fifty cents ($0.50).
"Ineffective Period" shall have the meaning set forth in the
Registration Rights Agreement.
"Initial Tranche" shall have the meaning set forth in Section
2.1.
"Initial Tranche Closing Date" shall have the meaning set forth
in Section 2.1.
"Initial Tranche Purchase Amount" shall have the meaning set
forth in Section 2.2.
"Initial Tranche Refund Amount" shall have the meaning set forth
in Section 2.2.6.
"Initial Tranche Share Price" shall have the meaning set forth in
Section 2.2.1.
"Initial Tranche Subscription Date" shall mean the date as agreed
upon by the parties, which shall be June 16, 1998.
"Initial Tranche Shares" shall have the meaning set forth in
Section 2.2.
"Intended Call Dollar Amount" shall have the meaning set forth in
Section 2.3.1(a).
"Key Employee" shall have the meaning set forth in Section 5.18,
as set forth in Exhibit N.
"Legend" shall have the meaning set forth in Section 4.7.
-9-
<PAGE> 6
"Major Transaction" shall mean and shall be deemed to have
occurred at such time upon any of the following events:
(i) a consolidation, merger or other business combination or
event or transaction following which the holders of Common Stock of the Company
immediately preceding such consolidation, merger, combination or event either
(i) no longer hold a majority of the shares of Common Stock of the Company or
(ii) no longer have the ability to elect the board of directors of the Company
(a "Change of Control"); provided, however, that if the other entity involved in
such consolidation, merger, combination or event is a publicly traded company
with "Substantially Similar Trading Characteristics" (as defined below) as the
Company and the holders of Common Stock are to receive solely Common Stock or no
consideration (if the Company is the surviving entity) or solely common stock of
such other entity (if such other entity is the surviving entity), such
transaction shall not be deemed to be a Major Transaction (provided the
surviving entity, if other than the Company, shall have agreed to assume all
obligations of the Company under this Agreement and the Registration Rights
Agreement). For purposes hereof, an entity shall have Substantially Similar
Trading Characteristics as the Company if the average daily dollar trading
volume of the common stock of such entity is equal to or in excess of $1,000,000
for the 90th through the 31st day prior to the public announcement of such
transaction;
(ii) the sale or transfer of all or substantially all of the
Company's assets; or
(iii) a purchase, tender or exchange offer made to the holders of
outstanding shares of Common Stock, such that following such purchase, tender or
exchange offer a Change of Control shall have occurred.
Notwithstanding the above, a Major Transaction shall not include the "Swiss
Transaction." The Swiss Transaction shall mean any investment managed by Swiss
Annuity of up to Twenty Million Dollars ($20,000,000) at a fixed price at the
lower of the bid price on the date of the transaction or Two Dollars ($2.00) per
share and/or an investment by the same group of up to Sixty Million Dollars
($60,000,000) in a European subsidiary of the Company; provided, however, that
under no circumstances shall the Swiss Transaction constitute a Variable Deal as
specified in Section 6.6.1 herein.
"Market Price" shall equal the lowest Closing Bid Price during
the ten (10) Trading Days immediately preceding the date in question.
"Maximum Call Dollar Amount" shall have the meaning set forth in
Section 2.3.2 (b).
"Maximum Call Shares" shall have the meaning set forth in Section
2.3.2 (a).
-10-
<PAGE> 7
"Maximum Offering Amount" shall have the meaning as set forth in
the Recitals hereto; provided, however, that if the Company enters into a
licensing/strategic-partnership transaction that results in the receipt by the
Company of gross proceeds equal to or greater than Fifteen Million Dollars
($15,000,000) within the time period that begins on the Initial Tranche Closing
Date and ends twelve (12) months thereafter, then the Maximum Offering Amount
shall be reduced to Eighteen Million Dollars ($18,000,000).
"Minimum Commitment Amount" shall have the meaning set forth in
Section 2.4.2.
"Monthly Period" shall mean the period of time beginning on the
numeric day in question in a calendar month (the "Numeric Day") and for Monthly
Periods thereafter, beginning on the earlier of (i) the same Numeric Day of the
next calendar month or (ii) the last day of the next calendar month. The Monthly
Period shall end on the day immediately preceding the beginning of the next
succeeding Monthly Period.
"Nasdaq 20% Rule" shall have the meaning set forth in Section
2.2.5.
"Offering" shall have the meaning set forth in Section 2.1.
"Opinion of Counsel" shall mean an opinion from Company's
independent counsel, in the form attached as Exhibit B, or such other form as
agreed upon by the parties, as to the Initial Tranche Closing and in the form
attached as Exhibit I, or such other form as agreed upon by the parties, as to
any Call Closing.
"Other Subscribers" shall have the meaning set forth in Section
2.1.
"Other Subscription Agreements" shall have the meaning set forth
in Section 2.1.
"Placement Agent" shall mean Swartz Investments LLC, d/b/a Swartz
Institutional Finance.
"Principal Market" shall mean the Nasdaq National Market, the
Nasdaq Small Cap Market, the American Stock Exchange or the New York Stock
Exchange, whichever is at the time the principal trading exchange or market for
the Common Stock.
"Quarterly Call Dollar Maximum" shall have the meaning set forth
in Section 2.3.2 (b).
-11-
<PAGE> 8
"Quarterly Call Share Limit" shall have the meaning set forth in
Section 2.3.2 (a).
"Registration Rights Agreement" shall mean that certain
registration rights agreement entered into by the Company and Subscriber on even
date herewith, in the form attached hereto as Exhibit A, or such other form as
agreed upon by the parties.
"Registrable Securities" shall have the meaning as set forth in
the Registration Rights Agreement.
"Registration Statement" shall have the meaning as set forth in
the Registration Rights Agreement.
"Regulation D" shall have the meaning set forth in the Recitals
hereto.
"Reporting Issuer" shall have the meaning set forth in Section
6.2.
"Risk Factors" shall have the meaning set forth in Section 3.2.4,
attached hereto as Exhibit J.
"SEC" shall mean the Securities and Exchange Commission.
"Securities" shall mean the Common Stock of the Company, together
with the Warrants and the Warrant Shares.
"Share Price" shall mean the purchase price per share of Common
Stock for the applicable Closing.
"Shareholder 20% Approval" shall have the meaning set forth in
Section 6.12.
"Six Month Reset Date" shall have the meaning set forth in
Section 2.2.2(b).
"Six Month Reset Price" shall have the meaning set forth in
Section 2.2.2(b).
"Six Month Reset Shares" shall have the meaning set forth in
Section 2.2.2(b).
"Soft Floor Price" shall equal One Dollar ($1.00).
"Subscriber" shall have the meaning set forth in the preamble
hereto.
"Subscriber Allocation" shall have the meaning as set forth in
Section 2.1.
"Term" shall mean the term of this Agreement, which shall be a
period of time ending on the date that is six (6) months after the earlier of
(i) the date that is three years after the Initial Tranche Closing Date, or (ii)
the Call Closing Date on which the sum of the Aggregate Initial
-12-
<PAGE> 9
Tranche Dollar Amount plus the aggregate of the Call Dollar Amounts for all Call
Closings equal the Maximum Offering Amount.
"Three Month Reset Date" shall have the meaning set forth in
Section 2.2.2(a).
"Three Month Reset Price" shall have the meaning set forth in
Section 2.2.2(a).
"Three Month Reset Shares" shall have the meaning set forth in
Section 2.2.2(a).
"Trading Cushion" shall have the meaning set forth in Section
2.3.1(b).
"Trading Day" shall mean any day during which the Principal
Market is open for business.
"Transaction Documents" shall have the meaning set forth in
Section 9.
"Use of Proceeds Schedule" shall have the meaning as set forth in
Section 3.2.4, attached hereto as Exhibit L.
"Warrant" shall have the meaning set forth in Section 2.4, in the
form attached hereto as Exhibit D, or such other form as agreed upon by the
parties.
"Warrant Shares" shall mean the Common Stock issuable upon
exercise of the Warrants.
2. Purchase and Sale of Common Stock
-13-
<PAGE> 10
2.1 Offer to Subscribe.
Subject to the terms and conditions herein and the satisfaction
of the conditions to closing set forth in Sections 2.2.4 and 2.3.4 below,
Subscriber hereby offers to subscribe for and purchase (i) an initial number of
shares Common Stock according to Section 2.2 below, for an initial purchase
price in the amount set forth in Section 2.2 below (the "Initial Tranche"), and
(ii) such additional amounts of Common Stock as the Company may, in its sole and
absolute discretion from time to time elect to issue and sell to Subscriber
according to a Call for Proceeds pursuant to Section 2.3 below.
Contemporaneously herewith, the Company may enter into agreements (the "Other
Subscription Agreements") with other subscribers (the "Other Subscribers") for
the sale and purchase of Common Stock. The aggregate dollar amount of Common
Stock purchased by the Subscriber and the Other Subscribers for all Initial
Tranches (the "Aggregate Initial Tranche Dollar Amount") and the aggregate
dollar amount of Common Stock purchased by the Subscriber and the Other
Subscribers for any and all Call for Proceeds shall be allocated pro rata among
the Subscriber and the Other Subscribers based on the Initial Tranche Purchase
Amount of Common Stock purchased by such subscriber in the Initial Tranche
(collectively, the "Offering"). The amount allocated to the Subscriber shall be
based on a percentage (the "Subscriber Allocation") equal to the quotient of (i)
Initial Tranche Purchase Amount of the Subscriber, divided by the (ii) the
Aggregate Initial Tranche Dollar Amount.
The parties hereto acknowledge that Swartz Investments, LLC, d/b/a Swartz
Institutional Finance is acting as placement agent (the "Placement Agent") for
this Offering and will be compensated by the Company in cash, Common Stock and
warrants to purchase Common Stock. The Placement Agent has acted solely as
placement agent in connection with the Offering by the Company of the Common
Stock pursuant to this Agreement. The information and data contained in the
Disclosure Documents (as defined in Section 3.2.4) have not been subjected to
independent verification by the Placement Agent, and no representation or
warranty is made by the Placement Agent as to the accuracy or completeness of
the information contained in the Disclosure Documents.
-14-
<PAGE> 11
2.2 Purchase of Initial Tranche. Subject to the terms and
conditions herein and the satisfaction of the conditions to closing set forth in
Section 2.2.4 below, Subscriber hereby agrees to subscribe for and purchase an
initial number of shares of Common Stock according to Section 11 below (the
"Initial Tranche Shares") at the initial purchase price per share of Common
Stock as determined pursuant to Section 2.2.1 below (the "Initial Tranche Share
Price"), for an initial purchase price in the amount set forth in Section 11
below (the "Initial Tranche Purchase Amount").
2.2.1 Initial Tranche Share Price. The purchase price
per share of Common Stock (the "Initial Tranche Share Price") for the Initial
Tranche shall be equal to the Market Price of the Common Stock, in effect on the
Initial Tranche Subscription Date; provided, however, that the Initial Tranche
Share Price shall be subject to the reset provision in Section 2.2.2 below.
2.2.2 Reset of Initial Tranche Share Price and Initial
Tranche Shares. The Initial Tranche Share Price and the Initial Tranche Shares
shall be subject to reset according to the following:
(a) If the Market Price on the date that is three
(3) months after the Effective Date (the "Three Month Reset Date") of the
Registration Statement is less than the Initial Tranche Share Price, then the
Initial Tranche Share Price, with respect to one-half (1/2) of the Initial
Tranche Shares, shall be reset to equal the Market Price on the Three Month
Reset Date (the "Three Month Reset Price") and the Subscriber shall be issued
additional Common Shares (the "Three Month Reset Shares") in an amount equal to
the difference of (i) a number of shares equal to the quotient of (x) one-half
(1/2) of the Initial Tranche Purchase Amount, divided by (y) the Three Month
Reset Price, minus (ii) one-half (1/2) of the number of Initial Tranche Shares:
provided, however, the Company's obligation to issue Three Month Reset Shares
shall be subject to the Cap Amount as specified in Section 2.2.5 below; provided
further that the provisions of this Section 2.2.2(a) shall be subject to
adjustment as provided in Section 2.2.7 below; provided further that if on the
Three Month Reset Date, the Registration Statement is subject to a Blackout
Period or is otherwise ineffective, then for purposes hereof, the Three Month
Reset Date shall be the first Trading Day thereafter that the Registration
Statement becomes effective. On or before the third (3rd) Business Day following
the Three Month Reset Date, the Company shall deliver to the Escrow Agent a
certificate or certificates (in denominations as instructed by Subscriber)
representing the Three Month Reset Shares registered in the name of Subscriber
or its nominee (as instructed by Subscriber).
(b) If the Market Price on the date that is six (6)
months after the Effective Date (the "Six Month Reset Date") of the Registration
Statement is less than the Initial Tranche Share Price, then the Initial Tranche
Share Price, with respect to one-half (1/2) of the Initial Tranche Shares, shall
be reset to equal the Market Price on the Six Month Reset Date (the "Six Month
Reset Price") and the Subscriber shall be issued additional Common Shares (the
"Six Month Reset Shares") in an amount equal to the difference of (i) a number
of shares equal to the quotient of (x) one-half (1/2) of the Initial Tranche
Purchase Amount, divided by (y) the Six Month Reset Price, minus (ii) one-half
(1/2) of the number of Initial Tranche Shares: provided, however, the Company's
obligation to issue Six Month Reset Shares shall be subject to the Cap Amount as
specified in Section 2.2.5 below; provided further that the provisions of this
Section 2.2.2(b) shall be subject to adjustment as provided in Section 2.2.7
below; provided further that if on the Six Month Reset Date,
-15-
<PAGE> 12
the Registration Statement is subject to a Blackout Period or is otherwise
ineffective, then for purposes hereof, the Six Month Reset Date shall be the
first Trading Day thereafter that the Registration Statement becomes effective.
On or before the third (3rd) Business Day following the Six Month Reset Date,
the Company shall deliver to the Escrow Agent a certificate or certificates (in
denominations as instructed by Subscriber) representing the Six Month Reset
Shares registered in the name of Subscriber or its nominee (as instructed by
Subscriber).
2.2.3 Initial Tranche Closing. Assuming that the Initial
Tranche Purchase Amount for the Initial Tranche and this Subscription Agreement,
accepted by the Company, are received into the Company's designated escrow
account for this Offering established pursuant to the Escrow Agreement and
Instructions (the "Escrow Agreement") by and among the Company, First Union
National Bank of Georgia (the "Escrow Agent") and the Subscriber (the "Escrow
Account"), the closing of a sale and purchase of Common Stock as to each
Subscriber (the "Closing") shall be deemed to occur (the "Initial Tranche
Closing Date") when this Agreement, the Registration Rights Agreement and the
Escrow Agreement have been executed, by both Subscriber and the Company and full
payment shall have been made by Subscriber, by wire transfer to the Escrow
Account as set forth in Section 8 for payment in consideration for the Company's
delivery of certificates representing the Common Stock and Warrants purchased by
Subscriber, and the other documents and instruments required to be delivered in
connection with the Closing.
2.2.4 Conditions to Closing of the Initial Tranche. As a
prerequisite to the Closing of the Initial Tranche and Subscriber's obligations
hereunder, all of the following shall have been satisfied prior to such Closing:
(a) the following documents shall have been deposited with the
Escrow Agent: (i) the Registration Rights Agreement, in the form
attached hereto as Exhibit A, or such other form as agreed upon
by the parties, (the "Registration Rights Agreement") (executed
by the Company and Subscriber), (ii) an opinion of independent
counsel, in the form attached hereto as Exhibit B, or such other
form as agreed upon by the parties, (the "Opinion of Counsel")
(signed by the Company's counsel), (iii) the Escrow Agreement,
in the form attached hereto as Exhibit C, or such other form as
agreed upon by the parties, (executed by the Company and
Subscriber), (iv) certificates representing the Common Stock for
which the Subscriber has subscribed issued in the name of the
Subscriber or its nominee, (v) Warrants, in the form attached
hereto as Exhibit D, or such other form as agreed upon by the
parties, issued in the name of the Subscriber, and (vi) a
secretary's certificate, as to (A) the resolutions of the
Company's board of directors authorizing this transaction, (B)
the Company's Certificate of Incorporation, and (C) the
Company's Bylaws;
(b) the Initial Tranche Purchase Amount and this Subscription
Agreement, accepted by the Company, shall have been received by
the Escrow Agent;
(c) an Aggregate Initial Tranche Dollar Amount of at least Three
Million Five Hundred Thousand Dollars ($3,500,000), this
Subscription Agreement and
-16-
<PAGE> 13
the Other Subscription Agreements, accepted by the Company,
shall have been received by the Escrow Agent;
(d) the Company's Common Stock shall be listed for and actively
trading on either the Nasdaq Small Cap Market, Nasdaq National
Market, American Stock Exchange or New York Stock Exchange;
(e) other than continuing losses described in the Risk Factors below
as described in the Disclosure Documents (as described in
Section 3.2.4), as of the Closing there have been no material
adverse changes in the Company's business prospects or financial
condition since the date of the last balance sheet included in
the Disclosure Documents, including but not limited to incurring
material liabilities;
(f) the representations and warranties of the Company are true and
correct in all material respects at the Initial Tranche Closing
Date as if made on such date and the conditions to Subscriber's
obligations set forth in this Section 2.2.4 are satisfied as of
such closing, and the Company shall deliver a certificate,
signed by an officer of the Company, to such effect to the
Escrow Agent;
(g) the Company shall have reserved for issuance a sufficient number
of Common Shares to effect the issuance of the Common Shares in
the Initial Tranche Closing and to effect exercise of the
corresponding Warrants, which number of shares shall initially
be equal to Ten Million (10,000,000) shares, provided, however,
that following the issuance of all Three Month Reset Shares and
all Six Month Reset Shares, the Company may reduce the number of
shares of Common Stock reserved for issuance to equal the number
of shares of Common Stock issuable upon the full exercise of all
outstanding Warrants; and
(h) the number of Initial Tranche Shares with respect to Subscriber
shall not exceed a number of shares of Common Stock equal to the
same number of shares of restricted securities that the
Subscriber would otherwise be able to sell within a ninety (90)
day period pursuant to Rule 144(e),promulgated under the Act,
with respect to the Initial Tranche Closing Date.
2.2.5 Cap Amount. Unless otherwise permitted by Nasdaq,
in no event shall the aggregate number of Initial Tranche Shares, Three Month
Reset Shares, Six Month Reset Shares and any Call Shares exceed the maximum
number of shares of Common Stock (the "Cap Amount") that the Company can,
without shareholder approval, so issue pursuant to Nasdaq Rule 4460(i)(1)(d)(ii)
(or any other applicable Nasdaq Rules or any successor rule) (the "Nasdaq 20%
Rule"). In the event the Company is prohibited from issuing the full amount of
Three Month Reset Shares or Six Month Reset Shares as a result of the operation
of this Section 2.2.5, the Company shall issue such number of shares of Common
Stock as are available without exceeding the Cap Amount (the "Cap Limit Shares")
to the Subscriber as partial consideration for its obligation to issue the Three
Month Reset Shares or Six Month Reset Shares, as the case may be, and shall pay
the Subscriber the refund amount as specified in Section 2.2.6 below.
-17-
<PAGE> 14
2.2.6 Refund due to Cap Amount. In the event the Company
is prohibited from issuing the full amount of either the Three Month Reset
Shares or the Six Month Reset Shares, or both, as a result of the operation of
Section 2.2.5, the Company shall refund to the Subscriber a dollar amount (the
"Initial Tranche Refund Amount") equal to the product of (a) the difference of
(i) the number of Three Month Reset Shares or Six Month Reset Shares, as the
case may be, required to be issued by the Company, minus (ii) the number of the
Cap Limit Shares, times (b) the Three Month Reset Price or the Six Month Reset
Price, as the case may be. On or before the third (3rd) Business Day following
the Three Month Reset Date, the Six Month Reset Date or both such dates, as the
case may be, the Company shall deliver to the Escrow Agent a certificate or
certificates (in denominations as instructed by Subscriber) representing the Cap
Limit Shares registered in the name of Subscriber or its nominee (as instructed
by Subscriber) and the Initial Tranche Refund Amount.
2.2.7 Adjustments to Reset of Initial Tranche Share Price
and Initial Tranche Shares.
(a) Adjustment Due to Stock Split or Combination.
If, at any time, after the Initial Tranche Closing Date but prior to either the
Three Month Reset Date or the Six Month Reset Date, as the case may be, the
number of outstanding shares of Common Stock is increased by a stock split,
stock dividend, or other similar event, or decreased by a combination or
reclassification of shares, or other similar event, then the Three Month Reset
Price or the Six Month Reset Price, as the case may be, shall be calculated
giving appropriate effect to the stock split, stock dividend, combination,
reclassification or other similar event.
(b) Adjustment Due to Merger, Consolidation, Etc.
If, after the Initial Tranche Closing Date but prior to either the Three Month
Reset Date or the Six Month Reset Date, as the case may be, there shall be any
merger, consolidation, exchange of shares, recapitalization, reorganization, or
other similar event (a "Reset Transaction"), as a result of which shares of
Common Stock of the Company shall be changed into (or the shares of Common Stock
become entitled to receive) the same or a different number of shares of the same
or another class or classes of stock or securities of the Company or another
entity, then, prior to the consummation of any Reset Transaction, the Company
will make appropriate provision (in form and substance reasonably satisfactory
to the Subscriber) to insure that the Subscriber shall thereafter have the right
to acquire and receive, upon the basis and upon the terms and conditions
specified herein and in lieu of or addition to (as the case may be) the shares
of Common Stock theretofore issuable upon such Three Month Reset Date or Six
Month Reset Date, as the case may be, such stock, securities and/or other assets
that would have been issued or payable in such Reset Transaction with respect to
or in exchange for the number of shares of Common Stock which would have been
acquirable or receivable upon the Three Month Reset Date or Six Month Reset
Date, as the case may be, had such Reset Transaction not taken place. In any
such case, the Company will make appropriate provision (in form and substance
reasonably satisfactory to the Subscriber) with respect to the Subscriber's
rights and interests to insure that the provisions of this Section 2.2.7(b) and
Section 2.2.2 will thereafter be enforceable and to give appropriate effect to
the reset provisions in Section 2.2.2(a) and Section 2.2.2(b) (including, in the
case of any such Reset Transaction in which the successor entity or purchasing
entity is other than the Company, an immediate revision of the Initial Tranche
Share Price to reflect the price of the common stock of the surviving entity and
the market in which such common stock is traded). The Company shall not effect
any transaction described in this Section
-18-
<PAGE> 15
2.2.7(b) unless the resulting successor or acquiring entity (if not the Company)
assumes by written instrument the obligations of the Company under this
Agreement including this Section 2.2.7(b).
(c) Adjustment Due to Distribution. Subject to the
restrictions herein contained, if at any time after the Initial Tranche Closing
Date but prior to either the Three Month Reset Date or the Six Month Reset Date,
as the case may be, the Company shall declare or make any distribution of its
assets (or rights to acquire its assets) or shares of its capital stock (other
than Common Stock) to holders of Common Stock as a partial liquidating dividend,
by way of return of capital or otherwise (including any dividend or distribution
to the Company's shareholders in cash or shares (or rights to acquire shares) of
capital stock of any other public or private company, including but not limited
to a subsidiary or spin-off of the Company (a "Distribution"), then the
Subscriber shall be entitled, upon issuance of either the Three Month Reset
Shares or Six Month Reset Shares, as the case may be, after the date of record
for determining shareholders entitled to such Distribution, to receive the
amount of such distribution (in kind) which would have been payable to the
Subscriber with respect to either the Three Month Reset Shares or Six Month
Reset Shares, as the case may be, had such Subscriber been the holder of such
shares of Common Stock on the record date for determination of shareholders
entitled to such Distribution.
2.3 Call for Proceeds.
2.3.1 Procedure to Exercise Call for Proceeds. During
any Monthly Period beginning on the date on which the Registration Statement is
declared effective by the SEC (the "Effective Date"), the Company may, in its
sole and absolute discretion, elect to exercise no more than one Call for
Proceeds according to the following procedure:
(a) at least ten (10) Trading Days prior to any
Call Date, the Company shall deliver advance written notice (the "Advance Call
Notice," the form of which is attached hereto as Exhibit E, the date of such
Advance Call Notice being the "Advance Call Notice Date") to Subscriber stating
the Call Date for which the Company shall, subject to the limitations and
restrictions contained herein, exercise a Call for Proceeds and the amount for
which the Company shall exercise a Call for Proceeds (the "Intended Call Dollar
Amount"). In order to effect delivery of the Advance Call Notice, the Company
shall (i) send the Advance Call Notice by facsimile on such date so that such
notice is received by the Subscriber by 6:00 p.m., New York, NY time, and (ii)
surrender such notice on such date to a common courier for overnight delivery to
the Subscriber (or two (2) day delivery in the case of a Subscriber residing
outside of the U.S.). Upon receipt by the Subscriber of a facsimile copy of the
Advance Call Notice, the Subscriber shall, within two (2) Business Days, send,
via facsimile, a confirmation of receipt (the "Advance Call Notice
Confirmation," the form of which is attached hereto as Exhibit F) of the Advance
Call Notice to Company specifying that the Advance Call Notice has been received
and affirming the intended Call Date and the Intended Call Dollar Amount;
(b) on the Call Date specified in the Advance Call
Notice, the Company shall deliver written notice (the "Call Notice," the form of
which is attached hereto as Exhibit G), the date of such Call Notice being the
"Call Date") to Subscriber stating (i) a purchase amount (the "Call Dollar
Amount") of Common Stock which Company intends to sell to Subscriber, (ii) the
Call Date, (iii) the Call Shares as determined pursuant to Section 2.3.1 (c),
and (iv) the Call Share Price as determined pursuant to Section 2.3.1 (d) (such
exercise a "Call for Proceeds");
-19-
<PAGE> 16
provided, however, that the Call Dollar Amount specified by the Company in the
Call Notice shall be equal to the Intended Call Dollar Amount, unless the Call
Dollar Amount must be restricted to the Maximum Call Dollar Amount pursuant to
Section 2.3.2 (b) below or the Call Shares must be restricted to the Maximum
Call Shares pursuant to Section 2.3.2(a); provided further that if the Call
Dollar Amount must be restricted pursuant to either Section 2.3.2(a) or Section
2.3.2(b), then for purposes hereof, the Call Dollar Amount shall equal either
the Maximum Call Dollar Amount or the purchase amount for the Maximum Call
Shares, whichever is less; provided, further, that the Company shall not send a
Call Notice unless at least fifteen (15) Trading Days, not including any Trading
Day for which the Registration Statement is ineffective or subject to a Blackout
Period, have elapsed (the "Trading Cushion") since the last Call Date for which
a Call for Proceeds was closed; provided further, that the Company may, in its
sole and absolute discretion, elect to void all or any portion of the amount set
forth in the Advance Call Notice and elect not to exercise all or any portion of
any Call for Proceeds on the Call Date specified in such Advance Call Notice, if
the Market Price on such Call Date is less than eighty percent (80%) of the
Closing Bid Price on such Advance Call Notice Date. In order to effect delivery
of the Call Notice, the Company shall (i) send the Call Notice by facsimile on
the Call Date so that such notice is received by the Subscriber by 6:00 p.m.,
New York, NY time, and (ii) surrender such notice on the Call Date to a common
courier for overnight delivery to the Subscriber (or two (2) day delivery in the
case of a Subscriber residing outside of the U.S.). Upon receipt by the
Subscriber of a facsimile copy of the Call Notice, the Subscriber shall, within
two (2) Business Days, send, via facsimile, a confirmation of receipt (the "Call
Notice Confirmation," the form of which is attached hereto as Exhibit H) of the
Call Notice to Company specifying that the Call Notice has been received and
affirming the Call Date, the Call Dollar Amount, the Call Shares and the Call
Share Price;
(c) the number of shares of Common Stock that the
Subscriber shall receive pursuant to such Call for Proceeds (the "Call Shares")
shall be determined by dividing the Call Dollar Amount specified in the Call
Notice by the Call Share Price with respect to such Call Date, subject to the
Call Limitations pursuant to Section 2.3.2 below; and
(d) the "Call Share Price" shall equal eighty five
percent (85%) of the Market Price on the Call Date.
2.3.2 Call Limitations. The Company's right to exercise
a Call for Proceeds shall be limited as follows:
(a) the Company shall not exercise any Call for
Proceeds for a number of Call Shares with respect to any individual Subscriber
in excess of the Maximum Call Shares. The "Maximum Call Shares" shall equal the
difference of (i) the Quarterly Call Share Limit, as defined below, minus (ii)
the aggregate number of all prior Call Shares sold to such Subscriber during the
three (3) month period immediately preceding the Call Date. The "Quarterly Call
Share Limit" applicable to a Call for Proceeds with respect to such Subscriber
shall mean a number of shares of Common Stock equal to the same number of shares
of restricted securities that the Subscriber would otherwise be able to sell
pursuant to Rule 144(e),promulgated under the Act, with respect to such Call
Date.;
(b) the Company shall not exercise a Call for
Proceeds for a Call Dollar Amount in excess of the Maximum Call Dollar Amount.
The Maximum Call Dollar Amount
-20-
<PAGE> 17
shall equal the difference of (i) the Quarterly Call Dollar Maximum, as defined
below, minus (ii) the aggregate of all prior Call Dollar Amounts with respect to
the Subscriber during the three (3) month period immediately preceding the Call
Date. The "Quarterly Call Dollar Maximum" shall be equal to the product of (i)
the Aggregate Quarterly Dollar Maximum, and (ii) the Subscriber Allocation;
(c) if the Closing Bid Price of the Common Stock on
any Trading Day during the ten (10) Trading Days preceding the Call Date is less
than Soft Floor Price and greater than the Hard Floor Price, then the Company
shall not exercise a Call for Proceeds for a Call Dollar Amount in excess of
fifteen percent (15%) of the Maximum Call Dollar Amount that would otherwise be
available; provided, however, that the Soft Floor Price and the Hard Floor Price
shall be proportionately increased in the event of any combination or reverse
stock split of the shares of Common Stock, or any recapitalization or
reorganization which results in less shares of Common Stock being outstanding,
and the Soft Floor Price and the Hard Floor Price shall be proportionately
reduced in the event of any stock split or Common Stock dividend with respect to
the shares of Common Stock;
(d) the Company shall not exercise a Call for
Proceeds on a Call Date for which the Closing Bid Price on any Trading Day
during the ten (10) Trading Days immediately preceding the Call Date is less
than or equal to the Hard Floor Price; provided that the Hard Floor Price shall
be adjusted, as necessary, according to Section 2.3.2(c) above;
(e) the Company shall not exercise a Call for
Proceeds on a Call Date for which the Company has announced a subdivision or
combination, including a reverse split, of its Common Stock or has subdivided or
combined its Common Stock during the ten (10) Trading Days immediately preceding
the Call Date;
(f) the Company shall not exercise a Call for
Proceeds on a Call Date for which the Company has paid a dividend of its Common
Stock or has made any other distribution of its Common Stock during the ten (10)
Trading Days immediately preceding the Call Date;
(g) the Company shall not exercise a Call for
Proceeds on a Call Date for which the Company has made, during the ten (10)
Trading Days immediately preceding the Call Date, a distribution of all or any
portion of its assets or evidences of indebtedness to the holders of its Common
Stock;
(h) the Company shall not exercise a Call for
Proceeds on a Call Date for which a Major Transaction has occurred or the Swiss
Transaction has closed during the ten (10) Trading Days immediately preceding
the Call Date;
(i) the Company shall not exercise a Call for
Proceeds during the ten (10) Trading Days before and after the Three Month Reset
Date and during the ten (10) Trading Days before and after the Six Month Reset
Date;
(j) the Company shall not exercise a Call for
Proceeds during the time period that is ninety (90) days after the Initial
Tranche Closing Date;
-21-
<PAGE> 18
(k) the Company shall not exercise a Call for
Proceeds if, at any time, either the Company or any director or executive
officer of the Company has engaged in a transaction or conduct that gives rise
to claims of fraud or misrepresentation, or, if prosecuted criminally, would
constitute a felony under applicable law. For purposes of determining whether
the Company is precluded from exercising a Call for Proceeds pursuant to this
paragraph, the Company shall be deemed to be precluded from exercising a Call
for Proceeds if any regulatory or criminal proceeding is initiated against
either the Company or any of its directors or executive officers and such
proceeding is not dismissed within thirty (30) days of the initiation thereof;
(l) the Company shall not exercise a Call for
Proceeds during the ten (10) Trading Days after the Effective Date of the
Registration Statement;
(m) the Company shall not exercise a Call for
Proceeds or any Call for Proceeds thereafter, on any date after (i) any
Ineffective Period or Delisting Event, both as defined in the Registration
Rights Agreement, that lasts for four (4) consecutive months, or (ii) after a
cumulative time period including both an Ineffective Period and a Delisting
Event that lasts for four (4) consecutive months;
(n) the Company shall not exercise a Call for
Proceeds on a Call Date for which the Company has filed for and/or is subject to
any bankruptcy, insolvency, reorganization or liquidation proceedings or other
proceedings for relief under any bankruptcy law or any law for the relief of
debtors instituted by or against the Company or any subsidiary of the Company
during the ten (10) Trading Days immediately preceding the Call Date; and
(o) the Company shall not exercise a Call for
Proceeds after (i) the date that is three years after the Initial Tranche
Closing, or (ii) the Call Closing Date on which the sum of the Aggregate Initial
Tranche Dollar Amount plus the aggregate of the Call Dollar Amounts for all Call
Closings equal the Maximum Offering Amount.
2.3.3 Call Closing. On or before the third (3rd) Business
Day following the Call Date for such Call for Proceeds (the "Company Due Date"),
(i) the Company shall deliver to the Escrow Agent a certificate or certificates
(in denominations as instructed by Subscriber) representing the Call Shares for
such Call for Proceeds, registered in the name of Subscriber or its nominee (as
instructed by Subscriber), and (ii) the Company shall deliver to the Escrow
Agent any and all documents, instruments and other writings required to be
delivered pursuant to Section 2.3.4 or any other provision of this Agreement in
order to implement and effect the transactions contemplated herein. On or before
the second (2nd) Business Day following notification by the Escrow Agent
(pursuant to the Escrow Agreement) to the Subscriber that the Company has
delivered such certificates and such documents (the "Subscriber Due Date"), the
Subscriber shall deliver to the Escrow Agent the Call Dollar Amount for such
Call for Proceeds as specified in the Call Notice in the manner specified in
Section 8 below; provided, however, if the Company does not deliver the
certificate or certificates representing the Call Shares on or before the
Company Due Date, then the Call Share Price for such Call for Proceeds shall be
reset to equal eighty five percent (85%) of the lower of the (i) the Market
Price on the Call Date, or (ii) the lowest Closing Bid Price on any Trading Day
from the Call Date until the date immediately preceding the date that the
Company delivers the certificate or certificates representing all of the Call
Shares to the Escrow Agent, including any additional shares required to be
issued based upon such reset of the Call Share Price, if
-22-
<PAGE> 19
applicable; provided, further, that if the Subscriber does not deliver to the
Escrow Agent the Call Dollar Amount for such Call for Proceeds on or before the
Subscriber Due Date, then the Subscriber shall pay to the Company, in addition
to the Call Dollar Amount, an amount (the "Late Payment Amount") at a rate of X%
per month, accruing daily, multiplied by such Call Dollar Amount, where "X"
equals one percent (1%) for the first month following the date in question, and
increases by an additional one percent (1%) for each month that passes after the
date in question, up to a maximum of five percent (5%). The closing (each a
"Call Closing") for each Call for Proceeds shall occur on the date that both (i)
the Company has delivered to the Escrow Agent such certificates representing all
of the Call Shares to the Escrow Agent, including any additional shares required
to be issued based upon a reset of the Call Share Price, if applicable and such
documents, and (ii) the Subscriber has delivered to the Escrow Agent such Call
Dollar Amount and any Late Payment Amount, if applicable (each a "Call Closing
Date").
2.3.4 Conditions to Closing of any Call for Proceeds.
As a prerequisite to the Closing of any Call for Proceeds and Subscriber's
obligations hereunder, all of the following shall have been satisfied prior to
such Closing:
(a) the following shall have been deposited with the Escrow Agent:
(i) the Call Dollar Amount, (ii) the certificates representing
the Common Stock for which the Subscriber has subscribed issued
in the name of the Subscriber, (iii) Warrants, in the form
attached hereto as Exhibit D, or such other form as agreed upon
by the parties, issued in the name of the Subscriber, and (iv)
an opinion of counsel, in the form attached hereto as Exhibit I
or such other form as agreed upon by the parties, (the "Opinion
of Counsel") (signed by the Company's counsel);
(b) the Company's Common Stock shall be listed for and actively
trading on either the Nasdaq Small Cap Market, Nasdaq National
Market, American Stock Exchange or New York Stock Exchange and
to the Company's knowledge there is no notice of any suspension
or delisting with respect to the trading of the shares of Common
Stock on such market or exchange;
(c) the Company shall have satisfied any and all obligations
pursuant to the Registration Rights Agreement, including, but
not limited to, the filing of the Registration Statement with
the SEC with respect to the resale of all Registerable
Securities and the requirement that the Registration Statement
shall have been declared effective by the SEC for the resale of
all Registerable Securities and the Company shall have satisfied
and shall be in compliance with any and all obligations pursuant
to the Subscription Agreement and the Warrants;
(d) as of the Closing there have been no material adverse changes in
the Company's business prospects or financial condition (defined
below in Section 5.2), including but not limited to incurring
material liabilities, except as disclosed in the SEC documents
filed by the Company since the Initial Tranche Closing Date;
-23-
<PAGE> 20
(e) the representations and warranties of the Company are true and
correct in all material respects at each Call Closing Date as if
made on such date and the conditions to Subscriber's obligations
set forth in this Section 2.3.4 are satisfied as of such
closing, and the Company shall deliver a certificate, signed by
an officer of the Company, to such effect to the Escrow Agent;
(f) the Company shall have reserved for issuance a sufficient number
of Common Shares for the purpose of enabling the Company to
satisfy any obligation to issue Common Shares pursuant to any
Call for Proceeds and to effect exercise of the Warrants;
(g) the Registration Statement is not subject to a Black Out Period
as defined in the Registration Rights Agreement, the prospectus
included therein is current and deliverable, and to the
Company's knowledge there is no notice of any investigation or
inquiry concerning any stop order with respect to the
Registration Statement;
(h) the Company shall have obtained the Shareholder 20% Approval as
specified in Section 6.12; and
(i) none of the events or occurrences as specified in Section 2.3.2
(d) through (h) have occurred between the Call Date and the Call
Closing Date.
2.3.5 Reset of Call Shares. In the event that the
Company makes a public announcement or press release during the ten (10) Trading
Days after any Call Date and the Closing Bid Price on the date that is ten (10)
Trading Days after such Call Date (the "Call Reset Price") is less than eighty
five percent (85%) of the Call Share Price on such Call Date, then the Company
shall issue to the Subscriber an additional number of shares of Common Stock
(the "Call Reset Shares") equal to the difference of (a) the quotient of (i) the
Call Dollar Amount on such Call Date, divided by (ii) the Call Reset Price,
minus (b) the number of Call Shares on such Call Date. On or before the third
(3rd) Business Day following the date that is ten (10) Trading Days after the
Call Date, the Company shall deliver to the Escrow Agent a certificate or
certificates (in denominations as instructed by Subscriber) representing the
Call Reset Shares registered in the name of Subscriber or its nominee (as
instructed by Subscriber).
2.4 Warrants.
2.4.1 Warrants upon Issuance of Common Stock. On the
Initial Tranche Closing Date and each Call Closing Date, the Company shall issue
a Warrant to the Subscriber to purchase a number of shares of Common Stock equal
to ten percent (10%) of the number of Common Shares issued to the Subscriber in
the applicable Closing. In the event that the Closing Bid Price on the date that
is ten (10) Trading Days after any Call Date is less than eighty five percent
(85%) of the Call Share Price on such Call Date, then the Company shall issue to
the Subscriber an additional Warrant to purchase a number of shares of Common
Stock equal to the difference of (i) ten percent (10%) of the number of Common
Shares that would have been issued to the Subscriber if the applicable Call Date
had occurred ten (10) Trading Days after the applicable Call Closing Date, minus
(ii) the number of shares of Common Stock that may be purchased by Subscriber
pursuant to
-24-
<PAGE> 21
the Warrant issued as a result of such original Call Date. The Warrant shall be
immediately exercisable at the Share Price (either the Initial Tranche Share
Price or the Call Share Price, as the case may be) of the Common Shares in the
applicable Closing, and shall have a term beginning on the date of issuance and
ending on December 31, 2004. The Warrant Shares shall be registered for resale
pursuant to the Registration Rights Agreement.
2.4.2 Commitment Warrants. On the anniversary date of
the Initial Tranche Closing Date and the two (2) succeeding anniversary dates
thereafter (each date a "Commitment Anniversary Date"), the Company shall issue
a Warrant to the Subscriber to purchase a number of shares of Common Stock equal
to ten percent (10%) of the quotient of (i) a dollar amount equal to the
difference of (a) the Minimum Commitment Amount, minus (b) the aggregate amount
of Common Stock sold to the Subscriber during all years preceding such
Commitment Anniversary Date, divided by (ii) the Market Price of the Common
Stock on such Commitment Anniversary Date. The Warrant shall be immediately
exercisable at the Market Price on such Commitment Anniversary Date and shall
have a term beginning on the date of issuance and ending on December 31, 2004.
The "Minimum Commitment Amount" shall equal $6,666,666.66 for the first year,
$13,333,333.32 for the second year and the Maximum Offering Amount for the third
year. The Warrant Shares shall be registered for resale pursuant to the
Registration Rights Agreement.
2.4.3 Issuance of Commitment Warrants upon Reorganization,
Consolidation, Merger, Ect. In case of any reorganization of the Company after
the Initial Tranche Closing Date, or in case, after such date, the Company shall
transfer all or substantially all of its properties or assets to or consolidate
with or merge into any other public or private company, including but not
limited to a subsidiary or spin-off of the Company, by way of return of capital
or otherwise (including any dividend or distribution to the Company's
shareholders in cash or shares (or rights to acquire shares) of capital stock of
any other public or private company, then in such case the Subscriber shall be
entitled to receive on the Trading Day prior to the date of consummation of such
reorganization, conveyance, consolidation or merger (the "Consummation Date"),
in lieu of any Warrants pursuant to Section 2.4.2, a warrant to purchase a
number of shares of Common Stock equal to ten percent (10%) of the quotient of
(i) a dollar amount equal to the difference of (a) the Maximum Offering Amount,
minus (b) the aggregate amount of Common Stock sold to the Subscriber pursuant
to this Agreement during all years preceding such Consummation Date, divided by
(ii) the Market Price of the Common Stock on the Trading Day (the "Valuation
Date") immediately prior to the date of the public announcement by the Company
of such reorganization, conveyance, consolidation or merger. Such warrant shall
be immediately exercisable at the Market Price on the Valuation Date and shall
entitle the Subscriber to receive, upon payment of the exercise price, in lieu
of the Common Stock issuable upon such exercise, the cash, securities or other
property to which the Subscriber would have been entitled upon such Consummation
Date if the Subscriber had so exercised such warrant immediately prior thereto.
2.5 Subscriber's Right to Defer Receipt. If at any time the
Subscriber would have the right to receive shares of Common Stock from the
Company, including, without limitation, by reason of Section 2.2.2 (Three Month
Reset Shares and Six Month Reset Shares), Section 2.3 (Call for Proceeds) or
Section 2.3.5 (Reset of Call Shares), and/or the right to receive a Warrant or
Warrants by reason of Section 2.4 hereof, and as a result of receiving such
additional shares of Common Stock or such Warrants the Subscriber would be
deemed to be, after taking into account Common Shares previously acquired from
the Company, Warrant Shares deemed to be beneficially owned pursuant to
ownership of the Warrants, and any other shares of Common Stock of the Company
deemed to be beneficially
-25-
<PAGE> 22
owned by the Subscriber, the beneficial owner (within the meaning of Section
13(d) of the Exchange Act) of 9.9% of the Common Stock of the Company, the
Subscriber may elect to defer receipt of all or any portion of such Common
Shares from the Company and/or defer receipt of all or any portion of such
Warrant or Warrants, by sending a notice to the Company of such election. Such
election shall not affect the Subscriber's obligation to pay for Call Shares, as
if such election had not been made, nor shall it affect (other than by way of
deferral, as set forth herein) the Subscriber's absolute and unconditional right
to receive the shares of Common Stock and/or Warrants to which it was otherwise
entitled. In the event the Subscriber makes such election, (i) it may waive such
election, in whole or in part, at any time effective on sixty one (61) days'
prior notice to the Company and (ii) may waive it effective immediately upon
notice to the Company in the event of the announcement by the Company or any
third party of a Major Transaction. The Company shall deliver the shares and/or
Warrants to which the Subscriber is entitled on the effective date of the waiver
in the case of clause (i) above, and within three (3) Trading Days of the date
of the waiver notice in the case of a waiver pursuant to clause (ii) above.
3. Representations, Warranties and Covenants of Subscriber. Subscriber
hereby represents and warrants to and agrees with the Company as follows:
3.1 Accredited Investor. Subscriber is an accredited investor, as
defined in Rule 501 of Regulation D, and has checked the applicable box set
forth in Section 12 of this Agreement.
3.2 Investment Experience; Access to Information; Independent
Investigation.
3.2.1 Access to Information. Subscriber or Subscriber's
professional advisor has been granted the opportunity to ask questions of and
receive answers from representatives of the Company, its officers, directors,
employees and agents concerning the terms and conditions of this Offering, the
Company and its business and prospects, and to obtain any additional information
which Subscriber or Subscriber's professional advisor deems necessary to verify
the accuracy and completeness of the information received.
3.2.2 Reliance on Own Advisors. Subscriber has relied
completely on the advice of, or has consulted with, Subscriber's own personal
tax, investment, legal or other advisors and has not relied on the Company or
any of its affiliates, officers, directors, attorneys, accountants or any
affiliates of any thereof and each other person, if any, who controls any of the
foregoing, within the meaning of Section 15 of the Act for any tax or legal
advice (other than reliance on information in the Disclosure Documents as
defined in Section 3.2.4 below and on the Opinion of Counsel). The foregoing,
however, does not limit or modify Subscriber's right to rely upon covenants,
representations and warranties of the Company in this Agreement.
3.2.3 Capability to Evaluate. Subscriber has such
knowledge and experience in financial and business matters so as to enable such
Subscriber to utilize the information made available to it in connection with
the Offering in order to evaluate the merits and risks of the prospective
investment, which are substantial, including without limitation those set forth
in the Disclosure Documents (as defined in Section 3.2.4 below).
-26-
<PAGE> 23
3.2.4 Disclosure Documents. Subscriber, in making
Subscriber's investment decision to subscribe for the Securities hereunder,
represents that (a) Subscriber has received and had an opportunity to review (i)
the Company's Annual Report on Form 10-K/A for the year ended April 30, 1997
(ii) the Company's quarterly report on Form 10-Q/A for the quarter ended January
31, 1998, (iii) the Risk Factors, attached as Exhibit J, (the "Risk Factors")
(iv) the Capitalization Schedule, attached as Exhibit K, (the "Capitalization
Schedule") and (v) the Use of Proceeds Schedule, attached as Exhibit L, (the
"Use of Proceeds Schedule"); (b) Subscriber has read, reviewed, and relied
solely on the documents described in (a) above, the Company's representations
and warranties and other information in this Agreement, including the exhibits,
documents prepared by the Company regarding the Swiss Transaction and the
Business Product Overview which has been specifically provided to Subscriber in
connection with this Offering (the documents described in this Section 3.2.4 (a)
and (b) are collectively referred to as the "Disclosure Documents"), and an
independent investigation made by Subscriber and Subscriber's representatives,
if any; (c) Subscriber has, prior to the date of this Agreement, been given an
opportunity to review material contracts and documents of the Company which have
been filed as exhibits to the Company's filings under the Act and the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and has had an opportunity
to ask questions of and receive answers from the Company's officers and
directors; and (d) is not relying on any oral representation of the Company or
any other person, nor any written representation or assurance from the Company
other than those contained in the Disclosure Documents or incorporated herein or
therein. The foregoing, however, does not limit or modify Subscriber's right to
rely upon covenants, representations and warranties of the Company in Sections 5
and 6 of this Agreement. Subscriber acknowledges and agrees that the Company has
no responsibility for, does not ratify, and is under no responsibility
whatsoever to comment upon or correct any reports, analyses or other comments
made about the Company by any third parties, including, but not limited to,
analysts' research reports or comments (collectively, "Third Party Reports"),
and Subscriber has not relied upon any Third Party Reports, including any
provided by the Placement Agent, in making the decision to invest.
3.2.5 Investment Experience; Fend for Self. Subscriber
has substantial experience in investing in securities and he, she or it has made
investments in securities other than those of the Company. Subscriber
acknowledges that Subscriber is able to fend for Subscriber's self in the
transaction contemplated by this Agreement, that Subscriber has the ability to
bear the economic risk of Subscriber's investment pursuant to this Agreement and
that Subscriber is an "Accredited Investor" by virtue of the fact that
Subscriber meets the investor qualification standards set forth in Section 3.1
above. Subscriber has not been organized for the purpose of investing in
securities of the Company, although such investment is consistent with
Subscriber's purposes.
3.3 Exempt Offering Under Regulation D.
3.3.1 Investment; No Distribution. Subscriber is
acquiring the Securities to be issued and sold hereunder for his, her or its own
account (or a trust account if such Subscriber is a trustee) for investment and
not as a nominee and not with a present view to the distribution thereof.
Subscriber is aware that there are legal and practical limits on Subscriber's
ability to sell or dispose of the Securities and, therefore, that Subscriber may
be required to bear the economic risk of the investment for an indefinite period
of time, has adequate means of providing for Subscriber's current needs and
possible personal contingencies and could afford a complete loss of such
investment. Subscriber's commitment to illiquid investments is reasonable in
relation to Subscriber's net worth.
-27-
<PAGE> 24
By making the representations in this Section 3.3.1, the Subscriber does not
agree to hold the Securities for any minimum or other specific term and reserves
the right to dispose of the Securities at any time in accordance with or
pursuant to a registration statement or an exemption from registration under the
Act, except as otherwise limited or required by this Agreement, and the
Registration Rights Agreement.
3.3.2 No General Solicitation. The Securities were not
offered to Subscriber through, and Subscriber is not aware of, any form of
general solicitation or general advertising, including, without limitation, (i)
any advertisement, article, notice or other communication published in any
newspaper, magazine or similar media or broadcast over television or radio, and
(ii) any seminar or meeting whose attendees have been invited by any general
solicitation or general advertising.
3.3.3 Restricted Securities. Subscriber understands that
the Common Stock issued at the Initial Tranche Closing, the Common Stock issued
at each Call Closing will be, and the Warrant Shares will be, characterized as
"restricted securities" under the federal securities laws inasmuch as they are
being acquired from the Company in a transaction exempt from the registration
requirements of the federal securities laws and that under such laws and
applicable regulations such securities may not be transferred or resold without
registration under the Act or pursuant to an exemption therefrom. In this
connection, Subscriber represents that Subscriber is familiar with Rule 144
under the Act, as presently in effect, and understands the resale limitations
imposed thereby and by the Act.
3.3.4 Disposition. Without in any way limiting the
representations set forth above, Subscriber further agrees not to sell,
transfer, assign, pledge (except for any bona fide pledge arrangement to the
extent that such pledge does not require registration under the Act or unless an
exemption from such registration is available) and provided further that if such
pledge is realized upon, any transfer to the pledgee shall comply with the
requirements set forth herein), or otherwise dispose of all or any portion of
the Securities unless and until:
(a) There is then in effect a registration
statement under the Act and any applicable state securities laws covering such
proposed disposition and such disposition is made in accordance with such
registration statement; or
(b) (i) Subscriber shall have notified the Company
of the proposed disposition and shall have furnished the Company with a
statement of the circumstances surrounding the proposed disposition to the
extent relevant for determination of the availability of an exemption from
registration, and (ii) if reasonably requested by the Company, Subscriber shall
have furnished the Company with an opinion of counsel, reasonably satisfactory
to the Company, that such disposition will not require registration of the
Securities under the Act or state securities laws. It is agreed that the Company
will not require the Subscriber to provide opinions of counsel for transactions
made pursuant to Rule 144 provided that Subscriber and Subscriber's broker, if
necessary, provide the Company with the necessary representations for counsel to
the Company to issue an opinion with respect to such transaction.
3.4 Due Authorization.
-28-
<PAGE> 25
3.4.1 Authority. The person executing this Subscription
Agreement, if executing this Agreement in a representative or fiduciary
capacity, has full power and authority to execute and deliver this Agreement and
each other document included herein for which a signature is required in such
capacity and on behalf of the subscribing individual, partnership, trust,
estate, corporation or other entity for whom or which Subscriber is executing
this Agreement. Subscriber has reached the age of majority (if an individual)
according to the laws of the state in which he or she resides.
3.4.2 Due Authorization. If Subscriber is a corporation,
Subscriber is duly and validly organized, validly existing and in good tax and
corporate standing as a corporation under the laws of the jurisdiction of its
incorporation with full power and authority to purchase the Securities to be
purchased by Subscriber and to execute and deliver this Agreement.
3.4.3 Partnerships. If Subscriber is a partnership, the
representations, warranties, agreements and understandings set forth above are
true with respect to all partners of Subscriber (and if any such partner is
itself a partnership, all persons holding an interest in such partnership,
directly or indirectly, including through one or more partnerships), and the
person executing this Agreement has made due inquiry to determine the
truthfulness of the representations and warranties made hereby.
3.4.4 Representatives. If Subscriber is purchasing in a
representative or fiduciary capacity, the representations and warranties shall
be deemed to have been made on behalf of the person or persons for whom
Subscriber is so purchasing.
3.5 Limitations on Shorting. Subscriber hereby covenants and
agrees that during the ten (10) Trading Days prior to any Call Date, Subscriber
will not create or increase a net short position with respect to the Common
Stock of the Company. Subscriber hereby covenants and agrees that during the
thirty (30) calendar days prior to either the Three Month Reset Date or the Six
Month Reset Date, as the case may be, Subscriber will not create or increase a
net short position with respect to the Common Stock of the Company. Subscriber
hereby covenants and agrees that Subscriber shall not engage in any trading
practice or activity for the purpose of manipulating the price of the Common
Stock or otherwise engage in any trading practice or activity that violates SEC
rules and regulations.
4. Acknowledgments. Subscriber is aware that:
4.1 Risks of Investment. Subscriber recognizes that an investment
in the Company involves substantial risks, including the potential loss of
Subscriber's entire investment herein. Subscriber recognizes that the Disclosure
Documents, this Agreement and the exhibits hereto do not purport to contain all
the information, which would be contained in a registration statement under the
Act;
4.2 No Government Approval. No federal or state agency has
passed upon the Securities, recommended or endorsed the Offering, or made any
finding or determination as to the fairness of this transaction;
4.3 No Registration, Restrictions on Transfer. The Securities and
any component thereof have not been registered under the Act or any applicable
state securities laws by reason of
-29-
<PAGE> 26
exemptions from the registration requirements of the Act and such laws, and may
not be sold, pledged (except for any limited pledge in connection with a margin
account of Subscriber to the extent that such pledge does not require
registration under the Act or unless an exemption from such registration is
available and provided further that if such pledge is realized upon, any
transfer to the pledgee shall comply with the requirements set forth herein),
assigned or otherwise disposed of in the absence of an effective registration of
the Securities and any component thereof under the Act or unless an exemption
from such registration is available;
4.4 Restrictions on Transfer. Subscriber may not attempt to sell,
transfer, assign, pledge or otherwise dispose of all or any portion of the
Securities or any component thereof in the absence of either an effective
registration statement or an exemption from the registration requirements of the
Act and applicable state securities laws;
4.5 No Assurances of Registration. There can be no assurance that
any registration statement will become effective at the scheduled time, or ever,
Subscriber acknowledges that it may be required to bear the economic risk of
Subscriber's investment for an indefinite period of time;
4.6 Exempt Transaction. Subscriber understands that the
Securities are being offered and sold in reliance on specific exemptions from
the registration requirements of federal and state law and that the
representations, warranties, agreements, acknowledgments and understandings set
forth herein are being relied upon by the Company in determining the
applicability of such exemptions and the suitability of Subscriber to acquire
such Securities.
4.7 Legends. It is understood that the certificates evidencing
the Common Stock delivered on the Initial Tranche Closing Date, the Warrants,
and the Warrant Shares, subject to legend removal under the terms of Section 6.9
below, shall bear the following legend (the "Legend"):
"The securities represented hereby have not been registered under
the Securities Act of 1933, as amended, or applicable state
securities laws, nor the securities laws of any other
jurisdiction. They may not be sold or transferred in the absence
of an effective registration statement under those securities
laws or pursuant to an exemption therefrom."
5. Representations and Warranties of the Company. The Company hereby
makes the following representations and warranties to Subscriber (which shall be
true at the signing of this Agreement, as of the Initial Tranche Closing and
each Call Closing, and as of any such later date as contemplated hereunder) and
agrees with Subscriber that:
5.1 Organization, Good Standing, and Qualification. The Company
is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware USA and has all requisite corporate power and
authority to carry on its business as now
-30-
<PAGE> 27
conducted and as proposed to be conducted. The Company is duly qualified to
transact business and is in good standing in each jurisdiction in which the
failure to so qualify would have a material adverse effect on the business or
properties of the Company and its subsidiaries taken as a whole. The Company is
not the subject of any pending, threatened or, to its knowledge, contemplated
investigation or administrative or legal proceeding (a "Proceeding") by the
Internal Revenue Service, the taxing authorities of any state or local
jurisdiction, or the Securities and Exchange Commission ("SEC"), The National
Association of Securities Dealer, Inc., The Nasdaq Stock Market, Inc. or any
state securities commission, or any other governmental entity, which have not
been disclosed in the Disclosure Documents. None of the disclosed Proceedings,
if any, will have a material adverse effect upon the Company or the market for
the Common Stock. The Company has one subsidiary, Peregrine Pharmaceuticals,
Inc..
5.2 Corporate Condition. The Company's condition is, in all
material respects, as described in the Disclosure Documents, except for changes
in the ordinary course of business and normal year-end adjustments that are not,
in the aggregate, materially adverse to the Company. Except for continuing
losses, there have been no material adverse changes to the Company's business,
financial condition, or prospects since the date of such Disclosure Documents.
The financial statements as contained in the 10-K/A and 10-Q/A have been
prepared in accordance with generally accepted accounting principles,
consistently applied (except as otherwise permitted by Regulation S-X of the
Exchange Act), and fairly present the financial condition of the Company as of
the dates of the balance sheets included therein and the consolidated results of
its operations and cash flows for the periods then ended. Without limiting the
foregoing, there are no material liabilities, contingent or actual, that are not
disclosed in the Disclosure Documents (other than liabilities incurred by the
Company in the ordinary course of its business, consistent with its past
practice, after the period covered by the Disclosure Documents). The Company has
paid all material taxes, which are due, except for taxes, which it reasonably
disputes. There is no material claim, litigation, or administrative proceeding
pending, or, to the best of the Company's knowledge, threatened against the
Company, except as disclosed in the Disclosure Documents. This Agreement and the
Disclosure Documents do not contain any untrue statement of a material fact and
do not omit to state any material fact required to be stated therein or herein
necessary to make the statements contained therein or herein not misleading in
the light of the circumstances under which they were made. No event or
circumstance exists relating to the Company which under applicable law, requires
public disclosure but which has not been so publicly announced or disclosed.
5.3 Authorization. All corporate action on the part of the
Company by its officers, directors and shareholders necessary for the
authorization, execution and delivery of this Agreement, the performance of all
obligations of the Company hereunder and the authorization, issuance and
delivery of the Common Stock being sold hereunder and the issuance (and/or the
reservation for issuance) of the Warrants and the Warrant Shares have been
taken, and this Agreement, the Escrow Agreement and the Registration Rights
Agreement constitute valid and legally binding obligations of the Company,
enforceable in accordance with their terms, except insofar as the enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, or other
similar laws affecting creditors' rights generally or by principles governing
the availability of equitable remedies. The Company has obtained all consents
and approvals required for it to execute, deliver and perform each agreement
referenced in the previous sentence.
-31-
<PAGE> 28
5.4 Valid Issuance of Common Stock. The Common Stock and the
Warrants, when issued, sold and delivered in accordance with the terms hereof,
for the consideration expressed herein, will be validly issued, fully paid and
nonassessable and, based in part upon the representations of Subscriber in this
Agreement, will be issued in compliance with all applicable U.S. federal and
state securities laws. The Warrant Shares, when issued in accordance with the
terms of the Warrants, shall be duly and validly issued and outstanding, fully
paid and nonassessable, and based in part on the representations and warranties
of Subscriber, will be issued in compliance with all applicable U.S. federal and
state securities laws. The Common Stock, the Warrants and the Warrant Shares
will be issued free of any preemptive rights. The Company currently has Ten
Million (10,000,000) Common Shares and Warrant Shares reserved for issuance upon
the Initial Tranche Closing and reserved for issuance upon exercise of the
Warrants.
5.5 Compliance with Other Instruments. The Company is not in
violation or default of any provisions of its Certificate of Incorporation or
Bylaws each as amended, and in effect on and as of the date of the Agreement or
of any material provision of any material instrument or material contract to
which it is a party or by which it is bound or of any provision of any federal
or state judgment, writ, decree, order, statute, rule or governmental regulation
applicable to the Company, which would have a material adverse effect on the
Company's business or prospects, or on the performance of its obligations under
this Agreement or the Registration Rights Agreement. The execution, delivery and
performance of this Agreement and the other agreements entered into in
conjunction with the Offering and the consummation of the transactions
contemplated hereby and thereby will not (a) result in any such violation or be
in conflict with or constitute, with or without the passage of time and giving
of notice, either a default under any such provision, instrument or contract or
an event which results in the creation of any lien, charge or encumbrance upon
any assets of the Company, which would have a material adverse effect on the
Company's business or prospects, or on the performance of its obligations under
this Agreement, the Registration Rights Agreement, (b) violate the Company's
Certificate of Incorporation or By-Laws or (c) violate any statute, rule or
governmental regulation applicable to the Company which violation would have a
material adverse effect on the Company's business or prospects.
5.6 Reporting Company. The Company is subject to the reporting
requirements of the Exchange Act, has a class of securities registered under
Section 12 of the Exchange Act, and has filed all reports required by the
Exchange Act since the date the Company first became subject to such reporting
obligations. The Company undertakes to furnish Subscriber with copies of such
reports as may be reasonably requested by Subscriber prior to consummation of
this Offering and thereafter, to make such reports available, for the full term
of this Agreement, including any extensions thereof, and for as long as
Subscriber holds the Securities. The Common Stock is duly listed on the Nasdaq
Small Cap Market. The Company is not in violation of the listing requirements of
the Nasdaq Small Cap Market and does not reasonably anticipate that the Common
Stock will be delisted by the Nasdaq Small Cap Market for the foreseeable
future. The Company has filed all reports required under the Exchange Act. The
Company has not furnished to the Subscriber any material nonpublic information
concerning the Company.
5.7 Capitalization. The capitalization of the Company as of June
1, 1998, is, and the capitalization as of the Closing, subject to conversion of
any outstanding Series C Preferred Stock, exercise of any outstanding warrants
and/or exercise of any outstanding stock options, after taking into account the
offering of the Securities contemplated by this Agreement and all other share
-32-
<PAGE> 29
issuances occurring prior to this Offering, will be, as set forth in the
Capitalization Schedule as set forth in Exhibit K. There are no securities or
instruments containing anti-dilution or similar provisions that will be
triggered by the issuance of the Securities. Except as disclosed in the
Capitalization Schedule, as of the date of this Agreement, (i) there are no
outstanding options, warrants, scrip, rights to subscribe for, calls or
commitments of any character whatsoever relating to, or securities or rights
convertible into or exercisable or exchangeable for, any shares of capital stock
of the Company or any of its subsidiaries, or arrangements by which the Company
or any of its subsidiaries is or may become bound to issue additional shares of
capital stock of the Company or any of its subsidiaries, and (ii) there are no
agreements or arrangements under which the Company or any of its subsidiaries is
obligated to register the sale of any of its or their securities under the Act
(except the Registration Rights Agreement, and registration rights relating to
the Class C Preferred Stock penalties, the BTD Warrants, the Rudolph and Sletton
Warrants and the 1998 private placement shares and warrants).
5.8 Intellectual Property. The Company has valid, unrestricted
and exclusive ownership of or rights to use the patents, trademarks, trademark
registrations, trade names, copyrights, know-how, technology and other
intellectual property necessary to the conduct of its business. Exhibit M lists
all patents, trademarks, trademark registrations, trade names and copyrights of
the Company. The Company has granted such licenses or has assigned or otherwise
transferred a portion of (or all of) such valid, unrestricted and exclusive
patents, trademarks, trademark registrations, trade names, copyrights, know-how,
technology and other intellectual property necessary to the conduct of its
business as set forth in Exhibit M. The Company has been granted licenses,
know-how, technology and/or other intellectual property necessary to the conduct
of its business as set forth in Exhibit M. To the best of the Company's
knowledge after due inquiry, the Company is not infringing on the intellectual
property rights of any third party, nor is any third party infringing on the
Company's intellectual property rights. There are no restrictions in any
agreements, licenses, franchises, or other instruments that preclude the Company
from engaging in its business as presently conducted.
5.9 Use of Proceeds. As of the date hereof, the Company expects
to use the proceeds from this Offering (less fees and expenses) for the purposes
and in the approximate amounts set forth on the Use of Proceeds Schedule set
forth as Exhibit L hereto. These purposes and amounts are estimates and are
subject to change without notice to any Subscriber.
5.10 No Rights of Participation. No person or entity, including,
but not limited to, current or former shareholders of the Company, underwriters,
brokers, agents or other third parties, has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in
the financing contemplated by this Agreement which has not been waived.
5.11 Company Acknowledgment. The Company hereby acknowledges that
Subscriber may elect to hold the Securities for various periods of time, as
permitted by the terms of this Agreement, the Warrants, and other agreements
contemplated hereby, and the Company further acknowledges that Subscriber and
the Placement Agent have made no representations or warranties, either written
or oral, as to how long the Securities will be held by Subscriber or regarding
Subscriber's trading history or investment strategies.
-33-
<PAGE> 30
5.12 Termination Date of Offering. In no event shall the Initial
Tranche Closing Date occur later than three (3) Business Days after the Initial
Tranche Subscription Date. If the Initial Tranche Closing does not occur within
three (3) Business Days of the Initial Tranche Subscription Date, then either
party may terminate this Agreement without affecting any liability either party
may have as a result of any breach of this Agreement prior to such termination.
5.13 Underwriter's Fees and Rights of First Refusal. The Company
is not obligated to pay in excess of two hundred thousand dollars ($200,000)
compensation or other fees, costs or related expenditures in cash or securities
to any underwriter, broker, agent or other representative other than the
Placement Agent in connection with this Offering.
5.14 Availability of Suitable Form for Registration. The Company
is currently eligible and agrees to maintain its eligibility to register the
resale of its Common Stock on a registration statement on a suitable form under
the Act.
5.15 No Integrated Offering. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has directly or
indirectly made any offers or sales of any of the Company's securities or
solicited any offers to buy any security under circumstances that would prevent
the parties hereto from consummating the transactions contemplated hereby
pursuant to an exemption from registration under the Act pursuant to the
provisions of Regulation D or would require the issuance of any other securities
to be integrated with this Offering under the Rules of Nasdaq. The Company has
not engaged in any form of general solicitation or advertising in connection
with the offering of the Common Stock or the Warrants.
5.16 Acknowledgment of Dilution. The number of Three Month Reset
Shares and Six Month Reset Shares that the Company may be obligated to issue on
either the Three Month Reset Date or the Six Month Reset Date may increase
substantially in certain circumstances, including the circumstance in which the
trading price of the Common Stock declines. Such shares, alone or in combination
with the Initial Tranche Shares, may represent a substantial portion of the
Company's capitalization and may have an adverse impact on the market for the
Common Stock. The Company's executive officers and directors have studied and
fully understand the nature of this Agreement and the Securities being sold
hereunder and recognize that they have a potential dilutive effect. The board of
directors of the Company has concluded in its good faith business judgment that
such issuance is in the best interests of the Company.
5.17 Foreign Corrupt Practices. Neither the Company, nor any of
its subsidiaries, nor any director, officer, agent, employee or other person
acting on behalf of the Company or any subsidiary has, in the course of its
actions for, or on behalf of, the Company, used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful expenses relating
to political activity; made any direct or indirect unlawful payment to any
foreign or domestic government official or employee from corporate funds;
violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended; or made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any foreign or domestic
government official or employee.
5.18 Key Employees. Each Key Employee (as defined below) is
currently serving the Company in the capacity disclosed in Exhibit N. No Key
Employee, to the best knowledge of the
-34-
<PAGE> 31
Company and its subsidiaries, is, or is now expected to be, in violation of any
material term of any employment contract, confidentiality, disclosure or
proprietary information agreement, non-competition agreement, or any other
contract or agreement or any restrictive covenant, and the continued employment
of each Key Employee does not subject the Company or any of its subsidiaries to
any liability with respect to any of the foregoing matters. No Key Employee has,
to the best knowledge of the Company and its subsidiaries, any intention to
terminate his employment with, or services to, the Company or any of its
subsidiaries. "Key Employee" means Larry Bymaster, President and Chief Executive
Officer.
5.19 Representations Correct. The foregoing representations,
warranties and agreements are true, correct and complete in all material
respects, and shall survive the Initial Tranche Closing and any Call Closing and
the issuance of the shares of Common Stock thereby.
5.20 Tax Status. The Company has made or filed all federal and
state income and all other tax returns, reports and declarations required by any
jurisdiction to which it is subject (unless and only to the extent that the
Company has set aside on its books provisions reasonably adequate for the
payment of all unpaid and unreported taxes) and has paid all taxes and other
governmental assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations, except those
being contested in good faith and as set aside on its books provision reasonably
adequate for the payment of all taxes for periods subsequent to the periods to
which such returns, reports or declarations apply. There are no unpaid taxes in
any material amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such
claim.
5.21 Transactions With Affiliates. Except as set forth in the
Disclosure Documents, none of the officers, directors, or employees of the
Company is presently a party to any transaction with the Company (other than for
services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the
knowledge of the Company, any corporation, partnership, trust or other entity in
which any officer, director, or any such employee has a substantial interest or
is an officer, director, trustee or partner.
5.22 Application of Takeover Protections. The Company and its
board of directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination or other
similar anti-takeover provision under Delaware law which is or could become
applicable to the Subscriber as a result of the transactions contemplated by
this Agreement, including, without limitation, the issuance of the Common Stock,
any exercise of the Warrants and ownership of the Common Shares and Warrant
Shares. The Company has not adopted and will not adopt any "poison pill"
provision that will be applicable to Subscriber as a result of transactions
contemplated by this Agreement.
5.23 Other Agreements. The Company has not, directly or
indirectly, made any agreements with the Subscriber, or any Other Subscribers,
under a subscription in the form of this Agreement for the purchase of Common
Stock, relating to the terms or conditions of the transactions contemplated
hereby or thereby except as expressly set forth herein or in the Other
Subscription Agreement, respectively, or in exhibits hereto or thereto.
-35-
<PAGE> 32
5.24 Major Transactions. There are no other Major Transactions
currently pending or contemplated by the Company, except for the Swiss
Transaction.
5.25 Financings. There are no other financings currently pending
or contemplated by the Company, except for a private placement of at least four
million dollars ($4,000,000) to fund the buyout of certain distribution rights
from Biotechnology Development Ltd. (the "BTD Buyout").
6. Covenants of the Company
6.1 Independent Auditors. The Company shall, until at least the
later of (i) the date that is three (3) years after the Initial Tranche Closing
Date or (ii) the issuance of all of the Common Stock purchased pursuant to any
Call for Proceeds under this Agreement, and the exercise of the Warrants,
maintain as its independent auditors an accounting firm authorized to practice
before the SEC.
6.2 Corporate Existence and Taxes. The Company shall, until at
least the later of (i) the date that is three (3) years after the Initial
Tranche Closing Date or (ii) the issuance of all of the Common Stock purchased
pursuant to any Call for Proceeds under this Agreement, and the exercise of the
Warrants, maintain its corporate existence in good standing and remain a
"Reporting Issuer" (defined as a Company which files periodic reports under the
Exchange Act) (provided, however, that the foregoing covenant shall not prevent
the Company from entering into any merger or corporate reorganization as long as
the surviving entity in such transaction, if not the Company, assumes the
Company's obligations with respect to the Common Stock and has Common Stock
listed for trading on a stock exchange or on Nasdaq and is a Reporting Issuer)
and shall pay all its taxes when due except for taxes which the Company
disputes.
6.3 Registration Rights. The Company will enter into a
registration rights agreement covering the resale of the Common Shares and the
Warrant Shares substantially in the form of the Registration Rights Agreement
attached as Exhibit A.
6.4 [Intentionally Omitted]
6.5 Asset Transfers. The Company shall not (i) transfer, sell,
convey or otherwise dispose of any of its material assets to any Subsidiary
except for a cash or cash equivalent consideration and for a proper business
purpose or (ii) ) transfer, sell, convey or otherwise dispose of any of its
material assets to any Affiliate, as defined below, during the Term of this
Agreement. For purposes hereof, "Affiliate" shall mean any officer of the
Company, director of the Company or owner of twenty percent (20%) or more of the
Common Stock or other securities of the Company.
6.6 Capital Raising Limitations; Rights of First Refusal.
6.6.1 Capital Raising Limitations. During the Term of
this Agreement, the Company shall not issue or sell, or agree to issue or sell,
for cash in private capital raising transactions (the following to be
collectively referred to herein as, the "Variable Deals"), (a) any debt or
equity securities which are convertible into, exercisable or exchangeable for,
or carry the right to receive additional shares of Common Stock either (i) at
any conversion, exercise or exchange rate or other price that is based upon
and/or varies with the trading prices of or quotations for Common Stock at any
time after the initial issuance of such debt or equity security, or (ii) with a
-36-
<PAGE> 33
fixed conversion, exercise or exchange price that is subject to being reset at
some future date at any time after the initial issuance of such debt or equity
security or upon the occurrence of specified contingent events directly or
indirectly related to the business of the Company of the market for the Common
Stock, or (b) any securities of the Company pursuant to an equity line structure
or format similar in nature to this Offering without obtaining the prior written
approval of the Subscribers of the Offering (the limitations referred to in this
sentence are collectively referred to as the "Capital Raising Limitations"). For
any private capital raising transactions not subject to the Capital Raising
Limitations, the Company agrees to deliver to Subscriber at least ten (10) days
prior to the closing of such transaction, written notice describing the proposed
transaction, including the terms and conditions thereof, and providing the
Subscriber and its affiliates an option during the ten (10) day period following
delivery of such notice to purchase securities being offered in such transaction
on the same terms as contemplated by such transaction. The maximum amount of
securities which a Subscriber is entitled to purchase (the "Participation
Amount") in such transaction shall be a number obtained by multiplying the
aggregate amount of securities being offered in such transaction by twenty
percent (20%); provided, however, that the lead investor or the placement agent
of such transaction may elect to purchase the Subscriber's right to participant
in such transaction by paying Subscriber a dollar amount equal to the greater of
(i) one percent (1%) of the purchase amount of the Participation Amount, or (ii)
Fifty Thousand Dollars ($50,000).
6.6.2 Exceptions to the Capital Raising Limitation. The
Capital Raising Limitations shall not apply to any transaction involving
issuances of securities in connection with a merger, consolidation, acquisition
or sale of assets, or in connection with any strategic partnership or joint
venture (the primary purpose of which is not to raise equity capital), or in
connection with the disposition or acquisition of a business, product or license
by the Company or exercise of options by employees, consultants or directors.
The Capital Raising Limitations also shall not apply to (a) the issuance of
securities pursuant to a firm commitment underwritten public offering, (b) the
issuance of securities upon exercise or conversion of the Company's options,
warrants or other convertible securities outstanding as of the date hereof, (c)
the grant of additional options or warrants, or the issuance of additional
securities, under any Company stock option or restricted stock plan for the
benefit of the Company's employees, directors or consultants, (d) the issuance
of debt securities, with no variable equity feature, incurred solely for working
capital purposes, (e) the Swiss Transaction, or (f) the BTD Buyout; provided,
however, that under no circumstances shall the issuance of securities pursuant
to clauses (a) through (f) constitute Variable Deals as specified in Section
6.6.1 above.
6.7 Financial 10-K Statements, Etc. and Current Reports on Form
8-K. The Company shall deliver to the Subscriber copies of its annual reports on
Form 10-K/A, and quarterly reports on Form 10-Q/A and shall deliver to the
Subscriber current reports on form 8-K within two (2) days of filing for the
Term of this Agreement.
6.8 Opinion of Counsel. Subscribers shall, concurrent with the
purchase of the Common Stock and accompanying Warrants pursuant to this
Agreement, receive an opinion letter from Stradling Yocca Carlson & Rauth, 660
Newport Center Drive, Suite 1600, Newport Beach, CA 92660-6441, Telephone: (714)
725-4000, Facsimile: (714) 725-4100, ("Counsel"), counsel to the Company, in the
form attached as Exhibit B or in such form as agreed upon by the parties, as to
the Initial Tranche Closing and in the form attached as Exhibit I or in such
form as agreed upon by the parties, as to any Call Closing.
-37-
<PAGE> 34
6.9 Removal of Legend. The Legend shall be removed and the
Company shall issue a certificate without such Legend to the holder of any
Security upon which it is stamped, and a certificate for a security shall be
originally issued without the Legend, if, (a) the sale of such Security is
registered under the Act, or (b) such holder provides the Company with an
opinion of counsel, in form, substance and scope customary for opinions of
counsel in comparable transactions (the reasonable cost of which shall be borne
by the Company), to the effect that a public sale or transfer of such Security
may be made without registration under the Act, or (c) such holder provides the
Company with reasonable assurances that such Security can be sold pursuant to
Rule 144. Each Subscriber agrees to sell all Securities, including those
represented by a certificate(s) from which the Legend has been removed, or which
were originally issued without the Legend, pursuant to an effective registration
statement and to deliver a prospectus in connection with such sale or in
compliance with an exemption from the registration requirements of the Act.
6.10 Listing. Subject to the remainder of this Section 6.10, the
Company shall ensure that its shares of Common Stock (including all Warrant
Shares) are listed and available for trading on the Nasdaq Small Cap Market
("NASDAQ"). Thereafter, the Company shall (i) use its best efforts to continue
the listing and trading of its Common Stock on the NASDAQ, or on the Nasdaq
National Market System ("NMS"), the New York Stock Exchange ("NYSE"), or the
American Stock Exchange ("AMEX") or any other national exchange or
over-the-counter market system; and (ii) comply in all material respects with
the Company's reporting, filing and other obligations under the By-Laws or rules
of the National Association of Securities Dealers ("NASD") and such exchanges,
as applicable.
6.11 The Company's Instructions to Transfer Agent. The Company
will instruct the Transfer Agent of the Common Stock to issue certificates,
registered in the name of each Subscriber or its nominee, for the Common Shares
and Warrant Shares in such amounts as specified from time to time by the Company
upon the Initial Tranche Closing, any exercise by the Company of a Call for
Proceeds and exercise of the Warrants. Such certificates shall bear a Legend
only to the extent permitted by Section 6.9 hereof and the Company shall use its
reasonable best efforts to cause the Transfer Agent to issue such certificates
without a Legend, except for the Initial Tranche Shares until such Initial
Tranche Shares are registered for resale under the Act. Nothing in this Section
shall affect in any way each Subscriber's obligations and agreement set forth in
Sections 3.3.3 or 3.3.4 hereof to resell the Securities pursuant to an effective
registration statement and to deliver a prospectus in connection with such sale
or in compliance with an exemption from the registration requirements of
applicable securities laws. If (a) a Subscriber provides the Company with an
opinion of counsel, which opinion of counsel shall be in form, substance and
scope customary for opinions of counsel in comparable transactions (the
reasonable cost of which shall be borne by the Company), to the effect that the
Securities to be sold or transferred may be sold or transferred pursuant to an
exemption from registration or (b) a Subscriber transfers Securities to an
affiliate which is an accredited investor pursuant to Rule 144, the Company
shall permit the transfer, and, in the case of Common Shares and Warrant Shares,
promptly instruct its transfer agent to issue one or more certificates in such
name and in such denomination as specified by such Subscriber. The Company
acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to a Subscriber by vitiating the intent and purpose of the
transaction contemplated hereby. Accordingly, the Company acknowledges that the
remedy at law for a breach of its obligations under this Section 6.11 will be
inadequate and agrees, in the event of a breach or threatened breach by the
Company of the provisions of this Section 6.11, that a Subscriber shall be
entitled, in addition to all
-38-
<PAGE> 35
other available remedies, to an injunction restraining any breach and requiring
immediate issuance and transfer, without the necessity of showing economic loss
and without any bond or other security being required.
6.12 Shareholder 20% Approval. The Company shall, at its next
annual shareholder meeting, to be held no later than October 31, 1998, use its
best efforts to obtain approval of its shareholders to authorize (i) the
issuance of the full number of shares of Common Stock which would be issuable
pursuant to this Agreement but for the Cap Amount and eliminate any prohibitions
under applicable law or the rules or regulations of any stock exchange,
interdealer quotation system or other self-regulatory organization with
jurisdiction over the Company or any of its securities with respect to the
Company's ability to issue shares of Common Stock in excess of the Cap Amount
(such approvals being the "Shareholder 20% Approval").
6.13 Press Release. The Company agrees that the Subscriber shall
have the right to review and comment upon any press release issued by the
Company in connection with the Offering which approval shall not be unreasonably
withheld by Subscriber.
7. Subscriber Covenant/Miscellaneous
7.1 Representations and Warranties Survive the Closing;
Severability. Subscriber's and the Company's representations and warranties
shall survive the Initial Tranche Closing and any Call Closing contemplated by
this Agreement notwithstanding any due diligence investigation made by or on
behalf of the party seeking to rely thereon. In the event that any provision of
this Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable or void, this Agreement shall continue in full force and
effect without said provision; provided that no such severability shall be
effective if it materially changes the economic benefit of this Agreement to any
party.
7.2 Successors and Assigns. The terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or
their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement. Subscriber may assign Subscriber's rights hereunder, in
connection with any private sale of the Common Stock of such Subscriber, so long
as, as a condition precedent to such transfer, the transferee executes an
acknowledgment agreeing to be bound by the applicable provisions of this
Agreement in a form acceptable to the Company and provides an original copy of
such acknowledgment to the Company.
7.3 Execution in Counterparts Permitted. This Agreement may be
executed in any number of counterparts, each of which shall be enforceable
against the parties actually executing such counterparts, and all of which
together shall constitute one (1) instrument.
7.4 Titles and Subtitles; Gender. The titles and subtitles used
in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. The use in this Agreement of a
masculine, feminine or neither pronoun shall be deemed to include a reference to
the others.
-39-
<PAGE> 36
7.5 Written Notices, Etc. Any notice, demand or request required
or permitted to be given by the Company or Subscriber pursuant to the terms of
this Agreement shall be in writing and shall be deemed given when delivered
personally, or by facsimile or upon receipt if by overnight or two (2) day
courier, addressed to the parties at the addresses and/or facsimile telephone
number of the parties set forth at the end of this Agreement or such other
address as a party may request by notifying the other in writing; provided,
however, that in order for any notice to be effective as to the Subscriber such
notice shall be delivered and sent, as specified herein, to all the addresses
and facsimile telephone numbers of the Subscriber set forth at the end of this
Agreement or such other address and/or facsimile telephone number as Subscriber
may request in writing .
7.6 Expenses. Except as set forth in the Registration Rights
Agreement, each of the Company and Subscriber shall pay all costs and expenses
that it respectively incurs, with respect to the negotiation, execution,
delivery and performance of this Agreement.
7.7 Entire Agreement; Written Amendments Required. This
Agreement, including the Exhibits attached hereto, the Common Stock
certificates, the Warrants, the Registration Rights Agreement, the Escrow
Agreement, and the other documents delivered pursuant hereto constitute the full
and entire understanding and agreement between the parties with regard to the
subjects hereof and thereof, and no party shall be liable or bound to any other
party in any manner by any warranties, representations or covenants except as
specifically set forth herein or therein. Except as expressly provided herein,
neither this Agreement nor any term hereof may be amended, waived, discharged or
terminated other than by a written instrument signed by the party against whom
enforcement of any such amendment, waiver, discharge or termination is sought.
7.8 Arbitration. Any controversy or claim arising out of or
related to the Transaction Documents or the breach thereof, shall be settled by
binding arbitration in Wilmington, Delaware in accordance with the Expedited
Procedures (Rules 53-57) of the Commercial Arbitration Rules of the American
Arbitration Association ("AAA"). A proceeding shall be commenced upon written
demand by Company or any Subscriber to the other. The arbitrator(s) shall enter
a judgment by default against any party, which fails or refuses to appear in any
properly noticed arbitration proceeding. The proceeding shall be conducted by
one (1) arbitrator, unless the amount alleged to be in dispute exceeds two
hundred fifty thousand dollars ($250,000), in which case three (3) arbitrators
shall preside. The arbitrator(s) will be chosen by the parties from a list
provided by the AAA, and if they are unable to agree within ten (10) days, the
AAA shall select the arbitrator(s). The arbitrators must be experts in
securities law and financial transactions. The arbitrators shall assess costs
and expenses of the arbitration, including all attorneys' and experts' fees, as
the arbitrators believe is appropriate in light of the merits of the parties'
respective positions in the issues in dispute. Each party submits irrevocably to
the jurisdiction of any state court sitting in Wilmington, Delaware or to the
United States District Court sitting in Delaware for purposes of enforcement of
any discovery order, judgment or award in connection with such arbitration. The
award of the arbitrator(s) shall be final and binding upon the parties and may
be enforced in any court having jurisdiction. The arbitration shall be held in
such place as set by the arbitrator(s) in accordance with Rule 55.
Although the parties, as expressed above, agree that all claims,
including claims that are equitable in nature, for example specific performance,
shall initially be prosecuted in the binding
-40-
<PAGE> 37
arbitration procedure outlined above, if the arbitration panel dismisses or
otherwise fails to entertain any or all of the equitable claims asserted by
reason of the fact that it lacks jurisdiction, power and/or authority to
consider such claims and/or direct the remedy requested, then, in only that
event, will the parties have the right to initiate litigation respecting such
equitable claims or remedies. The forum for such equitable relief shall be in
either a state or federal court sitting in Wilmington, Delaware. Each party
waives any right to a trial by jury, assuming such right exists in an equitable
proceeding, and irrevocably submits to the jurisdiction of said Delaware court.
Delaware law shall govern both the proceeding as well as the interpretation and
construction of the Transaction Documents and the transaction as a whole.
8. Subscription and Wiring Instructions; Irrevocability.
8.1 Subscription
(a) Wire transfer of Subscription Funds. Subscriber shall
send this signed Agreement by facsimile to the Placement
Agent at (770) 640-7150, and send the subscription funds
(as payment towards any Initial Tranche Purchase Amount
or any Call Dollar Amount) by wire transfer, to the
Escrow Agent as follows:
First Union National Bank - Atlanta
ABA No. 053000219
Account No. 465946
Attn: Sabrina Fuller
Reference: Techniclone Corporation #3072238563
Telephone No.: (404) 827-7352
SWIFT Code: FUNBUS33
(b) Irrevocable Subscription. Subscriber hereby acknowledges
and agrees, subject to the provisions of any applicable
laws providing for the refund of subscription amounts
submitted by Subscriber, that this Agreement is
irrevocable and that Subscriber is not entitled to
cancel, terminate or revoke this Agreement or any other
agreements executed by such Subscriber and delivered
pursuant hereto, and that this Agreement and such other
agreements shall survive the death or disability of such
Subscriber and shall be binding
-41-
<PAGE> 38
upon and inure to the benefit of the parties and their
heirs, executors, administrators, successors, legal
representatives and assigns. If the Securities
subscribed for are to be owned by more than one person,
the obligations of all such owners under this Agreement
shall be joint and several, and the agreements,
representations, warranties and acknowledgments herein
contained shall be deemed to be made by and be binding
upon each such person and his heirs, executors,
administrators, successors, legal representatives and
assigns. Notwithstanding the foregoing, (i) if the
conditions to Closing are not satisfied or (ii) if the
Disclosure Documents are discovered prior to Closing to
contain statements which are materially inaccurate, or
omit statements of material fact, Subscriber may revoke
or cancel this Agreement.
(c) Company's Right to Reject Subscription. Subscriber
understands that this Agreement is not binding on the
Company until the Company accepts it. This Agreement
shall be accepted by the Company when the Company
countersigns this Agreement. Subscriber hereby confirms
that the Company has full right in its sole discretion
to accept or reject the subscription of Subscriber, in
whole or in part, provided that, if the Company decides
to reject such subscription, the Company must do so
promptly and in writing. In the case of rejection, the
Company will promptly return any rejected payments and
(if rejected in whole) copies of all executed
subscription documents (including without limitation
this Agreement) to Subscriber. In the event of
rejection, no interest will be payable by the Company to
Subscriber on any return of payment, provided however,
that any such interest accrued on such funds in the
Escrow Account shall be returned to the Subscriber by
the Escrow Agent.
8.2 Acceptance of Subscription. Ownership of the number of
securities being purchased hereby will pass to Subscriber upon the Initial
Tranche Closing or any Call Closing.
8.3 [Intentionally Omitted]
9. Indemnification.
In consideration of the Subscriber's execution and delivery of
the Subscription Agreement, the Registration Rights Agreement, the Escrow
Agreement and the Warrants (the "Transaction Documents") and acquiring the
Securities thereunder and in addition to all of the Company's other obligations
under the Transaction Documents, the Company shall defend, protect, indemnify
and hold harmless Subscriber and the Placement Agent and all of their
stockholders, officers, directors, employees and direct or indirect investors
and any of the foregoing person's agents, members, partners or other
representatives (including, without limitation, those retained in
-42-
<PAGE> 39
connection with the transactions contemplated by this Agreement) (collectively,
the "Indemnitees") from and against any and all actions, causes of action,
suits, claims, losses, costs, penalties, fees, liabilities and damages, and
expenses in connection therewith (irrespective of whether any such Indemnitee is
a party to the action for which indemnification hereunder is sought), and
including reasonable attorney's fees and disbursements (the "Indemnified
Liabilities"), incurred by any Indemnitee as a result of, or arising out of, or
relating to (a) any misrepresentation or breach of any representation or
warranty made by the Company in the Transaction Documents or any other
certificate, instrument or documents contemplated hereby or thereby, (b) any
breach of any covenant, agreement or obligation of the Company contained in the
Transaction Documents or any other certificate, instrument or document
contemplated hereby or thereby, or (c) any cause of action, suit or claim,
derivative or otherwise, by any shareholder of the Company based on a breach or
alleged breach by the Company or any of its officers or directors of their
fiduciary or other obligations to the shareholders of the Company.
To the extent that the foregoing undertaking by the Company may
be unenforceable for any reason, the Company shall make the maximum contribution
to the payment and satisfaction of each of the Indemnified Liabilities which it
would be required to make if such foregoing undertaking was enforceable which is
permissible under applicable law.
Promptly after receipt by an Indemnified Party of notice of the
commencement of any action pursuant to which indemnification may be sought, such
Indemnified Party will, if a claim in respect thereof is to be made against the
other party (hereinafter "Indemnitor") under this Section 9, deliver to the
Indemnitor a written notice of the commencement thereof and the Indemnitor shall
have the right to participate in and to assume the defense thereof with counsel
reasonably selected by the Indemnitor, provided, however, that an Indemnified
Party shall have the right to retain its own counsel, with the reasonably
incurred fees and expenses of such counsel to be paid by the Indemnitor, if
representation of such Indemnified Party by the counsel retained by the
Indemnitor would be inappropriate due to actual or potential conflicts of
interest between such Indemnified Party and any other party represented by such
counsel in such proceeding. The failure to deliver
-43-
<PAGE> 40
written notice to the Indemnitor within a reasonable time of the commencement of
any such action, if prejudicial to the Indemnitor's ability to defend such
action, shall relieve the Indemnitor of any liability to the Indemnified Party
under this Section 9, but the omission to so deliver written notice to the
Indemnitor will not relieve it of any liability that it may have to any
Indemnified Party other than under this Section 9 to the extent it is
prejudicial.
10. Certain Additional Legends and Information.
FOR FLORIDA RESIDENTS:
THE SECURITIES REFERRED TO HEREIN WILL BE SOLD TO, AND ACQUIRED
BY, THE HOLDER IN A TRANSACTION EXEMPT UNDER SECTION 517.061 OF THE FLORIDA
SECURITIES ACT. THE SECURITIES HAVE NOT BEEN REGISTERED UNDER SAID ACT IN THE
STATE OF FLORIDA. IN ADDITION, ALL FLORIDA RESIDENTS SHALL HAVE THE PRIVILEGE OF
VOIDING THE PURCHASE WITHIN THREE (3) DAYS AFTER THE FIRST TENDER OF
CONSIDERATION IS MADE BY SUCH SUBSCRIBER TO THE ISSUER, AN AGENT OF THE ISSUER,
OR AN ESCROW AGENT OR WITHIN THREE DAYS AFTER THE AVAILABILITY OF THAT PRIVILEGE
IS COMMUNICATED TO SUCH SUBSCRIBER, WHICHEVER OCCURS LATER.
FOR MAINE RESIDENTS:
THESE SECURITIES ARE BEING SOLD PURSUANT TO AN EXEMPTION FROM
REGISTRATION WITH THE BANK SUPERINTENDENT OF THE STATE OF MAINE UNDER SECTION
10502(2)(R) OF TITLE 32 OF THE MAINE REVISED STATUTES. THESE SECURITIES MAY BE
DEEMED RESTRICTED SECURITIES AND AS SUCH THE HOLDER MAY NOT BE ABLE TO RESELL
THE SECURITIES UNLESS PURSUANT TO REGISTRATION UNDER STATE OR FEDERAL SECURITIES
LAWS OR UNLESS AN EXEMPTION UNDER SUCH LAWS EXISTS.
FOR PENNSYLVANIA RESIDENTS:
EACH PENNSYLVANIA RESIDENT WHO SUBSCRIBES FOR THE
-44-
<PAGE> 41
SECURITIES BEING OFFERED HEREBY AGREES NOT TO SELL THESE SECURITIES FOR A PERIOD
OF TWELVE MONTHS AFTER THE DATE OF PURCHASE UNLESS SUCH SECURITIES HAVE BEEN
REGISTERED FOR SALE. UNDER PROVISION OF THE PENNSYLVANIA SECURITIES ACT OF 1972
(THE "1972 ACT"), EACH PENNSYLVANIA RESIDENT SHALL HAVE THE RIGHT TO WITHDRAW
HIS ACCEPTANCE WITHOUT INCURRING ANY LIABILITY, TO THE SELLER, UNDERWRITER (IF
ANY) OR ANY PERSON, WITHIN TWO (2) BUSINESS DAYS FROM THE DATE OF RECEIPT BY THE
ISSUER OF HIS WRITTEN BINDING CONTRACT OF PURCHASE OR IN THE CASE OF A
TRANSACTION IN WHICH THERE IS NO WRITTEN BINDING CONTRACT OF PURCHASE, WITHIN
TWO BUSINESS DAYS AFTER HE MAKES THE INITIAL PAYMENT FOR THE SECURITIES BEING
OFFERED. TO ACCOMPLISH THIS WITHDRAWAL, A SUBSCRIBER NEED ONLY SEND A LETTER OR
TELEGRAM TO THE SELLING AGENT AT THE ADDRESS SET FORTH IN THE TEXT OF THE
MEMORANDUM, INDICATING HIS OR HER INTENTION TO WITHDRAW. SUCH LETTER OR TELEGRAM
SHOULD BE SENT AND POSTMARKED PRIOR TO THE END OF THE AFOREMENTIONED SECOND
BUSINESS DAY. IT IS PRUDENT TO SEND SUCH LETTER BY CERTIFIED MAIL, RETURN
RECEIPT REQUESTED, TO ENSURE THAT IT IS RECEIVED AND ALSO TO EVIDENCE THE TIME
WHEN IT WAS MAILED. IF THE REQUEST IS MADE ORALLY (IN PERSON OR BY TELEPHONE, TO
THE SELLING AGENT AT THE NUMBER LISTED IN THE TEXT OF THE MEMORANDUM) A WRITTEN
CONFIRMATION THAT THE REQUEST HAS BEEN RECEIVED SHOULD BE REQUESTED.
FOR NEW HAMPSHIRE RESIDENTS:
NEITHER THE FACT THAT A REGISTRATION STATEMENT OR AN APPLICATION
FOR A LICENSE HAS BEEN FILED WITH THE STATE OF NEW HAMPSHIRE NOR THE FACT THAT A
SECURITY IS EFFECTIVELY REGISTERED OR A PERSON IS LICENSED IN THE STATE OF NEW
HAMPSHIRE CONSTITUTES A FINDING BY THE SECRETARY OF STATE THAT ANY DOCUMENT
FILED UNDER RSA 421-B IS
-45-
<PAGE> 42
TRUE, COMPLETE AND NOT MISLEADING. NEITHER ANY SUCH FACT NOR THE FACT THAT AN
EXEMPTION OR EXCEPTION IS AVAILABLE FOR A SECURITY OR A TRANSACTION MEANS THAT
THE SECRETARY OF STATE HAS PASSED IN ANY WAY UPON THE MERITS OR QUALIFICATIONS
OF, OR RECOMMENDED OR GIVEN APPROVAL TO, ANY PERSON, SECURITY, OR TRANSACTION.
IT IS UNLAWFUL TO MAKE, OR CAUSE TO BE MADE, TO ANY PROSPECTIVE PURCHASER,
CUSTOMER OR CLIENT ANY REPRESENTATION INCONSISTENT WITH THE PROVISIONS OF THIS
PARAGRAPH.
[INTENTIONALLY LEFT BLANK]
-46-
<PAGE> 43
11. Number of Initial Tranche Shares, Initial Tranche Share Price and
Initial Tranche Purchase Amount. Subscriber subscribes for 2,036,363 shares of
Common Stock (in the amount of $1.375 per Share) and the accompanying
Warrants against payment by wire transfer in the amount of $2,800,000
("Initial Tranche Purchase Amount").
12. Accredited Investor. Subscriber is an "accredited investor" because
(check all applicable boxes):
(a) [X] it is an organization described in Section 501(c)(3) of the
Internal Revenue Code, or a corporation, limited duration
company, limited liability company, business trust, or
partnership not formed for the specific purpose of acquiring the
securities offered, with total assets in excess of $5,000,000.
(b) [ ] any trust, with total assets in excess of $5,000,000, not formed
for the specific purpose of acquiring the securities offered,
whose purchase is directed by a sophisticated person who has
such knowledge and experience in financial and business matters
that he is capable of evaluating the merits and risks of the
prospective investment.
(c) [ ] a natural person, who
[ ] is a director, executive officer or general partner of the
issuer of the securities being offered or sold or a director,
executive officer or general partner of a general partner of
that issuer.
[ ] has an individual net worth, or joint net worth with that
person's spouse, at the time of his purchase exceeding
$1,000,000.
[ ] had an individual income in excess of $200,000 in each
of the two most recent years or joint income with that person's
spouse in excess of $300,000 in each of those years and has a
reasonable expectation of reaching the same income level in the
current year.
(d) [ ] an entity each equity owner of which is an entity described in
a - b above or is an individual who could check one (1) of the
last three (3) boxes under subparagraph (c) above.
(e) [ ] other [specify] _____________________________________________
-47-
<PAGE> 44
The undersigned acknowledges that this Agreement and the
subscription represented hereby shall not be effective unless accepted by the
Company as indicated below.
IN WITNESS WHEREOF, the undersigned Subscriber does represent and
certify under penalty of perjury that the foregoing statements are true and
correct and that Subscriber by the following signature(s) executed this
Agreement.
Dated this 16 day of June, 1998.
<TABLE>
<S> <C>
/s/ Joan L. Thompson /s/Sherrill Fletscher The Tail Wind Fund Ltd
- ----------------------------------------------- --------------------------------------------
Your Signature PRINT EXACT NAME IN WHICH YOU WANT THE
SECURITIES TO BE REGISTERED
Joan L. Thompson Sherrill Pletscher SECURITY DELIVERY INSTRUCTIONS:
- ------------------------------------------------ --------------------------------------------
Name: Please Print Please type or print address where your
security is to be delivered
Brighton Holdings Limited as Sole Director ATTN: D Freedman, Bishop Rosen & Co.
- ----------------------------------------------- --------------------------------------------
Title/Representative Capacity (if applicable)
The Tail Wind Fund Ltd 111 Broadway
- ----------------------------------------------- --------------------------------------------
Name of Company You Represent (if applicable) Street Address
Nassau, Bahamas New York 10006
- ----------------------------------------------- --------------------------------------------
Place of Execution of this Agreement City, State or Province, Country, Offshore
Postal Code
NOTICE DELIVERY INSTRUCTIONS: WITH A COPY DELIVERED TO:
Please print address where any Notice Please print address where Copy is to be
is to be delivered delivered
</TABLE>
-48-
<PAGE> 45
<TABLE>
<CAPTION>
<S> <C>
ATTN: S. Pletscher ATTN: D. Crook / EASI
- ----------------------------------------------- --------------------------------------------
Windermere House, 404 east bay Street 4th Floor, 1 Regent Street
- ----------------------------------------------- --------------------------------------------
Street Address Street Address
Nassau, Bahamas London SWIY
- ----------------------------------------------- --------------------------------------------
City, State or Province, Country, Offshore City, State or Country, Offshore Postal Code
Postal Code
Telephone: Telephone:
- ----------------------------------------------- --------------------------------------------
Facsimile: Facsimile:
- ---------------------------------------------- --------------------------------------------
Facsimile: Facsimile:
- ---------------------------------------------- --------------------------------------------
THIS AGREEMENT IS ACCEPTED BY THE COMPANY IN THE AMOUNT OF 80%/16 million ON
THE ____ DAY OF ______________, 1998.
Techniclone Corporation
By: /s/ Elizabeth A. Gorbett-Frost
Name: Elizabeth A. Gorbett-Frost
Title: Chief Financial Officer
Address: Techniclone Corporation
14282 Franklin Avenue
Tustin, CA 92780
Telephone No. (714) 508-6000
Facsimile No. (714) 838-4094
</TABLE>
-49-
<PAGE> 46
11. Number of Initial Tranche Shares, Initial Tranche Share Price and
Initial Tranche Purchase Amount. Subscriber subscribes for 509,091 shares of
Common Stock (in the amount of $1.375 per Share) and the accompanying
Warrants against payment by wire transfer in the amount of $700,000
("Initial Tranche Purchase Amount").
12. Accredited Investor. Subscriber is an "accredited investor" because
(check all applicable boxes):
(a) [X] it is an organization described in Section 501(c)(3) of the
Internal Revenue Code, or a corporation, limited duration
company, limited liability company, business trust, or
partnership not formed for the specific purpose of acquiring the
securities offered, with total assets in excess of $5,000,000.
(b) [ ] any trust, with total assets in excess of $5,000,000, not formed
for the specific purpose of acquiring the securities offered,
whose purchase is directed by a sophisticated person who has
such knowledge and experience in financial and business matters
that he is capable of evaluating the merits and risks of the
prospective investment.
(c) [ ] a natural person, who
[ ] is a director, executive officer or general partner of the
issuer of the securities being offered or sold or a director,
executive officer or general partner of a general partner of
that issuer.
[ ] has an individual net worth, or joint net worth with that
person's spouse, at the time of his purchase exceeding
$1,000,000.
[ ] had an individual income in excess of $200,000 in each
of the two most recent years or joint income with that person's
spouse in excess of $300,000 in each of those years and has a
reasonable expectation of reaching the same income level in the
current year.
(d) [ ] an entity each equity owner of which is an entity described in
a - b above or is an individual who could check one (1) of the
last three (3) boxes under subparagraph (c) above.
(e) [ ] other [specify] _____________________________________________
-50-
<PAGE> 47
The undersigned acknowledges that this Agreement and the
subscription represented hereby shall not be effective unless accepted by the
Company as indicated below.
IN WITNESS WHEREOF, the undersigned Subscriber does represent and
certify under penalty of perjury that the foregoing statements are true and
correct and that Subscriber by the following signature(s) executed this
Agreement.
Dated this 17 day of June, 1998.
<TABLE>
<S> <C>
/s/ M. Mandel Resonance Limited
- ----------------------------------------------- --------------------------------------------
Your Signature PRINT EXACT NAME IN WHICH YOU WANT THE
SECURITIES TO BE REGISTERED
M. Mandel SECURITY DELIVERY INSTRUCTIONS:
- ----------------------------------------------- --------------------------------------------
Name: Please Print Please type or print address where your
security is to be delivered
ATTN: c/o ISAC Securities
- ----------------------------------------------- --------------------------------------------
Title/Representative Capacity (if applicable)
310 Madison Ave., Suite 503
- ----------------------------------------------- --------------------------------------------
Name of Company You Represent (if applicable) Street Address
New York, NY 10017
- ----------------------------------------------- --------------------------------------------
Place of Execution of this Agreement City, State or Province, Country, Offshore
Postal Code
NOTICE DELIVERY INSTRUCTIONS: WITH A COPY DELIVERED TO:
Please print address where any Notice Please print address where Copy is to be
is to be delivered delivered
</TABLE>
-51-
<PAGE> 48
<TABLE>
<S> <C>
ATTN: Moe Bodner, c/o ISAC Securities ATTN: Peregrine Corporate Services LTD.
- ----------------------------------------------- --------------------------------------------
310 Madison Avenue Burleigh Manor Peel Road
- ----------------------------------------------- --------------------------------------------
Street Address Street Address
New York, NY 10017 Douglas, Isle of Man, 1M2SEP, British Isles
- ----------------------------------------------- --------------------------------------------
City, State or Province, Country, Offshore City, State or Country, Offshore Postal Code
Postal Code
Telephone: Telephone:
- ----------------------------------------------- --------------------------------------------
Facsimile: Facsimile:
- ----------------------------------------------- --------------------------------------------
Facsimile: Facsimile:
- ----------------------------------------------- --------------------------------------------
THIS AGREEMENT IS ACCEPTED BY THE COMPANY IN THE AMOUNT OF 20% / $4 million ON
THE ____ DAY OF ______________, 1998.
Techniclone Corporation
By: /s/ Elizabeth A. Gorbett-Frost
Name: Elizabeth A. Gorbett-Frost
Title: Chief Financial Officer
Address: Techniclone Corporation
14282 Franklin Avenue
Tustin, CA 92780
Telephone No. (714) 508-6000
Facsimile No. (714) 838-4094
</TABLE>
-52-
EXHIBIT 23.2
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in this Registration Statement of
Techniclone Corporation (the Company) on Form S-3 of our report dated June 15,
1998, except for Note 12, as to which the date is July 17, 1998 (which expresses
an unqualified opinion and includes an explanatory paragraph regarding
substantial doubt about the Company's ability to continue as a going concern),
appearing in the Annual Report on Form 10-K of Techniclone Corporation for the
year ended April 30, 1998 and to the reference to us under the heading "Experts"
in the Prospectus, which is a part of this Registration Statement.
/s/ DELOITTE & TOUCHE LLP
Costa Mesa, California
April 30, 1999
